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Thesis summary 
 
Transmembrane proteins play crucial roles in many important physiological processes. 
The intracellular domain of membrane proteins is key for their function by interacting 
with a wide variety of cytosolic proteins. It is therefore important to examine this 
interaction. A recently developed method to study these interactions, based on the use 
of liposomes as a model membrane, involves the covalent coupling of the cytoplasmic 
domains of membrane proteins to the liposome membrane. This allows for the analysis 
of interaction partners requiring both protein and membrane lipid binding. 
This thesis further establishes the liposome recruitment system and utilises it to 
examine the intracellular interactome of the amyloid precursor protein (APP), most 
well-known for its proteolytic cleavage that results in the production and accumulation 
of amyloid beta fragments, the main constituent of amyloid plaques in Alzheimer’s 
disease pathology. Despite this, the physiological function of APP remains largely 
unclear. Through the use of the proteo-liposome recruitment system two novel 
interactions of APP’s intracellular domain (AICD) are examined with a view to gaining a 
greater insight into APP’s physiological function.  
One of these novel interactions is between AICD and the mTOR complex, a 
serine/threonine protein kinase that integrates signals from nutrients and growth 
factors. The kinase domain of mTOR directly binds to AICD and the N-terminal amino 
acids of AICD are crucial for this interaction. 
The second novel interaction is between AICD and the endosomal PIKfyve complex, a 
lipid kinase involved in the production of phosphatidylinositol-3,5-bisphosphate 
(PI(3,5)P2) from phosphatidylinositol-3-phosphate, which has a role in controlling 
ensdosome dynamics. The scaffold protein Vac14 of the PIKfyve complex binds 
directly to AICD and the C-terminus of AICD is important for its interaction with the 
PIKfyve complex. Using a recently developed intracellular PI(3,5)P2 probe it is shown 
that APP controls the formation of PI(3,5)P2 positive vesicular structures and that the 
PIKfyve complex is involved in the trafficking and degradation of APP. Both of these 
novel APP interactors have important implications of both APP function and 
Alzheimer’s disease. 
The proteo-liposome recruitment method is further validated through its use to examine 
the recruitment and assembly of the AP-2/clathrin coat from purified components to 
two membrane proteins containing different sorting motifs.  
Taken together this thesis highlights the proteo-liposome recruitment system as a 
valuable tool for the study of membrane proteins intracellular interactome. It allows for 
the mimicking of the protein in its native configuration therefore identifying weaker 
interactions that are not detected by more conventional methods and also detecting 
interactions that are mediated by membrane phospholipids.  
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Chapter 1.0 Introduction 
 
1.1 The importance of membrane proteins 
Roughly 38% of all proteins encoded for by the mammalian genome are membrane 
proteins which represent one-third of biomarker candidates and two-thirds of the 
current drug targets (Rucevic et al., 2011). Membrane proteins are an integral part of 
biological membranes where they contribute up to  50% of the mass of these 
membranes (Tan et al., 2008). Biological membranes form an essential barrier 
between cells and their environment and exhibit specialist functions between cell 
types. In eukaryotes they also form a barrier between intracellular organelles and the 
cytosol of the cell. The membranes of these organelles are highly specific to that 
particular organelle. This is due to a difference in lipid composition of these 
membranes and the diverse range of proteins that are associated with them. Biological 
membranes act as selective barriers and are necessary for creating osmotic, electrical 
and chemical gradients that provide the foundation of bioenergetics and signal 
transduction. They also function as reaction interfaces due to the wide variety of 
interactions that take place both within and on the surface of the membrane. 
Interactions between membrane lipids and proteins are crucial for membrane 
homeostasis. Protein-protein interactions on or near the membrane are vital for 
processes such as signal transduction (Barenholz and Cevc, 2000).  
1.1.1 Types of membrane protein 
Membrane proteins can be categorised into peripheral and integral membrane 
proteins. Peripheral membrane proteins associate with either the extracellular or 
cytosolic side of the membrane. Integral membrane proteins transverse the membrane 
  18 
  
and can be broadly categorised into three types. Type 1 membrane proteins are single 
pass and have an extracellular N-terminus and a cytoplasmic C-terminus. Type 2 
membrane proteins are single pass and have an extracellular C-terminus and a 
cytoplasmic N-terminus (Chou and Elrod, 1999). Type 3 or multipass membrane 
proteins have either or both of their N and C-terminus in the cytoplasm or in the 
extracellular space, and they pass through the membrane multiple times (Tan et al., 
2008). This thesis will focus on type 1 trans-membrane proteins. 
1.1.2 Membrane protein diversity 
Membrane proteins are diverse in both their structure and function, and are therefore 
involved in a wide variety of physiological processes. As a consequence they are also 
linked to several diseases with membrane proteins representing over 60% of current 
drug targets (Arinaminpathy et al., 2009). Some membrane proteins act as receptors 
which transmit external signals eliciting specific cellular responses. Others act as 
transport proteins, transporting small molecules such as sugars and amino acids as 
well as ions. Channel proteins also allow for the transport of small molecules across 
membranes by forming a channel in the membrane. Membrane proteins have roles in 
cell adhesion by linking the extracellular matrix to cytoskeletal components, therefore 
maintaining cell shape. It is important to understand the physiological functions of 
membrane proteins and the mechanisms required for these proteins to exert their 
function, due to their vital role in multiple biological processes.  
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1.2 Intracellular trafficking 
The localisation of membrane proteins within the cell is of vital importance to their 
function. Membrane proteins exert different specialist functions depending on their 
intracellular localisation. In order for membrane proteins to carry out their function there 
are mechanisms in place that allow the correct trafficking and sorting of membrane 
proteins to the correct intracellular organelles.  This process is known as intracellular or 
vesicular trafficking, and allows for the continuous movement of membrane proteins 
between different cellular compartments. There are two main pathways in intracellular 
trafficking, exocytosis and endocytosis (Figure 1). Exocytosis is the transport of newly 
synthesised membrane proteins to the plasma membrane, and endocytosis is the 
internalisation of these proteins from the plasma membrane to different organelles 
(Tokarev et al., 2009).  Both of these pathways work alongside each other and 
disruption of one pathway has an effect on the other pathway, therefore both are 
required for correct membrane protein trafficking and homeostasis. These pathways 
are tightly regulated by several different protein complexes that are specific to each 
individual stage of the trafficking pathways. Components of membrane trafficking 
protein complexes are able to interact with the membrane protein being transported, 
and therefore are crucial regulators in membrane transport.  
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1.2.1 The exocytic pathway 
Exocytosis involves the transport of membrane proteins to the plasma membrane via 
the Golgi complex. Membrane proteins are synthesised in the endoplasmic reticulum 
(ER) and are then transported to the Golgi. This process is mediated by COPII coated 
vesicular transport (Lee and Miller, 2007). Membrane proteins are synthesised in the 
rough ER (RER) and are either inserted into the RER membrane or translocated to the 
RER lumen. Proteins can only be exported from the RER by ER exit sites (ERES). 
These sites are coated with COPII and give rise to COPII coated vesicles (Szul and 
Sztul, 2011). The COPII coat is recruited to the ER membrane allowing membrane 
deformation, and causing vesicle release from the ER (Lee and Miller, 2007). These 
COPII coated vesicles, containing membrane protein cargos, then fuse with the cis 
cisternae membrane of the Golgi complex. The fusion of transport vesicles with their 
target membranes is crucial for membrane trafficking, and is mediated by several 
Figure 1. The two main pathways in intracellular trafficking 
Exocytosis transports newly synthesised proteins from the endoplasmic reticulum to 
the plasma membrane via the Golgi complex. Endocytosis is the internalisation of 
proteins at the plasma membrane through the endosomal compartments to the 
lysosomes for degradation. These proteins can be recycled back to the plasma 
membrane , first by trafficking between both early and late endosomes and the Golgi, 
and secondly by Golgi-to-plasma membrane trafficking. This therefore links the 
exocytic and endocytic pathways. Figure from Tokarev et al. (2009). 
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proteins including SNAREs. Once at the Golgi membrane proteins can be recycled 
back to the ER by COPI coated vesicular transport (Szul and Sztul, 2011). ER to Golgi 
transport is crucial to organelle homeostasis and in maintaining the identity between 
the ER and Golgi. This transport pathway is important for the correction of misfolded 
proteins, the retrieval of ER resident proteins, and the recycling of machinery that is 
involved in vesicle formation and fusion, such as SNARE proteins (Lee et al., 2004).  
Those membrane proteins destined for secretion are trafficked from the cis cisternae of 
the Golgi through the medial cisternae to the trans cisternae. The exact mechanism for 
this has been extensively debated with the cisternal maturation model being most 
widely recognised. This model suggests that the cargo membrane proteins remain in 
the same cisternal structure, which undergoes several re-modelling stages through the 
loss of early Golgi enzymes and the gain of late Golgi proteins (Szul and Sztul, 2011). 
Once at the TGN (trans-Golgi network) membrane proteins are transported to the 
plasma membrane in secretory vesicles. This vesicular transport involves cytoskeletal 
components such as microtubules. These secretory vesicles then dock and fuse with 
the plasma membrane (Kelly, 1985). Once at the plasma membrane, membrane 
proteins can be internalised for degradation or recycled back to the plasma membrane. 
One of the primary methods of internalisation is clathrin mediated endocytosis. 
This thesis will mainly focus on aspects of the endocytic pathway such as clathrin 
mediated endocytosis and trafficking between endosomes and the TGN. 
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1.2.2 Clathrin mediated endocytosis 
Clathrin mediated endocytosis (CME) is the classical method for the endocytosis of 
membrane receptors from the plasma membrane (Mayor and Pagano, 2007) (Figure 
2A). It involves the internalisation of fragments of the plasma membrane as well as all 
of its contents, into the cell, in vesicles coated with polymerised clathrin. Clathrin 
coated vesicles can also be formed from other membranes at different stages of the 
trafficking process, such as TGN-to-endosome transport (Crottet et al., 2002). CME is 
a versatile process as many different cargoes can be packaged using a wide variety of 
cytosolic accessory and adaptor proteins (McMahon and Boucrot, 2011). It can be 
triggered by ligand binding to a membrane protein as is the case with the epidermal 
growth factor receptor (EGFR) (Vieira et al., 1996). However some receptors such as 
the transferrin receptor are constitutively internalised (Ajioka and Kaplan, 1986). The 
mechanism of clathrin mediated endocytosis is thought to occur in five stages: initiation 
or nucleation, cargo selection, coat assembly, scission, and uncoating (Figure 2B). The 
formation of the clathrin coat requires a complex network of protein-protein interactions 
(Figure 2C). The initiation of coated pit formation defines plasma membrane sites for 
clathrin recruitment, to form clathrin coated vesicles (CCVs). Initiation involves a 
nucleation model composed of FCH domain (FES-CIP4 homology) only proteins 
(FCHO), EGFR pathway substrate 15 (EPS15) and intersectins (Henne et al., 2010, 
Reider et al., 2009). This module binds to plasma membrane regions rich in the inositol 
lipid phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) causing a slight bend in the 
membrane. Loss of any of these components inhibits clathrin coat formation (Henne et 
al., 2010).  
The second stage is cargo selection and involves the recruitment of the clathrin 
adaptor AP-2. AP-2 binds to PI(4,5)P2 in the membrane, the cytoplasmic domains of 
membrane proteins, and proteins of the initiation module (Collins et al., 2002, Kelly et 
al., 2008, Henne et al., 2010). AP-2 also recruits a plethora of clathrin accessory 
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proteins such as AP180, which help stabilise the coat, aid in the selective cargo 
recruitment process and help to induce membrane curvature (Schmid et al., 2006). 
Due to the fact that AP-2 binds the cargo, lipids, accessory proteins and clathrin it is 
the core part of the clathrin coat.  
The third stage is the assembly of the clathrin coat itself. Clathrin triskelia are recruited 
from the cytosol by AP-2. Clathrin binds to the flexible region of AP-2, and the 
accessory proteins AP180 and epsin (Kalthoff et al., 2002). Clathrin then polymerises 
to stabilise the coat and the membrane is curved further by the redistribution of 
curvature proteins like epsin to the edge of the clathrin coated pit (Tebar et al., 1996). 
Vesicle scission is the fourth stage in the process and requires the enzyme dynamin 
(Kosaka and Ikeda, 1983). Dynamin is recruited to the neck of the vesicle by BAR 
domain containing proteins such as amphiphysin, which aid in the curvature and 
formation of the vesicle neck (Wigge et al., 1997). Dynamin polymerises around the 
neck of the vesicle causing GTP hydrolysis and vesicle scission from the plasma 
membrane (Sundborger et al., 2011).  
The final stage in the process is the uncoating of the released vesicle and the fusion of 
the vesicle with the endosomal compartment. The clathrin coat is disassembled by the 
ATPase heat shock cognate 70 (HSC70), a J domain co-factor, and either auxilin in 
neuronal cells or GAK (G-associated kinase) elsewhere (Schlossman et al., 1984, 
Chappell et al., 1986, Ungewickell et al., 1995). Auxilin is recruited to the vesicle after 
scission by binding to the clathrin triskelia. This then recruits Hsc70 causing uncoating 
(Xing et al., 2010). The phosphatase synaptojanin is also thought to function in the 
uncoating process by modifying the phosphoinositide composition of the vesicle due to 
dephosphorylation of PI(4,5)P2, therefore causing the release of PI(4,5)P2 binding 
proteins such as AP-2 and AP180 (Chang-Ileto et al., 2011). The vesicle is then able to 
fuse with its target membrane delivering its cargo to the endosomal compartment. 
From here the membrane protein can be targeted for degradation in the lysosome via 
the late endosomal compartment. The cargo membrane protein can also be recycled 
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back to the plasma membrane via recycling endosomes or the TGN (Grant and 
Donaldson, 2009).  
Clathrin mediated endocytosis functions in the internalisation of membrane proteins 
involved in many physiological processes meaning that CME also plays a role in these 
processes. CME is key to synaptic vesicle recycling, which is highlighted by the 
abundance of AP-2/clathrin coated vesicles in brain samples.  
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Figure 2. The process of clathrin mediated endocytosis 
(A)A basic overview of clathrin mediated endocytosis. The cargo protein recruits the adaptor 
protein AP-2 as well as other clathrin accessory proteins. Clathrin is then recruited by AP-2 
forming clathrin coated pits. The coated pits are pinched off and traffic towards the early 
endosome where the vesicle is uncoated and then fuses with the early endosome. (figure 
modified from Grant and Sato (2006)). (B) The five steps of clathrin mediated endocytosis. 
Nucleation: FCH domain only proteins bind to PI(4,5)P2 rich membrane regions  and initiate 
clathrin coated pit formation by recruiting EPS15 and intersections that bind to and recruit 
AP-2. Cargo selection: AP-2 binds to the cytoplasmic domains of membrane proteins and 
recruits cargo specific adaptors that aid in the selection of membrane proteins. Coat 
assembly: AP-2 recruits clathrin triskelia which polymerise to form the characteristic clathrin 
lattice around the pit. Scission: Dynamin is recruited to the neck of the pit by BAR domain 
containing proteins where it polymerises and causes membrane scission via the hydrolysis 
of GTP. Uncoating: Auxilin in the clathrin coated vesicle recruits the ATPase heat shock 
cognate 70 (HSC70) which causes the disassembly of the clathrin coat. (C) The clathrin coat 
interaction network. The protein-protein interactions at each stage of CME. The main 
proteins are shown by central coloured circles. The diagram indicates the complexity of 
clathrin coat formation and uncoating. (Figures B and C from McMahon and Boucrot (2011)). 
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1.2.2.1 Clathrin 
Clathrin is the protein that forms the outer coat of vesicles in clathrin mediated 
endocytosis. It exists as triskelia which polymerise to form the clathrin lattice. The 
clathrin triskelion is made up of 3 heavy chains of approximately 190 kDa and three 
clathrin light chains of roughly 25 kDa. The heavy chains provide the support of the 
clathrin lattice and the light chains help to regulate the formation and the disassembly 
of the clathrin lattice (Liu et al., 1995). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The clathrin heavy chain can be separated into the N-terminal globular domain,  the 
alpha helical linker, ankle, distal, proximal, and trimerisation domains (Knuehl et al., 
2006). The N-terminal domain is a seven bladed beta propeller structure which binds to 
the clathrin box motifs of adaptor proteins such as AP-2 (Knuehl et al., 2006). The 
proximal domain of the clathrin heavy chain serves as the binding site for the light 
chain. Clathrin light chains contain charged amino acid residues that negatively 
regulate the assembly of the clathrin heavy chain by preventing the self-assembly at 
physiological pH caused by a conformational change in the clathrin heavy chain 
Figure 3. The structure of the clathrin triskelion 
The clathrin triskelion is composed of three heavy chains (blue) and three light 
chains (yellow). The heavy chain is composed of the terminal adaptor protein 
binding domain, the linker, ankle, distal and knee domains. The proximal 
segment contains the light chain binding domain. (Figure from Fotin et al. (2004)). 
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(Wilbur et al., 2010). This can be overcome by adaptor molecules through the 
alignment of the distal domain with the proximal domain from different triskelia (Greene 
et al., 2000). The distal domain of the heavy chain is thought to be key in the 
interaction with other clathrin triskelia and therefore in clathrin lattice assembly 
(Schmid, 1997).  
There are several different structures of the clathrin lattice. This variability is required 
for the function of the coats as they must be able to coat cargos of different shapes 
and sizes. Clathrin coats can range from the 28 triskelion mini coats and the 36 
triskelion hexagonal coats to extended hexagonal arrays (Fotin et al., 2004).  The 
clathrin triskelia are not able to form direct interactions with either cargo membrane 
proteins or the membrane itself (Knuehl et al., 2006). Instead clathrin is linked to the 
membrane and cargos by adaptor proteins.   
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1.2.2.2 Adaptor proteins  
Adaptor proteins are a group of proteins that act as a central hub in the formation of 
clathrin coated vesicles by acting as a bridge between the membrane, membrane 
cargos and the clathrin lattice. There are five main adaptor protein complexes which all 
localise to different intracellular compartments and aid in the membrane trafficking in 
distinct pathways (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The role of adaptor proteins in membrane trafficking. 
AP-1 localises to the TGN and recycling endosomes and is involved in 
the transport between them. AP-2 localises to the plasma membrane 
and is key to clathrin mediated endocytosis. AP-3 localises to 
endosomes and is involved in lysosomal- related organelle (LRO) 
biogenesis.  AP-4 localises to the TGN and is important in TGN to 
endosome transport. AP-5 localises to late endosomes however its 
function still remains largely unclear. (Figure adapted from Park and 
Guo (2014)). 
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The first two adaptor protein complexes (AP-1 and AP-2) are clathrin associated, 
whereas AP-4 and AP-5 are not. AP-3 is thought to be clathrin associated however this 
is not fully clear. AP-1 localises to the TGN and endosomes in a ADP-ribosylation 
factor (Arf1) and a phosphatidylinositol 4 phosphate (PI(4)P) dependent manner (Zhu 
et al., 1999).  AP-1 is known to mediate the bidirectional transport between the TGN 
and the recycling endosomes, and is thought to be involved in polarised cell sorting in 
epithelial cells (Bonifacino, 2014). AP-3 and AP-4 also localise to the TGN and/or 
endosomal membranes in an Arf1 dependent manner. AP-3 mediates the transport 
from tubular endosomes to late endosomes/lysosomes, and is involved in the 
biogenesis of lysosome-related organelles (LROs) (Baust et al., 2008, Peden et al., 
2004). AP-4 is primarily localised to the TGN and mediates transport from the TGN to 
endosomes in a clathrin independent manner. AP-4 is also involved in polarised cell 
sorting, and mutations in the AP-4 gene lead to progressive spastic paraplegia (Hirst et 
al., 2013). AP-5 is the most recently discovered adaptor, it localises to late endosomes 
and  also plays a role in progressive spastic paraplegia (Hirst et al., 2013, Hirst et al., 
2011). The primary focus of this thesis will be on the AP-2 adaptor protein complex 
involved in clathrin mediated endocytosis. 
 
 
 
 
Figure 5. The structure of the adaptor protein complexes 1-5 
All the adaptor protein complexes contain core, hinge and ear domains except 
AP-5 which lacks the hinge domain. The core domains are required for the 
membrane localisation and cargo binding whereas the hinge and ear domains 
bind accessory proteins. (Figure from Park and Guo (2014)).  
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1.2.2.2.1 AP-2 structure and function 
AP-2 localises to the plasma membrane where it plays a key role in clathrin mediated 
endocytosis. AP-2’s structure is similar to that of the other adaptors (Figure 5). All 
adaptors including AP-2 are hetrotetrameric protein complexes. AP-2 is composed of 
two large subunits of between 100 and 130 kDa known as the α and β subunits. AP-2 
also contains a medium sized subunit of about 50 kDa known as the µ subunit, as well 
as a small 17 kDa σ subunit. There is a high degree of homology between the β, µ and 
σ subunits of AP-2 and AP-1. The α subunit of AP-2 corresponds to the γ subunit of 
AP-1 both of which are more diverse (Edeling et al., 2006).  
AP-2 functions in CME by providing a link between the membrane, membrane proteins 
and clathrin. AP-2 interacts with several components of the clathrin coat complex. A 
comprehensive list of these coat components can be seen in McMahon and Boucrot 
(2011). AP-2 is recruited to the plasma membrane via three main interactions. AP-2 is 
able to bind to protein cargos within the membrane and to phospholipid head groups 
(Ohno et al., 1995). AP-2 is known to recognise the proteins of the nucleation complex 
such as FCH domain proteins, EPS15 and intersectins, required for the initialisation of 
clathrin coated pit formation (Henne et al., 2010). Both EPS15 and intersectin 1 and 2 
were found to directly bind the µ subunit of AP-2 (Henne et al., 2010). This interaction 
is one of three main interactions that helps recruit AP-2 to the plasma membrane. The 
second interaction is between AP-2 and the plasma membrane lipid PI(4,5)P2. AP-2 
binds to PI(4,5)P2 via basic residues at the N-terminus of the α subunit, and via lysine 
residues on the µ subunit (Collins et al., 2002). AP-2 recruitment to PI(4,5)P2 is initially 
thought to take place via the α binding site, and also a second binding site in the β 
subunit (Jackson et al., 2010). The binding of PI(4,5)P2 by the µ subunit is then thought 
to stabilise the interaction (Höning et al., 2005). This binding of PI(4,5)P2 by AP-2 
causes a conformational change in AP-2 from an inactive or locked form to an active or 
open form, allowing AP-2 to bind to the membrane protein cargo (Jackson et al., 2010, 
  31 
  
Kelly et al., 2014). The stabilisation of this open form of AP-2 occurs through the 
interaction of its µ subunit with PI(4,5)P2 and by the phosphorylation of Thr156 in the µ 
subunit by α-adaptin-associated kinase 1 (AAK1) (Höning et al., 2005). The 
stabilisation of the open form of AP-2 is also achieved by AP-2 binding to cargo 
proteins in the plasma membrane.  
AP-2 is known to recognise and bind to two different sorting motifs located in the 
cytoplasmic domains of membrane proteins. The tyrosine based motif YXXϕ (where ϕ 
can be F, I, L, M or V) is recognised by hydrophobic patches in the µ2 subunit of AP-2 
(Ohno et al., 1995). A second motif known as an acidic dileucine based motif 
[E/D]XXXL[L/I] is recognised by hydrophobic pockets in the σ subunit of AP-2  (Kelly et 
al., 2008). AP-2 has different binding affinities for each motif. It is thought that AP-2 
has a higher affinity for the tyrosine motifs than the dileucine motifs (Höning et al., 
2005). The binding of AP-2 to tyrosine motifs is enhanced and stabilised by the 
phosphorylation of Thr156 in the µ subunit, whereas dileucine based motifs bind to a 
different site (σ subunit) and binding is therefore not enhanced by this phosphorylation 
(Höning et al., 2005).  
Once bound to PI(4,5)P2 and cargo, AP-2 interacts with a number of accessory 
proteins via its appendage or ear domains. Cargo specific adaptor proteins bind AP-2 
via its appendage domains. These cargo specific adaptor proteins aid in the 
recruitment of specific receptors to AP-2, and are expressed in distinct cell types to 
confer tissue specificity, therefore allowing for a wide range of proteins to be recruited 
to clathrin coated vesicles (McMahon and Boucrot, 2011). An example of a cargo 
specific adaptor protein is ARH (autosomal recessive hypercholesterolemia protein). It 
is primarily expressed in the liver where it acts as a cargo specific adaptor for low 
density lipoprotein receptors (LDLRs) (He et al., 2002). AP-2 also binds the accessory 
proteins AP180/CALM (Drosophila/mammalian nomenclature) and synaptojanin. 
AP180 is brain specific whereas CALM is ubiquitously expressed. AP180 binds to the 
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alpha appendage domain of AP-2 (Praefcke et al., 2004). It also binds to PI(4,5)P2 and 
clathrin and functions in clathrin polymerisation, and is thought to regulate vesicle size 
(Ford et al., 2001). The lipid phosphatase synaptojanin is also recruited to the α 
appendage domain of AP-2 (Chang-Ileto et al., 2011). It is thought to modify the lipid 
composition of clathrin coated vesicles therefore aiding in the release of PI(4,5)P2 
binding proteins such as AP-2 and AP180 from the membrane (Haffner et al., 2000).  
The appendage domains of AP-2 are crucial for the interaction between AP-2 and 
clathrin. The N-terminal domain of the clathrin heavy chain contains a WD40 like β 
propeller domain (Ter Haar et al., 2000). WD40 domains are widespread and involved 
in protein-protein interactions in cell signalling and sorting. This clathrin N-terminal 
domain binds to the hinge domain of the β subunit of AP-2 (Ter Haar et al., 2000). 
Clathrin also binds to the appendage domain of the β subunit (Owen et al., 2000).  
AP-2 acts as a central point in the dynamic system that is the formation of clathrin 
coated vesicles in CME due to the number of interactions it forms with proteins of the 
clathrin complex. These interactions allow for the strict regulation of this crucial 
endocytic pathway.  
1.2.2.3 Clathrin mediated endocytosis and human disease 
Clathrin mediated endocytosis has been linked to several human diseases. The loss of 
function of any of the main components of CME results in embryonic lethality 
(Mitsunari et al., 2005). Many proteins of the CME machinery have been implicated in 
cancers. Mutations in clathrin and its adaptors EPS15 and CALM (AP180) have been 
linked to breast and lung cancers (Kan et al., 2010). However the link between these 
mutations and the development of the disease remains unclear. There have also been 
links between CME and neurodegenerative diseases. CME is known to be crucial for 
synaptic vesicle recycling, with any impairment in this process playing a role in 
neurodegenerative diseases such as Alzheimer’s disease (Yao, 2004). CME is also 
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important in the endocytosis of the amyloid precursor protein (APP), and therefore its 
processing to form amyloid beta, a key player in Alzheimer’s disease (Wu and Yao, 
2009). Mutations in the LDLR specific cargo specific adaptor ARH have been seen in 
autosomal recessive hypercholesterolemia (He et al., 2002). The process of CME is 
also exploited by several toxins, viruses and bacteria (Abrami et al., 2003, Rust et al., 
2004, McMahon and Boucrot, 2011).  
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1.3 Model membrane methods for examining the 
intracellular interactions of membrane proteins 
The formation of protein transport machinery provides a link between the secretory and 
endocytic trafficking pathways through their continuous movement and recycling. Their 
formation requires the recruitment of various cytosolic proteins to specific membrane 
domains within each trafficking organelle. These complexes aid the trafficking of 
membrane proteins at different intracellular compartments, which helps to maintain the 
identity of the specific trafficking organelles (Niehage et al., 2013). These trafficking 
proteins and protein coat complexes recognise and bind to specialist sorting motifs in 
the cytoplasmic domains of membrane proteins (Kurten, 2003). Therefore, the 
intracellular domains of membrane proteins are key to their function. They act as 
mediators between the membrane protein and cytosolic proteins. Many cytosolic 
proteins bind to the cytoplasmic domains of membrane proteins and help to relay 
signals or aid in the trafficking of the protein.   
1.3.1 Techniques for studying protein-protein interactions 
Due to the fact that the cytosolic binding partners of membrane proteins are vital in the 
function and trafficking of that membrane protein it is crucial that we develop ways to 
examine these interactions. There are several different methods previously used for 
examining protein-protein interactions. A selection of these include two-hybrid based 
systems, affinity chromatography and co-immunoprecipitation (Phizicky and Fields, 
1995). Two-hybrid systems are  genetic methods that utilise transcriptional activity as a 
measure of protein-protein interactions (Fields and Song, 1989). It works on the 
principle that many site-specific transcriptional activators contain a DNA binding 
domain and a transcription activation domain (Keegan et al., 1986). In order to 
examine protein-protein interactions a DNA binding domain is fused to one protein of 
interest and a transcription activation domain is fused to a second protein of interest. 
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Both of these hybrids are generally expressed in yeast cells, with expression in 
mammalian cells also possible. If the two proteins interact a functional activator is 
created by bringing the two domains (DNA binding and transcription activation 
domains) together which can be detected by the expression of reporter genes (Fields 
and Song, 1989). As this yeast two-hybrid system only allows for the detection of 
interactions between proteins localised to the nucleus a split ubiquitin assay was 
developed to detect protein-protein interactions elsewhere within the cell (Johnsson 
and Varshavsky, 1994). It relies on the fusion of the C-terminal fragment of ubiquitin to 
one protein and the N-terminal fragment of ubiquitin to a second protein, which if in 
close proximity, can be cleaved by ubiquitin specific proteases (Johnsson and 
Varshavsky, 1994). The two-hybrid systems can be used to screen libraries of 
activation domain hybrids to identify multiple interactors of a specific protein. The main 
weakness of two-hybrid systems is that there are a high number of false positives, 
estimated at 70% (Deane et al., 2002). This assay also relies on fusion proteins which 
may inhibit protein-protein interactions.  
Tandem affinity purification (TAP) coupled to mass spectrometry has also been 
previously used to study protein-protein interactions (Puig et al., 2001). It involves the 
fusion of a TAP tag to the C-terminus of the protein of interest. The TAP tag consists of 
a calmodulin binding peptide (CBP), a tobacco etch virus protease (TEV protease) 
cleavage site followed by Protein A. The fusion protein can be expressed in both yeast 
and mammalian cells. The cells are then lysed and the fusion complex isolated through 
the binding of Protein A of the TAP tag to an IgG matrix. The proteins are eluted 
through TEV protease cleavage of the TAP tag and analysed by mass spectrometry 
(Puig et al., 2001). The TEV protease can be removed by the binding of CBP to 
calmodulin resin. This technique allows for the detection of protein interactions without 
any prior knowledge of possible interactions. The use of a tag limits this technique as 
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the tagged protein may not bind sufficiently to the affinity resin or the tag may affect the 
function of the protein (Puig et al., 2001).   
Co-immunoprecipitation is the most commonly used method for detecting protein-
protein interactions. Essentially cell lysates are produced, antibody added, the bound 
antigen precipitated and washed, and the interacting proteins are eluted and can be 
analysed by several methods including SDS-PAGE and mass spectrometry (Moresco 
et al., 2010). Affinity purification can also be used for detecting protein-protein 
interactions. It involves the use of particular protein of interest fused to an affinity tag, 
such as a glutathione S-transferase (GST) tag. This can then be used to pull out 
interacting proteins from cytosol samples as well as from purified proteins. One 
advantage of using specific antibody rather than a fusion protein is that the native 
expression of the protein of interest is unaltered (Moresco et al., 2010). Limitations 
exist when using a tagged protein as the tag may interfere with protein-protein 
interactions. Also the use of polyclonal antibodies means that there may be non- 
specific binding leading to the production of false positives.  
These well-established techniques for examining protein-protein interactions have 
several limitations when investigating interactions of membrane proteins. Firstly, the 
majority of these techniques require the lysis of the cell, primarily through the use of 
detergents. These detergents disrupt binding; therefore weak protein-protein 
interactions that are functionally significant may not be detected. The disruption of the 
membranes is also not ideal when examining membrane protein interactions. The main 
drawback of these methods for examining membrane protein interactions is the fact 
that they do not take into account any interaction between both the membrane protein 
and cytosolic factors with membrane lipids, and therefore fail to detect physiologically 
relevant interactions that require an interaction with lipids.  
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The formation of protein complexes on the cytoplasmic domains of membrane proteins 
is aided by interactions between cytosolic proteins and membrane proteins with 
membrane lipids at specific domains of the organelle membrane. Phosphoinositides 
are a group of signalling lipids that play a crucial role in this process. They are tightly 
regulated by sets of specific kinases and phosphatases that reside on different 
secretory and endocytic compartments (Mayinger, 2012). It is this tight regulation of 
phosphoinositides that also helps in the maintenance of trafficking organelle identity 
(Krauss and Haucke, 2007). Phosphoinositides are recognised by several proteins 
involved in trafficking and aid in the assembly of trafficking machinery.  
The role played by phosphoinositides in the recruitment of cytosolic proteins to the 
membrane, their marking of organelle identity, and their role in membrane trafficking is 
vital. This needs to be taken into consideration when examining the cytosolic binding 
partners of membrane proteins. The inability of previous methods to take the native 
environment of a membrane protein into account when examining interactions, and the 
crucial role played by membrane lipids in these interactions, calls for the development 
of techniques that overcome these drawbacks.  A method has recently been developed 
to examine these interactions based on a model membrane system. Engineered lipid 
vesicles known as liposomes provide a membrane environment (Kinuta and Takei, 
2002). The biochemical and physical properties of liposomes can be controlled. This 
allows for the analysis of binding partners in vitro by mimicking the native environment 
of a membrane protein. 
1.3.2 A liposome based model membrane system 
Liposomes are engineered lipid vesicles and range in size from 50 nm to about 500 nm 
in diameter, and have previously been used to study the interaction between 
phospholipids and membrane proteins. They are produced by re-suspending a dry lipid 
film in an aqueous solution, followed by several flash freezing and thawing cycles. 
Liposomes of 50-200 nm in diameter are used in pharmacology as drug delivery 
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systems (Samad et al., 2007) and can be used for the biochemical analysis of the 
interaction between proteins and lipids (Walde et al., 2010).  
Liposome based systems have been used previously to examine the assembly of 
protein coats or parts of these coats. The use of protein-free liposomes to study the 
assembly of the clathrin coat complex is well characterised (Höning et al., 2005, Drake 
et al., 2000, Ford et al., 2001, Zhu et al., 1999). Recent advances now allow for the 
use of so called proteo-liposomes, whereby proteins can be covalently linked to these 
liposomes. Crottet et al. (2002) utilised liposomes presenting peptides containing 
tyrosine based sorting motifs, to examine the recruitment of the clathrin adaptor AP-1. 
This AP-1 recruitment was dependent on several factors including ARF1, GTP and the 
phosphoinositide PI(4,5)P2.  
Bourel-Bonnet et al. (2005) developed and synthesised a hydrazine based lipid anchor 
allowing for the covalent attachment of peptides in a single biologically relevant 
orientation, to the surface of liposomes. They validated this system by coupling the 
cytoplasmic domain of the lysosomal associated membrane protein (LAMP) to 
liposomes. The adaptor protein AP-3 was recruited from brain cytosol samples onto 
these liposomes, and recruitment was abolished when a single tyrosine residue in the 
cytoplasmic domain was substituted for alanine, indicating its importance in AP-3 
binding.  The development of lipid anchors allowing for the covalent attachment of 
peptides to liposomes was a major technical advance. The intracellular domain of 
membrane proteins can be presented in their native configuration. 
In 2006 Baust et al utilised a liposome based system to study the assembly of AP-1A 
protein coats required for transport between the secretory pathway, and the endosomal 
and lysosomal systems. The cytoplasmic tails of the gpI envelope glycoprotein of the 
Varicella zoster virus, and the lysosomal integral membrane protein Limp II were 
covalently coupled to the liposomes using a lipid anchor with an aldehyde-derived 
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head group, which reacted with a hydrazine group at the N-terminus of the peptides 
(Baust et al., 2006). The recruitment of the AP-1A coat from brain cytosol was 
analysed and approximatly 40 proteins were identified. It was found that the assembly 
of the coat triggered the recruitment of Rac1, the Wave/Scar complex, Rab11 and 
Rab14. The liposome technique was successfully used to examine the coordinated 
assembly of the AP-1A coat.  
Jackson et al. (2010) and Kelly et al. (2014) both utilised liposomes presenting a 
tyrosine based sorting motif peptide amongst other techniques to examine the 
assembly of the AP-2/clathrin coat. A large scale conformational change in AP-2 was 
observed, driven by its binding to PI(4,5)P2 and to cargo (tyrosine based motif peptide). 
This was necessary for the recruitment of clathrin and, therefore the formation of 
clathrin coated vesicles.  
In 2011 Pocha et al designed a liposome based system to establish that the retromer 
complex, important for mediating endosome to TGN trafficking, is an interaction partner 
of the apical determinant Crumbs (Crb) (Pocha et al., 2011).  Briefly the method 
involved the covalent coupling of the Crb2 intracellular domain to liposomes via a lipid 
anchor containing an activated maleimide head group. The intracellular domain of Crb2 
was expressed and purified from E. coli. The bacterial expression plasmid contained 
an N-terminal tandem affinity tag followed by a TEV protease cleavage site and a 
single cysteine residue to allow for the covalent coupling of the intracellular domain of 
Crumbs 2 to liposomes. These proteo-liposomes were incubated in brain cytosol to 
allow for the determination of interaction partners by mass spectrometry and western 
blotting. Using the liposome recruitment technique, Pocha et al. (2011) showed that the 
intracellular domain of Crb2 interacts with the Vps35 subunit of the retromer complex.  
This interaction was crucial for the trafficking of Crb2 (Pocha et al, 2011).  
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A powerful advantage of this liposome recruitment system is that a membrane context 
is provided for the cytoplasmic domain of a receptor. This allows for the assembly and 
isolation of intricate protein complexes and coats that require both the binding of the 
receptor to intracellular factors, as well as the binding to membrane lipid head groups. 
The main advantage of this liposome system over conventional protein-protein 
interaction techniques such as  yeast two hybrid and co-immunoprecipitation methods, 
is its increased sensitivity and specificity due to the membrane context provided 
(Pocha and Wassmer, 2011).  
The primary focus of this thesis will be on the use, validation and characterisation of a 
liposome recruitment system based on that by (Pocha et al., 2011) to examine novel 
intracellular interaction partners of a model membrane protein. The major protein that 
will be utilised as a model is the amyloid precursor protein known as APP.    
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1.4 The amyloid precursor protein as a model 
membrane protein 
The amyloid precursor protein or APP is a type 1 transmembrane protein best 
characterised for its role in Alzheimer’s disease. APP belongs to the APP family of 
proteins consisting of APP itself, and the APP-like proteins APLP1 and APLP2. The 
APP family members exhibit functional redundancy (Caldwell et al., 2013). 
Homologues of APP have also been identified in Drosophila, C. elegans and Xenopus 
(De Strooper and Annaert, 2000). The gene coding for APP lies on chromosome 21 
and contains 19 exons, of which exons 7, 8 and 15 can be alternatively spliced. This 
splicing leads to the production of 3 main isoforms of APP known as APP695, APP751 
and APP770. APP is ubiquitously expressed in mammalian cells with varying levels of 
expression of each isoform in different tissues and cell types (Tanzi et al., 1987, 
Wasco et al., 1992, Caldwell et al., 2013). APP695 is the predominant isoform in 
neuronal tissue whereas non-neuronal cells mainly express the APP751 and APP770 
isoforms (Kang et al., 1987) (de Silva et al., 1997).  
APP is a type 1 transmembrane protein characterised by its large extracellular domain 
and a relatively small intracellular domain. The structure and the potential functions of 
each APP domain are shown in figure 6. APP’s large ectodomain consists of a 
cysteine rich globular domain called E1, a helical domain known as E2, a 
transmembrane domain, and a C-terminal intracellular domain termed AICD. The 
longer APP isoforms also contain a Kunitz-type protease inhibitor (KPI) domain. The 
primary focus of previous research on APP has been on its processing by secretases, 
and the production of the amyloid beta (Aβ) peptide, a key contributor to amyloid 
plaques in the pathology of Alzheimer’s disease (Robakis et al., 1987).  
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1.4.1 APP processing and Alzheimer’s disease 
 
APP is a key player in the pathology of Alzheimer’s disease. Alzheimer’s disease is a 
neurodegenerative disease characterised by progressive memory loss and reduced 
cognitive function (DeKosky and Scheff, 1990). It is primarily a disease that occurs 
during the later stages of life (Rossor et al., 1984). However, mutations in the gene 
encoding APP are known to lead to a familial or early onset form of Alzheimer’s 
Figure 6. The structure and likely functions of APP. 
APP has a large ectodomain comprising of the E1, E2 and the KPI domains. The KPI 
domain is not found in the APP695 isoform. The transmembrane domain of APP can 
be cleaved by a number of secretases. The C-terminal domain of APP (AICD) is 
physiologically the most interesting domain due to its large number of binding partners. 
Figure from (Dawkins and Small, 2014). 
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disease, which can occur earlier in life (Goate et al., 1991, Murrell et al., 1991). The 
cleavage of APP by secretases is also known to play a major role in Alzheimer’s 
disease. Mutations in gamma secretase have been identified which also lead to a 
familial form of Alzheimer’s disease (Sherrington et al., 1995).  
Alzheimer’s disease is characterised by two main neuropathophysiological features; 
the presence of both amyloid plaques and neurofibrillary tangles (Lewis et al., 1987). 
Neurofibrillary tangles stem from the hyperphosphorylation of the microtubule 
associated protein Tau (Grundke-Iqbal et al., 1986). This hyperphosphorylation causes 
the aggregation of Tau as paired helical filaments, contributing to the neurofibrillary 
tangles (Augustinack et al., 2002). Amyloid beta (Aβ), formed by the aberrant cleavage 
of APP by secretases is the primary constituent of amyloid plaques, and plays a key 
role in the pathology of Alzheimer’s disease (O'Brien and Wong, 2011).  
 
 
 
 
Figure 7. The secretase processing of APP. 
Cleavage of APP first with α secretase and then γ secretase is thought to be 
non-amyloidogenic. The amyloidogenic cleavage of APP occurs with β and γ 
secretase cleavage releasing the amyloid beta (Aβ40, Aβ42) peptide which 
forms oligomers and is the main constituent of amyloid plaques. Figure 
adapted from Zhang (2012).  
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There are two different types of APP processing, which depend on two different sets of 
secretases. Non-amyloidogenic processing of APP occurs when it is first cleaved by α 
secretase between the 16th Lys and 17th Leu (residues 612 and 613 of APP). This 
cleaves APP in the Aβ sequence, therefore Aβ cannot be produced (hence non-
amyloidogenic pathway) (De Strooper and Annaert, 2000). ADAM-10 (a disintegrin and 
metalloproteinase 10) is thought to be one of the major α-secretases involved in APP 
processing, where it resides primarily on the plasma membrane, Golgi, and exocytotic 
transport vesicles (Sambamurti et al., 1992). Cleavage by α-secretase releases a 
soluble APPα ectodomain, and subsequent cleavage by γ-secretase releases the P3 
fragment and AICD. Only a small fraction of the APP pool is cleaved by α-secretase, 
which leaves most of APP as full length (Haass et al., 1992).  
The amyloidogenic processing of APP occurs when APP is first cleaved by β-secretase 
and then γ-secretase. As with α-secretase, β-secretase cleavage also occurs in 
physiological conditions, meaning all the fragments of APP produced by secretase 
cleavage, including the Aβ fragment, are part of the normal cellular process (Haass et 
al., 1992). BACE-1 (beta-site APP cleaving enzyme) is a type 1 integral membrane 
protein and is the most widely studied β-secretase candidate. BACE-1 cleaves APP at 
the N-terminus of the Aβ peptide, releasing the soluble APPβ fragment (Haass et al., 
1992). BACE-1 functions at a low pH and is thought to mainly reside in endocytic 
compartments such as endosomes and lysosomes, as well as the Golgi (Vassar et al., 
1999, Haass et al., 1995). After BACE-1 cleavage the C99 peptide of APP can then be 
further processed by γ-secretases. Presenilin-1 is a subunit of γ-secretase, and 
contains 8 transmembrane domains. γ-secretase is localised to several intracellular 
compartments including; the ER, Golgi, endosomes, autophagosomes and the plasma 
membrane. γ-secretases cleave APP at the C-terminal end of the Aβ sequence 
releasing Aβ and AICD (Haass and De Strooper, 1999). The released Aβ fragment can 
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form toxic oligomers aggregating in amyloid fibres, the main constituent of the amyloid 
plaques found in the brains of patients with Alzheimer’s disease.  
1.4.2 The function of APP and its intracellular domain AICD 
Despite the importance of APP in Alzheimer’s disease the physiological role of APP 
still remains largely unclear. This is partly due to previous research primarily focusing 
on the Aβ peptide itself. APP has been implicated in several physiological processes 
such as cell adhesion, proliferation and differentiation, as well as neurite outgrowth, 
synaptogenesis and synaptic plasticity (reviewed in (Zheng and Koo, 2011).  This 
section will briefly outline the role played by APP in these processes. 
1.4.2.1 APP and neurite outgrowth, synaptic plasticity and synaptogenesis 
Neurite outgrowth, synaptogenesis and synaptic plasticity are some of the 
physiological process APP is thought to be involved in. APP is known to promote 
neurite outgrowth in cell culture through its role in cell adhesion. APP binds to laminin, 
collagen type 1 and heparin sulphate, which all influence neurite outgrowth (Kibbey et 
al., 1993, Beher et al., 1996). APP is also thought to be involved in cell-cell adhesion. It 
is known to form homo- or hetero-dimers, with trans-dimerisation able to promote cell 
adhesion, as well as the binding of heparin sulphate to the E1 or E2 domains of APP 
(Soba et al., 2005, Dahms et al., 2010). APP is also thought to influence the activity of 
other cell adhesion molecules such as β1-integrin, and plays an important role in 
regulating adult hippocampal neurogenesis (Young-Pearse et al., 2008, Wang et al., 
2014a). 
APP is expressed at both pre and post synaptic sites during development, as is highly 
expressed during periods of synaptogenesis. Therefore it is thought to be involved in 
regulating synaptogenesis (Dawkins and Small, 2014). APP knock out mice show 
neurological defects like impaired locomotor activity, which may be explained by an 
effect on synaptogenesis (Zheng et al., 1995). APP knock out mice also show altered 
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synaptic function. Mice with double knock out of APP and APLP2 have impaired 
neuromuscular junction formation, observed by a reduction in synaptic vesicles and 
impaired synaptic transmission, which may be responsible for the lethality of the 
APP/APLP2 double knock out (Wang et al., 2005). APP is also thought to be involved 
in synaptic plasticity mainly by affecting synaptic calcium homeostasis. It is thought to 
alter the expression of the GluR2 subunit of the AMPA receptor, a regulator of synaptic 
calcium permeability (Lee et al., 2010). Aged knock out mouse models of APP show 
defects in long term potentiation (LTP), a persistent strengthening of synapses (Ring et 
al., 2007). Knock in (KI) mice of the soluble ectodomain of APP (APPsα) in an APLP2 
knock out background (APPsα-KI/APLP2-KO) survive to adulthood, unlike APP/APLP2 
KO mice. A reduction in LTP is also observed in APPsα-KI/APLP2-KO mice (Weyer et 
al., 2011). The data from these mouse models reveal that APP and APLP2 are 
important in the function and plasticity of central synapses (Korte et al., 2012).  
1.4.2.2 APP and cell signalling 
The structure of APP has led to the theory that APP acts as a receptor, and therefore 
has a potential role in cell signalling. Due to the similarity of the proteolytic processing 
of APP with that of the Notch receptor, APP has been proposed to function in cell 
signalling in a manner similar to Notch signalling (Nakayama et al., 2011). In Notch 
signalling the intracellular domain of Notch is cleaved by γ-secretases and is 
translocated to the nucleus where it is known to activate gene transcription. The 
intracellular domain of APP (AICD) is also translocated to the nucleus, where it is 
known to control gene expression (Cupers et al., 2001). This supports the theory that 
APP may function in a similar way to Notch. APP may also play a role in cell signalling 
via its binding to G-proteins, mediated by AICD. It is thought that binding of a ligand to 
the ectodomain of APP may result in signal transduction via activation of the GTP-
binding protein Gαo (Okamoto et al., 1995). Recently, the interaction of the insect APP 
homologue APPL with Gαo has been shown to be involved in the control of neuronal 
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migration (Ramaker et al., 2013).  In support of APP’s role in cell signalling its 
homologue APPL in Drosophila was shown to be involved in wnt/planar cell polarity 
signalling (Soldano et al., 2013).  
The intracellular domain of APP is known to be key to the function of the protein, and in 
its role as a cell signalling molecule. APP cleavage by secretases releases AICD which 
is known to translocate to the nucleus, where it has a role in gene expression. AICD is 
able to bind to Fe65 via the YENPTY motif at the C-terminus of AICD  (Fiore et al., 
1995). Fe65 contains two phosphotyrosine binding (PTB) domains, and binds to AICD 
via PTB2, the binding of which is thought to stabilise AICD (Beckett et al., 2012). Fe65 
interacts with the histone acetyltransferase tat-interactive protein (Tip60) via PTB1, and 
together with AICD are delivered to the nucleus by dynamin mediated retrograde 
trafficking, where they affect gene expression (Beckett et al., 2012). AICD is reported 
to affect the expression of several different genes including APP itself, BACE-1, Aβ-
degrading enzyme neprilysin (NEP) and epidermal growth factor receptor genes (von 
Rotz et al., 2004, Pardossi-Piquard et al., 2005, Belyaev et al., 2009, Zhang et al., 
2007a). AICD, via its YENPTY motif is also known to bind to mDAB-1 which, when 
phosphorylated, is able to recruit kinases such as Src therefore providing a link 
between APP and phosphorylation dependent signalling pathways (De Strooper and 
Annaert, 2000).  
APP has been linked to a wide variety of physiological functions and is probably one of 
the most well studied proteins. Despite this there is still currently no molecular model 
available for exactly how APP is involved in neurite outgrowth, synaptic plasticity, and 
synaptogenesis, and how it functions as a cell signalling molecule. This is primarily due 
to the lack of understanding of how APP can regulate such a wide variety of 
processes.   
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1.4.3 APP trafficking 
Intracellular trafficking is known to play a key role in the pathophysiology of Alzheimer’s 
disease. Intracellular trafficking is important in maintaining normal neuronal function. Of 
particular importance in neurones is the endocytic pathway, required for synapse 
function. In Alzheimer’s disease there is thought to be a hyper activation of the 
endocytic pathway, as evidenced by the increased size and volume of neuronal 
endosomes in Alzheimer’s disease brain samples (Nixon et al., 2000). The exact 
location of Aβ production is debated.  It is thought to primarily occur in endosomal and 
lysosomal compartments and depends on the location of γ-secretase. The 
accumulation of Aβ disrupts the integrity of the lysosomal membrane (Yang et al., 
1998, Tam et al., 2014). Lysosomal exocytosis of Aβ has also been shown to be 
important in Alzheimer’s disease mouse models, with deficiency of the lysosomal 
sialidase NEU1 leading to an amyloidogenic type process (Annunziata et al., 2013). 
 
As APP is a type 1 transmembrane protein, the trafficking of APP is crucial to its 
function. APP is produced in the ER and processed in the Golgi. It undergoes several 
post translational modifications such as glycosylation, and phosphorylation and 
ubiquitination of its intracellular domain (Watanabe et al., 2012, Acevedo et al., 2014, 
Oishi et al., 1997). It is then trafficked to the plasma membrane where it can be 
processed by α-secretase, releasing the ectodomain (Groemer et al., 2011). Figure 8 
shows an overview of the trafficking of APP. APP is also known to traffic directly from 
the TGN to lysosomes in an AP-3 dependent manner. It is then rapidly degraded which 
is in line with the fact APP turnover is thought to be quite rapid (Tam et al., 2014). The 
trafficking of APP from the Golgi is also thought to be mediated by the adaptor Mint3 
(Caster and Kahn, 2013). Mint proteins are implicated in the localisation of proteins to 
the plasma membrane. They are able to bind ARFs and regulate the trafficking of APP 
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from the Golgi (Hill et al., 2003). The adaptor protein AP-4 has also been implicated in 
the TGN-to-endosome transport of APP (Burgos et al., 2010).  
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  Figure 8. APP, BACE-1 and γ-secretase  trafficking pathways 
APP (blue bars) is internalised by clathrin mediated endocytosis whereas 
BACE-1 (red bars) is endocytosed by a ARF-6 dependent pathway. Both 
APP and BACE-1 are sorted into early endosomes where APP can be 
cleaved producing the βCTF which is a substrate for γ secretase, producing 
AICD which can be translocated to the nucleus and Aβ. Aβ (pink bar) is 
sorted in multivesicular bodies and secreted via exosomes. APP retrieval 
from the early endosomes to the TGN is mediated by the retromer complex. 
γ secretase (purple lines) is produced and processed in the ER and Golgi 
and then transported to the plasma membrane and endosomes. The red 
membrane areas represent lipid raft domains. Figure from Rajendran and 
Annaert (2012).  
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Intracellular trafficking is important in the processing of APP as it is required for the 
correct localisation of not only APP but the β and γ-secretases also (Figure 8). In order 
for Aβ generation APP and the two secretases need to be trafficked to the endosomal 
compartments. The trafficking of these proteins regulates their intracellular localisation, 
and therefore the processing of APP and the production of Aβ (Rajendran and Annaert, 
2012).   
 
The intracellular domain of APP (AICD) is crucial for the trafficking of APP. The 
YENPTY motif of AICD is completely conserved from C. elegans to humans, and 
contains the tyrosine based sorting motif recognised by many adaptor proteins 
involved in membrane trafficking (King and Turner, 2004).  This domain is important for 
the clathrin mediated endocytosis of APP. The YENPTY motif of AICD contains a 
tyrosine based sorting signal, and is recognised by clathrin adaptor proteins such as 
AP-2 that help regulate clathrin dependent endocytosis (King and Turner, 2004). 
Deletion of AICD and the YENPTY motif impairs the internalisation of plasma 
membrane APP, and decreases Aβ secretion by stopping the processing of APP in 
endocytic compartments (Leblanc and Gambetti, 1994, Essalmani et al., 1996). AICD 
also contains the motif YxxI at its N-terminus. Deletion of this motif does not affect 
internalisation but does affect the sorting of APP in polarised epithelial cells (Zheng et 
al., 1998). Both the YENPTY and YxxI motifs are required for the rapid degradation of 
full length APP in the lysosome (Lai et al., 1998). Clathrin is also required for the 
endocytosis of the β-secretase BACE-1. Mutation of the sorting motif in BACE-1, AP-2 
or clathrin decreases the endosomal localisation and increases the plasma membrane 
localisation of BACE-1 (Prabhu et al., 2012). The clathrin adaptor CALM/AP180 
(human/Drosophila nomenclature) is also thought to play a role in the pathophysiology 
of Alzheimer’s disease (Ando et al., 2013). Taken together this demonstrates the 
importance of clathrin mediated endocytosis in the processing of APP.  
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The trafficking of APP from the endosomes to the TGN is also important in APP 
processing.  The APP binding and sorting protein SorLA is known to be decreased in 
Alzheimer’s disease (Rogaeva et al., 2007, Dodson et al., 2006). SorLA is a part of the 
mammalian family of vacuolar protein sorting 10 (VPS10) containing proteins, and acts 
as a retromer binding receptor (Seaman, 2004, Nielsen et al., 2007). The retromer is a 
multi-subunit complex important for regulating the endosome to TGN transport of 
membrane proteins such as the mannose 6-phosphate receptor (Arighi et al., 2004, 
Seaman, 2004). The retromer is composed of two distinct sub complexes. The cargo 
selective sub complex contains the vacuolar sorting proteins (VPS) 35, 29 and 26 with 
VPS35 binding to the cytoplasmic domains of membrane proteins. VPS35 also 
interacts with the sortin nexins (SNX) 1 and 2 of the membrane binding subcomplex. 
SNX1 and 2 interact with SNX5 and 6 and bind to phosphoinositides via their PX 
domain (Seaman, 2004, Seaman, 2005, Bonifacino and Hurley, 2008, Wassmer et al., 
2007, Wassmer et al., 2009). The retromer subunit VPS35 co-localises with APP 
positive vesicular structures (Bhalla et al., 2012). Loss of VPS35 causes an increase of 
APP in endosomes and a decreased half-life of APP (Bhalla et al., 2012). The 
phosphorylation of APP at S655 in the YTSI (YxxI) motif of AICD enhances retromer 
mediated retrieval from endosomes (Vieira et al., 2010). The hemizygous deletion of 
VPS35 in a mouse model of Alzheimer’s disease was shown to accelerate the 
Alzheimer’s disease neuropathophysiology (Wen et al., 2011). The transport of the β-
secretase BACE-1 from the endosomes to the TGN is also retromer dependent. Both 
SNX6 and VPS35 have been shown to interact with BACE-1 and control its retrieval 
from endosomes (Sullivan et al., 2011, Small et al., 2005). Loss of VPS35 reduces the 
retrieval of both APP and BACE-1 back to the TGN, meaning there is an increase of 
both in endosomes, leading to an increase in Aβ levels and the enlargement of 
endosomes (Bhalla et al., 2012).  
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This highlights the importance of trafficking pathways in Alzheimer’s disease, in 
particular in the transport of APP. It suggests that the pathogenesis of Alzheimer’s 
disease may at least, in part, be caused by the impaired transport of proteins from the 
endosomes to the TGN. Clathrin mediated endocytosis also plays a crucial role in 
Alzheimer’s disease. Both of these transport pathways have the potential to be future 
therapeutic targets. The pathophysiology of Alzheimer’s disease is highly complex. The 
main focus of previous research has been on disease causing mutations and Aβ, 
rather than understanding the physiological roles of proteins such as full length APP.  
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1.5 The PIKfyve complex 
The retromer dependent trafficking of APP from the endosomes to the TGN is 
important for APP function, processing and the production of Aβ. The PIKfyve complex 
is another protein complex, and like the retromer it is implicated in endosome to TGN 
transport amongst other functions. The PIKfyve complex is a multimeric protein 
complex that catalyses the conversion of the endosomal signalling lipid PI(3)P to 
PI(3,5)P2.  
1.5.1 Phosphoinositides 
PI(3)P and PI(3,5)P2 belong to a group of signalling lipids known as phosphoinositides, 
minor constituents of phospholipid bilayers. Phosphoinositides derive from 
phosphatidylinositol (PI) and differ only in the phosphorylation of the inositol ring. PI is 
produced in the ER, and its phosphorylation is known to occur at many intracellular 
organelles, giving rise to distinct intracellular phosphoinositide pools, specific to 
different intracellular compartments (Cockcroft and De Matteis, 2001). Levels of 
phosphoinositides at these compartments are tightly regulated by specific sets of 
phosphoinositide kinases and phosphatases.  
PI(4,5)P2 is probably the most well characterised phosphoinositide. It is primarily 
localised to the plasma membrane where it acts as a precursor for soluble and 
membrane bound secondary messengers in signal transduction, and lipid signalling 
pathways. PI(4,5)P2 can be hydrolysed to produce the secondary metabolites diacyl-
glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), by phospholipase C (PLC) 
enzymes, which are activated through ligand binding to G protein-coupled receptors 
(GPCRs) (Taylor et al., 1991). DAG remains bound to the plasma membrane where it 
activates protein kinase C (PKC), stimulating its translocation from the cytosol to the 
plasma membrane (Berridge, 1984). DAG can be phosphorylated to form phosphatidic 
acid (PA), which interacts with CTP (cytidine triphosphate) to form the cytidine 
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diphosphate diacylglycerol that replenishes PI, along with inositol (Berridge, 1984). IP3 
is soluble, and diffuses through the cytoplasm to the ER, where it binds to the IP3 
receptor on ligand gated calcium channels, triggering the release of calcium into the 
cytoplasm (Ferris and Snyder, 1992). It is also recycled back to inositol, required for 
the re-synthesis of PI, through an inositol phosphatase cycle (Berridge, 1984). The 
production of second messengers is described as the canonical function of PIs 
(Payrastre et al., 2001). Phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) and 
phosphatidylinositol-3,4,5-tiphosphate (PI(3,4,5)P3) are signalling molecules produced 
in response to extracellular stimuli. They activate Akt, and are involved in cell survival 
and proliferation (Alessi et al., 1997).  
Phosphoinositides are important in membrane trafficking events. Different 
phosphoinositides are localised to distinct intracellular compartments, and are 
described as markers for organelle identity, due to their ability to recruit proteins to 
specific intracellular compartments (Munro, 2002). These proteins contain protein 
modules that bind specific phosphoinositides (PIBMs), including the pleckstrin 
homology (PH) domain, the Fab1, YPTB, Vac1 and EEA1 (FYVE) domain, the phox 
homology (PX) domain, the epsin amino-terminal homology (ENTH) domain  and the 
band 4.1, ezrin, radixin and moesin (FERM) domain (Cullen et al., 2001). Some 
phosphoinositide binding proteins are able to interact with small GTPases from the Ras 
protein superfamily, such as Arf and Rab GTPases (Behnia and Munro, 2005). 
Together, phosphoinositides, phosphoinositide binding proteins, and these GTPases 
help control the recruitment of proteins to membranes that are involved in membrane 
trafficking (Mayinger, 2012) PLCδ1 contains a PH domain that binds to PI(4,5)P2, 
causing its translocation to the plasma membrane (Stauffer et al., 1998). PI(4,5)P2 can 
be produced from PI(4)P, PI(3,4,5)P3 and PI(5)P by PI(4)P 5-kinases, PTEN and 
PI(5)P 4-kinases respectively (Rameh et al., 1997). PI(4,5)P2 plays a crucial role in 
clathrin mediated endocytosis, described earlier in this chapter. As well as serving as a 
precursor for PI(4,5)P2, PI(4)P is localised to the Golgi where it is important in 
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controlling exit from the Golgi to both the plasma membrane and the yeast vacuole (De 
Matteis et al., 2002). 
Yeast VPS34 and its mammalian orthologue are phosphoinositide 3-kinases and 
phosphorylate PI to produce PI(3)P (Schu et al., 1993). PI(3)P is localised to the early 
endosome membrane where it is crucial for endocytic trafficking. The FYVE domain of 
EEA1 binds to PI(3)P. EEA1 interacts with the active GTPase Rab5, and helps to 
stimulate endosome fusion (Simonsen et al., 1998). The yeast protein Vam7p contains 
a PX domain that binds to PI(3)P, which is important for vacuolar sorting (Cheever et 
al., 2001). PI(3)P is also bound by the PX domain of the sorting nexin SNX3. This 
interaction is important for the targeting or proteins, including the transferrin receptor, 
to endosomal compartments, and in doing so enables SNX3 to regulate the structure 
and function of endosomes (Xu et al., 2001).  
PI(3)P serves as the precursor to PI(3,5)P2, a crucial regulator of late endosome 
dynamics, in a reaction catalysed by the PI(3)P 5-kinase PIKfyve/fab1 
(mammalian/yeast nomenclature) (Dove et al., 1997, Whiteford et al., 1997, Gary et al., 
1998).  
1.5.2 PIKfyve structure  
The PIKfyve complex was first discovered in yeast and is made up of three main 
proteins; the Fab1/PIKfyve kinase, a scaffold protein known as Vac14/ArPIKfyve and 
the phosphatase Fig4/Sac3 (yeast/mammal nomenclature).  
The PIKfyve complex is found in all eukaryotic cells studied to date. It was first 
discovered in hyperosmotically stressed yeast, that increased Fab1 (yeast PIKfyve 
homologue) activity, and lead to an increase in the levels of PI(3,5)P2 (Dove et al., 
1997). Vac14 was also discovered to be important in this increase of PI(3,5)P2 . This 
increase showed that PI(3,5)P2 plays an important role in osmotic stress by regulating 
the vacuolar volume  (Bonangelino et al., 2002, Cooke et al., 1998).  
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The first stage in the assembly of the PIKfyve complex is the multimerisation of the 
scaffolding adaptor protein Vac14 (Alghamdi et al., 2013). Vac14 and PIKfyve have 
been shown to physically associate in mammalian cells giving rise to the name 
ArPIKfyve (associated regulator of PIKfyve), with Vac14 required for the PIKfyve 
dependent production of PI(3,5)P2 (Sbrissa et al., 2004, Bonangelino et al., 2002, Jin et 
al., 2008). Vac14 is composed almost entirely of HEAT repeats (17 in human Vac14) 
that help mediate protein-protein interactions (Dove et al., 2002, Jin et al., 2008). 
HEAT repeat containing proteins primarily function as scaffolds with several binding 
partners. Vac14 is the scaffold for Fig4 and PIKfyve of the PIKfyve complex (Jin et al., 
2008). Vac14 is known to form a homodimer through its conserved C-terminal domain 
(Sbrissa et al., 2008, Alghamdi et al., 2013).  The Vac14 homodimer then binds to the 
C-terminus of the phosphatase Fig4 via the same C-terminal fragment required for 
Vac14 homodimerisation.  This sub-complex is independent of PIKfyve, and likely 
catalyses the Fig4 dependent dephosphorylation of PI(3,5)P2  to PI(3)P (Sbrissa et al., 
2008, Rudge et al., 2004).This sub-complex then binds to PIKfyve and is required for 
PIKfyve’s kinase activity (Ikonomov et al., 2009a). 
Figure 9. The structure  and formation of the PIKfyve complex. 
The phosphatase of Fig4 binds to a homodimer of Vac14, which in turn binds to the 
Cpn160_TCP1 domain of PIKfyve via  HEAT repeats at the N-terminus of Vac14. 
The N-terminal FYVE domain of PIKfyve binds to PI(3)P on endosomal 
membranes. The PIKfyve complex then catalyses the conversion of PI(3)P  to 
PI(3,5)P2. Figure adapted from (Ikonomov et al., 2009a).  
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PIKfyve contains an N-terminal FYVE domain that binds to PI(3)P, followed by a DEP 
(Dishevelled, EG110 and Pleckstrin) domain, only found in the molecules of higher 
eukaryotes, and is absent from yeast and plant PIKfyve, with its function largely 
unknown (Shisheva, 2008). Following this is the Cpn60_TCP1 (HSP chaperonin_T-
complex protein 1) domain that is thought to mediate several interactions, and is 
important for PIKfyve’s kinase activity (Shisheva, 2008). PIKfyve contains a C-terminal 
kinase domain responsible for its catalytic activity. The Vac14/Fig4 subcomplex binds 
to the CPn60_TCP1 domain of PIKfyve, which is bound to PI(3)P via the FYVE 
domain. This binding induces a conformational change in PIKfyve, stabilising the 
complex interaction. The C-terminus of PIKfyve also aids in stabilising the complex 
(Ikonomov et al., 2009a). The formation of this PAS (PIKfyve, ArPIKfyve, Sac3) 
complex is required for the kinase activity of PIKfyve and, therefore the production of 
PI(3,5)P2. Interestingly Fig4 is required for PIKfyve activation and is also catalytically 
active within the PAS complex (Ikonomov et al., 2009a). This demonstrates that the 
PAS complex contains proteins with antagonistic effects, which are both required for 
PI(3,5)P2 production, indicating that the complex is able to tightly regulate PI(3,5)P2 
production and turnover.  
1.5.3 PIKfyve function 
The PIKfyve complex is expressed in all tissues which implies that it is vital in normal 
physiology (Zhang et al., 2007b). PIKfyve is both cytosolic and membrane bound, 
however, the membrane association of PIKfyve is key to its function (Ikonomov et al., 
2009a). Membrane associated PIKfyve is found in compartments of the endocytic 
pathway. It is associated with the endosomal system, and localises to early and late 
endosomes/lysosomes, and multivesicular bodies (MVB), depending on cell type, 
protein expression level, and the rate of PI(3)P to PI(3,5)P2 conversion (Shisheva, 
2008). The primary role of PIKfyve is as a lipid kinase, catalysing the 5’ 
phosphorylation of PI(3)P to PI(3,5)P2, aided by Vac14 and Fig4. PI(3,5)P2 produced 
  59 
  
by PIKfyve can be dephosphorylated by myotubularin related protein 3 (MTMR3) to 
produce PI(5)P, therefore implicating PIKfyve in the production of PI(5)P as well as 
PI(3,5)P2  (Zolov et al., 2012) (Oppelt et al., 2013). Although PIKfyve’s primary function 
is as a lipid kinase it is also known to have protein kinase activity (Ikonomov et al., 
2003).  
1.5.2.1 PIKfyve’s primary function in membrane trafficking 
The PIKfyve complex is involved in the transport of membrane proteins in and out of 
the endosomal system (Figure 10).  PIKfyve’s role in the endosomal system was first 
indicated by an enlarged yeast vacuole, and vacuolation in mammalian cells upon 
deletion of any of the three components of the PIKfyve complex (Dove et al., 2009, 
Shisheva, 2008). This vacuolation is thought to be due to a drop in PI(3,5)P2  levels 
caused by decreased synthesis (Ikonomov et al., 2002a). These vacuoles are derived 
from late endosomal pathway compartments in lower organisms, such as yeast. The 
identity of these vacuoles in mammalian cells is still up for debate. However, the 
common consensus is that these vacuoles co-localise with late endosomal/lysosomal 
markers, as well as a degree of co-localisation with early endosomal markers 
(Rutherford et al., 2006, Ikonomov et al., 2006). This points towards the fact that they 
are likely derived from endosomal structures and the preference for which endosomal 
compartment depends on the cell type (Shisheva, 2008).  
In yeast, a molecular defect that contributes to the swollen vacuole phenotype 
observed in fab1∆ cells, is that the retrieval of membrane proteins from the vacuole is 
PI(3,5)P2  dependent. In cells lacking PI(3,5)P2 failure in recycling out of the vacuole 
might contribute to the enlargement of the vacuolar membrane (Dove et al., 2004).  
In mammalian cells the mechanism contributing to vacuole formation is less clear.  
Endosome-to-TGN transport was found to be impaired upon the depletion of PIKfyve 
(Rutherford et al., 2006). This suggests that the PIKfyve catalysed conversion of PI(3)P 
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to PI(3,5)P2  is required for the exit of membrane proteins from the endosomes (see 
figure 10). The trafficking from endosomes to the TGN occurs through endosomal 
transport intermediates, which are either carrier vesicles or maturing endosomes with 
distinct characteristics. PIKfyve has been shown to stimulate the formation of transport 
intermediates from early endosomes, and that this function of PIKfyve in endosome 
fusion and fission may play a role in the increase in endosome size observed upon 
PIKfyve inhibition (Sbrissa et al., 2007, Ikonomov et al., 2006). 
Evidence for the role of PIKfyve in endosome-TGN transport also stems from the fact 
PIKfyve was found to phosphorylate the transport factor protein p40 (Ikonomov et al., 
2003). p40 interacts with Rab9 and stimulates the late-endosome to TGN transport of 
the cation-independent mannose 6 phosphate receptor (CI-MPR) (Díaz et al., 1997). 
PIKfyve is linked to the retromer dependent endosome-TGN transport. The SNX1 and 
SNX2 subunits of the retromer complex bind in vitro to both PI(3)P and PI(3,5)P2  
(Carlton et al., 2004). Rutherford et al. (2006) found that PIKfyve regulates the 
endosome-to-TGN transport of the CI-MPR, whereas the internalisation and recycling 
of the EGF and transferrin receptors was unaffected by PIKfyve suppression. These 
results all support a role for PIKfyve in endosome to TGN trafficking. 
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Figure 10. The trafficking processes of the PIKfyve complex 
The PIKfyve complex is required for transport out of endosomes. It 
effects the exit from endosomes via several different routes (purple 
arrows). PIKfyve binds to PI(3)P in the early endosomal membrane 
catalysing its conversion to PI(3,5)P2 causing the 
formation/detachment of endosomal transport vesicles. Sac3 is then 
though to dephosphorylate PI(3,5)P2 allowing for endosomal fusion. 
This process is likely to occur on other PI(3)P containing 
compartments such as the MVB. Figure from (Shisheva, 2008). 
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PIKfyve is thought to be implicated in endosomal processes other than endosome-to-
TGN transport. PIKfyve is also linked to the sorting of membrane proteins into the 
intraluminal vesicles of the MVB, required for the degradation of these proteins in the 
lysosome (Shisheva, 2008, Dove et al., 2002). This process is controlled by the 
ESCRT protein complexes 0, I, II and III which act sequentially on the inclusion of 
cargo into the MVB (Wollert and Hurley, 2010). In yeast impaired Fab1 causes an 
increase in vacuole size, and a decrease the hydrolytic activity of the vacuole, partly 
caused by defects in the acidification of the vacuole lumen (Odorizzi et al., 2000). 
Impaired Fab1 function also inhibits the degradation of some proteins, including the 
type 2 transmembrane protein carboxypeptidase S (CPS), a vacuolar hydrolase 
(Odorizzi et al., 1998). Fewer intraluminal vacuolar vesicles are observed in yeast with 
impaired Fab1 activity, which may contribute to the enlargement of the vacuole, 
through the delivery of additional membrane to the vacuole surface (Downes et al., 
2005, Odorizzi et al., 2000). PIKfyve is known to interact with the mammalian VPS4 
orthologue SKD1 which catalyses the dissociation of the ESCRT complexes from the 
endosomes. The expression of a catalytically inactive dominant negative form of SKD1 
also causes the formation of cytoplasmic vacuoles as observed with PIKfyve inhibition 
(Ikonomov et al., 2002b). The fact that PI(3,5)P2 and therefore PIKfyve may be 
involved in degradative sorting downstream of ESCRT is also supported by the binding 
of the VPS24 ESCRT III subunit to PI(3,5)P2 (Whitley et al., 2003). This provides 
another mechanism by which PIKfyve may influence endosome dynamics.  
These findings support the role of PIKfyve and therefore PI(3,5)P2 in endosomal 
system where PIKfyve catalyses PI(3,5)P2 production. This production of PI(3,5)P2 
regulates endosomal processing and membrane protein transport, in both endosome 
to TGN transport, and trafficking through late endocytic compartments.  
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1.5.4 PI(3,5)P2 and its effectors 
In order to further investigate the function of PIKfyve and PI(3,5)P2, particularly in 
endosomal homeostasis, PI(3,5)P2  effectors need to be identified. PI(3,5)P2  is of low 
abundance in both yeast and mammalian cells, in mammalian cells; it represents 
between 0.04-0.08% of total phosphoinositides (Whiteford et al., 1997). This low 
abundance has not only led to difficulties in detecting intracellular PI(3,5)P2, but also in 
the establishment of PI(3,5)P2 effectors. Despite this, several PI(3,5)P2 effectors have 
recently been identified. One of the first established effectors was the yeast protein 
ATG18 (also known as SVP1), isolated from a screen of swollen vacuole phenotypes 
(Dove et al., 2004). ATG18 is a member of PROPPIN (β-propellers that bind 
phosphoinositides and epsins) and its deletion leads to a swollen vacuole in yeast. 
ATG18 binds to PI(3,5)P2  in the vacuole membrane of yeast, where it exerts inhibitory 
control of Fab1 (Dove et al., 2009, Dove et al., 2004). ATG18 and its mammalian 
orthologues (WIPI’s) also function in autophagy. Autophagy in yeast does not require 
Fab1 and PI(3,5)P2  (Dove et al., 2009). However, in Drosophila Fab1 is required for 
autophagy (Rusten et al., 2007). It appears to be required for the fusion of 
autolysosomes with the late endosome (Dove et al., 2009). There is now also evidence 
that PI(3,5)P2  plays an important role in autophagy in the mammalian nervous system, 
where mutations in Fig4 and Vac14 cause the accumulation of autophagy 
intermediates in the brain and spinal cord of mice (Ferguson et al., 2009).  
Another recently established PI(3,5)P2  effector is the mucolipin transient receptor 
potential channel (TRPML-1). TRPML-1 belongs to a family of calcium permeable 
cation channels that are localised to both the plasma membrane, and the membranes 
of intracellular organelles. TRPML-1 is localised to endosomes where it binds to 
PI(3,5)P2  causing channel activation, and the release of calcium from the lumen of the 
endosomes into the cytosol (Dong et al., 2010, Bach et al., 2010). Interestingly 
deficiency of TRPML-1 causes an enlargement of the endosomes/lysosomes similar to 
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those observed upon PI(3,5)P2 deficiency (Dong et al., 2010). This enlargement is due 
to impaired calcium release from the endosomal lumen.  This finding suggests that 
TRPML-1 is involved in the regulation of membrane trafficking in the late endocytic 
pathway by linking the level of PI(3,5)P2 with the release of calcium, which controls 
membrane fusion and fission (Dong et al., 2010).  
PI(3,5)P2  provides a link between the PIKfyve complex and the mammalian target of 
rapamycin complex 1 (mTORC1). mTORC1 is a protein kinase that is controlled by 
insulin, amino acids and growth factors. Insulin, amino acids and growth factors also 
increase PI(3,5)P2 levels in 3T3-LI adipocytes (Bridges et al., 2012). Knock out of 
components of the PIKfyve complex, prevented the stimulation of the ribosomal protein 
S6 kinase, which requires mTORC1, and reduced mTORC1 localisation to the plasma 
membrane. It was found that the Raptor subunit of mTORC1 is a PI(3,5)P2  effector 
and binds to PI(3,5)P2 via its β-propeller domain (Bridges et al., 2012). The localisation 
of mTORC1 to lysosomes is required for mTORC1 activation in response to amino 
acids. Jin et al. (2014) showed that PI(3,5)P2 is required for TORC1 activity in yeast, 
and for its localisation to the yeast vacuole, the equivalent of the mammalian 
lysosome. The yeast homologue of S6 kinase (Sch9) is recruited to the vacuole by 
PI(3,5)P2, where it can be phosphorylated by TORC1. PI(3,5)P2  is required for several 
downstream pathways by TORC1 dependent phosphorylation.  Taken together these 
results assign another role to PI(3,5)P2 in that it is required for the mTORC1 dependent 
input of nutrient signals.  
1.5.5 PIKfyve and PI(3,5)P2 in neurodegeneration 
PI(3,5)P2  and the PIKfyve complexes are thought to play crucial roles in neurons and 
at synapses, although the mechanisms remain elusive. Vac14 is concentrated at 
excitatory synapses, which suggest a possible role for PI(3,5)P2  in synapse formation 
and plasticity (Zhang et al., 2012). PI(3,5)P2 levels are known to increase during 
synaptic depression (McCartney et al., 2014b).  PIKfyve is known to be involved in the 
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trafficking, in particular, the endocytosis and recycling of the GluA1 and GluA2 subunits 
of the AMPA receptor, which mediates fast neurotransmission in the brain, with 
PI(3,5)P2  synthesis inhibition causing defects in AMPA receptor trafficking (McCartney 
et al., 2014b).  
Loss of the PIKfyve complex and PI(3,5)P2 are associated with profound 
neurodegeneration (Zhang et al., 2007b, Zolov et al., 2012). Mutations in the Fig4 gene 
are linked to Charcot-Marie-Tooth syndrome type 4J (CMT4J) (Chow et al., 2007, 
Nicholson et al., 2011). Charcot-Marie-Tooth syndrome is disease of the peripheral 
nervous system, characterised by the progressive deterioration of nerves which results 
in reduced nerve conduction, leading to loss of touch sensation and muscle tissue. 
These defects are observed in Fig4-/- mice which show spongiform degeneration of the 
brain and loss of neurons from the dorsal root ganglia, which results in lethality 
between the ages of 1-2 months (Chow et al., 2007). Patients with CMT4J are 
compound heterozygotes and carry the missense allele FIG4-I41T in combination with 
a null allele. This I41T mutation disrupts the interaction of Fig4 with Vac14 (Lenk et al., 
2011). 
Mutations in the Fig4 gene are also found in patients with amyotrophic lateral sclerosis 
(ALS) (Chow et al., 2009). ALS is a severe neurological disorder characterised by the 
neurodegeneration of lower and upper motor neurones in the spinal cord, brain stem 
and cortex. Fig4 is also linked to several other neurodegenerative diseases. It is 
present in the Lewy bodies of Parkinson’s disease and in inclusion bodies in other 
diseases (Kon et al., 2014).   
Mutations in PIKfyve and Vac14 have not been linked with neurological disorders to 
date however, heterozygous null mutations in PIKfye are associated with Francois-
Mouchetee Felck Corneal Dystropgy (CFD) (Li et al., 2005a). This leads to white flecks 
in the corneal stroma of the eye which are thought to be enlarged vacuoles in enlarged 
keratocytes. Also Vac14 is down-regulated in patients with chronic fatigue syndrome 
(McCartney et al., 2014a).  
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One of the most interesting observations of the role of the PIKfyve complex and 
PI(3,5)P2 in neurodegeneration is in Vac14 null mice, which show profound 
neurodegeneration. Vac14 null mice die 1-2 days after birth and show a significant 
reduction in PI(3,5)P2 levels (Zhang et al., 2007b). Several neuronal defects were 
observed including lesions in various regions of the brain, including the preoptic area, 
thalamus, hypothalamus, which were filled with enlarged vacuole structures, consistent 
with the loss of PI(3,5)P2. Fibroblasts from Vac14 null mice also showed defects in 
retrograde trafficking from the endosomes to the TGN. 
Zolov et al. (2012) created a PIKfyve gentrap mouse (PIKfyveβ-geo/β-geo), a hypomorph 
with a 90% reduction in PIKfyve protein level). PIKfyveβ-geo fails to interact with Vac14, 
and a decrease in PI(3,5)P2 levels is observed, with an increase in PI(3)P. The majority 
of PIKfyveβ-geo/β-geo mice exhibit perinatal lethality. A small number survived for up to 19 
days. These mice showed impaired mobility, with extensive vacuolation observed in 
cerebellar nuclei, the brain stem, and the spinal cord, leading to profound 
neurodegeneration. This vacuolation was also observed in other tissues causing 
defects to the heart, lungs, kidneys, thymus and spleen (Zolov et al., 2012). 
 
Taken together the mutations in Fig4 associated with neurodegenerative diseases and 
the profound neurodegeneration seen in both Vac14 and Fig4 knock out mice, as well 
as the PIKfyveβ-geo/β-geo mice, demonstrates the importance of the PIKfyve complex, and 
its tight regulation of the signalling lipid PI(3,5)P2  in normal neuronal function.   
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1.6 mTOR 
PI(3,5)P2  has recently been identified as a crucial component of the mTORC1 
dependent input of nutrient signals, via its binding to the Raptor regulatory subunit of 
mTORC1 (Bridges et al., 2012, Jin et al., 2014).  
1.6.1 mTOR, structure, function and signalling 
The mammalian target of rapamycin known as mTOR is a serine/threonine protein 
kinase, a key integrator of various signalling inputs, and is involved in a wide variety of 
physiological processes. It is involved in complex processes such as the control of 
development, regulation of fat, sugar and amino acid metabolism, as well as playing an 
important role in the control of an organism’s life span. It integrates cellular stimuli of 
growth factor receptors such as the insulin-like growth factor receptor, the availability of 
amino acids, the ATP/ADP ratio and cellular stress (Laplante and Sabatini, 2012).  
mTOR mediates these various physiological processes via two mTOR complexes; 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Figure 11). The main 
component of both complexes is the mTOR kinase itself. mTOR belongs to the 
phosphoinositide-3-kinase  (PI3K) related protein kinase family. The N-terminus of 
mTOR is highly conserved and is composed of HEAT repeats that mediate protein-
protein interactions. The C-terminus of mTOR contains the kinase domain required for 
its activity (Baretić and Williams, 2014). mTORC1 is composed of the mTOR kinase 
itself, regulatory associated protein of mTOR (Raptor), mammalian lethal SEC13 
protein 8 (MLST8), as well as other mTORC1 specific proteins. mTORC2 is composed 
of the following subunits, mTOR, rapamycin-insensitive companion of mTOR (Rictor), 
mammalian stress-activated protein kinase interacting protein 1 (mSIN1), mammalian 
lethal SEC13 protein 8 (MLST8), as well as other mTORC2 specific proteins (Laplante 
and Sabatini, 2012). 
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mTOR complex 1 (mTORC1) is the better characterised of the two complexes and is 
known to control protein translation initiation, ribosome biogenesis and cell cycle 
progression, mainly through its downstream effectors (Figure 12). It is activated by a 
set of diverse upstream signals. It integrates inputs from growth factors, stress, energy 
status, oxygen and amino acids, and in doing so controls several major physiological 
process like protein synthesis and autophagy (Laplante and Sabatini, 2012) (Figure 
12). The growth factor activated mTOR pathway has been extensively studied. Growth 
factors bind to receptor tyrosine kinases, which activate the PI3K-Akt and/or the Ras-
MAPK pathways, which stimulates mTORC1, by phosphorylation of the tuberous 
sclerosis complex 2 (TSC2) (Inoki et al., 2003a, Tee et al., 2003). TSC2 in complex 
with TSC1 functions as a GTPase activating protein (GAP) for the GTPase Rheb (Inoki 
et al., 2003a) (Kim et al., 2013). Rheb is present on the membranes of the endosomal 
Figure 11. The components of the mTOR complexes. 
mTORC1 is mainly composed of mTOR itself, the scaffold protein Raptor 
which helps to regulate  mTORC1 assembly and localisation, and the 
MTORC1 inhibitor PRAS40. mTORC2 is primarily composed of mTOR, 
the scaffold protein Rictor , mSIN1 which helps to regulate complex 
assembly, and protor 1/2. The mLST8 subunit is common to both 
mTORC1 and mTORC2, as is the mTOR inhibitor deptor. Figure adapted 
from Takei and Nawa (2014). 
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system and is negatively regulated by the TSC1/2 complex (Saito et al., 2005). Rheb, 
in its active form (Rheb-GTP) increases mTOR signalling. The TSC complex is 
responsible for converting active GTP bound Rheb to its inactive GDP bound form. The 
phosphorylation of the TSC complex by growth factor stimulation, inactivates TSC, 
thereby increases active Rheb and mTORC1 signalling. The TSC is also involved in 
the activation of mTORC1 upon stress signals, such as low oxygen and energy levels. 
Adenosine monophosphate-activated protein kinase (AMPK) phosphorylates TSC2 in 
response to these stresses increasing Rheb, and consequently mTORC1 activity (Inoki 
et al., 2003c).  
mTORC1 also mediates the input of amino acids particularly leucine and arginine in a 
process that requires the Rag GTPases (Sancak et al., 2008). There are four Rag 
proteins in mammals which form heterodimers consisting of RagA or RagB with RagC 
or RagD. The two sets of heterodimers have different GTP loading states, when 
RagA/RagB is GTP bound RagC/RagD is GDP bound (Sancak et al., 2008). Amino 
acids stimulate GTP binding to RagA and RagB causing the Rag GTPases dock to a 
multi subunit complex known as the Ragulator, located on the lysosomal membrane 
(Bar-Peled et al., 2012). The Rag heterodimer then interacts with the Raptor subunit of 
mTORC1 causing the translocation of mTORC1 from the cytoplasm to the lysosomal 
membrane allowing for the activation of mTORC1 (Sancak et al., 2010) (Figure 12). 
Therefore the Rag GTPases and the Ragulator tightly control mTORC1 activation in 
the presence of amino acids, regardless of the presence of any other positive signals.   
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Figure 12. The mTOR signalling pathway 
mTORC1 integrates signals from growth factors and amino acids, whereas the 
integration of growth factor signals by mTORC2 is not as well characterised. In 
the presence of growth factors Akt inhibits TSC1/2 via phosphorylation causing 
an increase in active GTP bound Rheb, which directly activates mTORC1. Amino 
acids activate the Rag GTPase which causes the translocation of mTORC1 to the 
lysosomal membrane, subsequently activating mTORC1. mTORC1 
phosphorylates several downstream effectors which stimulates protein synthesis 
and decreases autophagy. mTORC1 is also involved in mitochondrial biogenesis 
and lipogenesis. mTORC2 has roles in the organisation of the cytoskeleton and in 
metabolism and stress response. Red arrows represent inhibition and black 
arrows represent activation, with (P) indicating phosphorylation of the 
downstream target.  
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mTORC1 regulates many physiological processes due to its importance in the cells 
energy and nutritional status. The most well characterised downstream process of 
mTORC1 is the control of protein synthesis (figure 12). mTORC1 phosphorylates the 
translational regulators the eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1 (4EBP1), and the S6 kinase 1 (S6K1), which both promote protein synthesis 
(Laplante and Sabatini, 2012). 4EBP1 phosphorylation by mTORC1 prevents its 
binding to the eIF4E, allowing it to participate in the complex that initiates cap-
dependent translation. S6K1 increases mRNA biogenesis, translation initiation and 
elongation through a number of different effectors (Magnuson et al., 2012). mTORC1 
also controls lipid synthesis through the sterol regulatory element-binding protein 1 
SREBP1, controlling the expression of several genes involved in fatty acid and 
cholesterol synthesis (Wang et al., 2011). mTORC1 promotes the activity and 
expression of the peroxisome proliferator activated receptor – γ (PPARγ) which 
regulates adipogenesis (Zhang et al., 2009). mTORC1 regulates metabolism and ATP 
production by activating glycolytic genes through the translation of the hypoxia 
inducible factor 1α, and by mediating the interaction between PPAR-γ co-activator 1α 
(PGC1α) and Ying-Yang 1 (YY1), which regulate mitochondrial biogenesis 
(Cunningham et al., 2007). mTORC1 negatively regulates autophagy which promotes 
cell growth (Hosokawa et al., 2009). mTORC1 inhibition causes an increase in 
autophagy. It directly phosphorylates the kinase complex ULK1/Atg13/FIP200 which is 
required to initiate autophagy. This phosphorylation renders the complex inactive, and 
therefore supresses autophagy (Ganley et al., 2009). The mammalian orthologue of 
yeast autophagy protein ATG18, WIPI2, is an mTOR effector  (Hsu et al., 2011). 
mTORC1 is also known to regulate the biogenesis of lysosomes (Puertollano, 2014).  
The mTORC2 pathway is much less understood than that of mTORC1. mTORC2 
responds to growth factors such as insulin, through an ill-defined mechanism. 
mTORC2 is known to directly phosphorylate the kinase Akt causing its activation 
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(Hresko and Mueckler, 2005). Akt itself phosphorylates several proteins and in doing 
so regulates metabolism, apoptosis, growth and proliferation. mTORC2 also activates 
serum and glucocorticoid-induced protein kinase 1 (SGK1) which controls growth and 
ion transport, and protein kinase Cα (PKCα) which functions in many physiological 
processes such as cell adhesion and cell volume by controlling the actin cytoskeleton 
(Sarbassov et al., 2005).  
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1.6.2 The roles of mTOR in human diseases and ageing 
Due to mTOR’s role in a wide variety of physiological processes it is to be expected 
that defects in the mTOR signalling pathways are implicated in several diseases. The 
mTOR pathway is known to be important in the pathogenesis of many cancers. In 
many human cancers several components of the PI3K signalling pathway which inputs 
into the mTOR pathway are mutated (LoPiccolo et al., 2008, Morgensztern and 
McLeod, 2005). Loss of the tumour protein p53, key in regulating cell cycle and 
functioning as a tumour suppressor, increases mTORC1 activation. This results in 
cancer cell proliferation, growth and survival (Feng et al., 2005). The dysregulation of 
protein synthesis is a major player in tumour formation. Increased mTORC1 activation 
increases 4EBP1 phosphorylation, leading to increased protein translation. 4EBP1 and 
eIF4E affect tumour formation by promoting the translation of mRNAs encoding 
oncogenic proteins that increase cell cycle, cell proliferation and energy metabolism, 
amongst others (Dowling et al., 2010). An increase in mTOR controlled lipid synthesis 
is found in proliferating cancer cells. Taken together these results indicate that the 
inhibition of mTOR could play a role in cancer therapy. Indeed there are several 
analogues of rapamycin currently being tested and one of these has been approved for 
the treatment of renal cell carcinoma (Laplante and Sabatini, 2012). Due to its role in 
regulating nutrient input, it is not surprising that the mTOR pathway is implicated in 
metabolic disorders such as type 2 diabetes, with both loss and hyperactivation of 
mTORC1 affecting insulin sensitivity (Um et al., 2004).  
The mTOR pathway has been implicated in the aging process (Johnson et al., 2013). 
This link was first discovered in the RNAi suppression of the C. elegans orthologue of 
mTOR, let363 which significantly increased the lifetime of the worm (Vellai et al., 
2003). The inhibition of mTORC1 with rapamycin also increases the life span of mice, 
most likely by slowing age related pathologies (Miller et al., 2010). The mechanisms for 
the extension of life span upon mTORC1 inhibition are not fully known, however they 
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seem to include changes in mRNA translation, increasing stress resistance, changes in 
mitochondrial activity, and protecting stem cell function (Parkhitko et al., 2014). 
Nutrient restriction also extends life span (Walker et al., 2005). It is therefore 
interesting that mTORC1 plays such a crucial role in integrating nutritional signals.  
Given the link between mTOR and ageing it is therefore not surprising that mTOR has 
also been implicated in age-related neurological disorders. In neurodegenerative 
diseases that stem from the accumulation of protein aggregates, protein degradation 
pathways such as autophagy are deregulated (Martinez-Vicente and Cuervo, 2007). 
Due to the control of autophagy by mTORC1, its role in neurodegeneration has been 
increasingly investigated. The inhibition of mTORC1 by rapamycin stimulates 
autophagy and the degradation of proteins that form aggregates in neurodegeneration. 
This mTORC1 inhibition reduces the severity of neurodegeneration in animal models of 
neurodegenerative disorders (Sarkar, 2013). The inhibition of mTORC1 by rapamycin 
has been shown to reduce protein aggregation by decreasing protein synthesis (King 
et al., 2008).  
mTOR signalling is increased in the brains of Alzheimer’s disease patients, and mTOR 
deregulation is visible before the development of the disease pathology (Li et al., 
2005c). This defect in mTOR signalling in Alzheimer’s disease is systemic and not only 
restricted to the brain (Yates et al., 2013). mTOR regulates the protein tau, 
phosphorylation and degradation in animal models of tauopathies (Wang et al., 2014b). 
Genetically increasing mTOR causes an increase in the protein level and the 
phosphorylation of tau (Caccamo et al., 2013). This hyperphosphorylation of tau is 
observed in tauopathies such as Alzheimer’s disease. The inhibition of mTORC1 with 
rapamycin reduces tau pathology, and the associated behavioural deficits observed in 
a mouse model overexpressing human mutant tau (Caccamo et al., 2013). mTOR and 
tau are thought to be linked through the glycogen synthase kinase β (GSK3β), also 
  75 
  
known to contribute to tau hyperphosphorylation and autophagy (Caccamo et al., 
2013). 
Taken together the defects of mTOR signalling in human disease add increasing 
evidence to its importance in a wide variety of physiological functions. In fact it is often 
thought that mTOR is involved in most physiological processes either directly or 
indirectly.  
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1.7 Project aims  
Membrane proteins play key roles in a wide variety of physiological processes. This 
project aims to aid in the development of techniques to examine the interaction of the 
intracellular domains of membrane proteins with cytosolic proteins, and with 
phospholipids. 
This project will focus on the continued development of a model membrane liposome 
recruitment system (based on that used by (Pocha et al., 2011)) to examine the 
intracellular interactome of membrane proteins using the amyloid precursor protein as 
a model, with a view to gaining new insight into APP’s physiological function.  
Recent unpublished studies (Balklava et al., under review A; Balklava et al., under 
review B) utilised a liposome based technique coupled to label free quantitative mass 
spectrometry to identify the intracellular interactome of APP. They identified 327 
potential interacting proteins with roles in cell signalling, gene expression, trafficking 
and metabolism. Amongst APP’s well known binding partners, such as Fe65, several 
novel interaction partners were detected. This thesis will focus on two of these novel 
interaction partners; the mTOR complex, and the PIKfyve complex. When identified by 
mass spectrometry these complexes were found to be significantly enriched in AICD 
liposome samples compared to controls. The interaction between AICD and these 
complexes were selected for further characterisation in this thesis primarily due to this 
significant enrichment as well as to gain a greater insight into the functions of APP. 
The link between the PIKfyve complex and neurodegeneration (Zhang et al., 2012) and 
APPs role in Alzheimers disease made it a good candidate for further study. mTOR 
signalling controls a wide range of physiological processes and is also found to be 
increased in Alzheimers disease (Li et al., 2005c), therefore the interaction between 
APP and the mTOR complex was selected for further investigation.  
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In this thesis the novel interaction between APP and the mTOR complex will be 
characterised using the proteo-liposome recruitment system, as well as the interaction 
of APP with the PIKfyve complex. The interaction of APP with the PIKfyve complex will 
be further investigated in terms of APP function and trafficking. 
The liposome recruitment system will also be further developed to allow for the 
assessment of the recruitment protein coats from their purified components using the 
AP-2/clathrin coat as a model.  
This thesis hypothesises that the proteo-liposome recruitment system will be able to 
analyse the interaction partners of the intracellular domains of membrane proteins, and 
that the mTOR and PIKfyve complexes will interact with AICD as detected using this 
technique.  
These assessments will demonstrate and solidify the effectiveness of a liposome 
based model membrane system for the analysis of the cytosolic binding partners of 
membrane proteins.   
  
  78 
  
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Materials and Methods  
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Chapter 2- Materials and Methods 
 
2.1 Materials 
2.1.1 Buffers and solutions 
All the buffers and solutions used for the methods are given in the table below.  
1 x 1 M Tris buffer 0.05 M Tris Base 
0.95 M Tris HCl 
1 mM EDTA (Ethylenediaminetetraacetic 
acid) 
0.1% (v/v) ß-mercaptoethanol 
0.02% (v/v) Sodium azide 
pH 8.0 
1 x Blotting buffer  50 mM Glycine 
400 mM Tris Base 
20% (v/v) Methanol 
pH 8.3 
1 x Phosphate buffered saline (PBS) 
solution  
137 mM Sodium chloride 
10 mM Disodium phosphate 
1.8 mM Potassium dihydrogen phosphate 
2.7 mM Potassium chloride 
pH 7.4 
10 mM PEI solution 0.95 mg/ml polyethylenimine (PEI) (25 kD, 
Sigma Aldrich) 
pH 7.5 (adjust with HCl) 
10 x Blotting buffer 0.25 M Tris Base 
1.9 M Glycine 
pH 8.3 
10 x PCR buffer 100 mM Tris Cl pH 8.8 
500 mM Potassium chloride 
25 mM Magnesium chloride 
1% (v/v) Triton X 100 
10 x TBS 0.2 M Tris Base 
1.5 M Sodium chloride 
pH 7.5 
2 x 1 M Tris buffer 0.1 M Tris base   
1.9 M Tris HCl    
2mM EDTA     
0.2% (v/v)  ß -mercaptoethanol 
0.04% (v/v) sodium azide 
pH 8.0 
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4 x Laemmli buffer 200 mM Tris, pH 6.8 
40% (v/v)  Glycerol 
4% (w/v) SDS (Sodium dodecyl sulphate) 
0.04% (w/v) Bromophenol blue 
4% (v/v)  ß-mercaptoethanol 
4 x Separation gel buffer  1.5 M Tris 
pH 8.8 
4 x Stacking gel buffer 0.5 M Tris 
pH 6.5 
ATG18 Dialysis Buffer 1 x Phosphate buffered saline (PBS) 
10% (v/v)   Glycerol 
ATG18 Elution buffer 1 x Phosphate buffered saline (PBS) 
10 mM Reduced glutathione 
ATG18 Lysis buffer 1 x Phosphate buffered saline (PBS) 
Blocking solution 5% (w/v) Bovine serum albumin (BSA) in 
TBSt 
0.1% (v/v) Sodium azide 
Buffer C (10x) 200 mM HEPES pH 7.0 
250 mM Potassium chloride 
 
Buffer C (1x) 100 ml of Buffer C (10x) 
1.5 ml 2 M Magnesium chloride 
 
Cell culture medium Dulbecco’s Modified Eagle Medium 
(DMEM) (Gibco –Life Technologies) 
10% (v/v)Foetal Calf Serum (Gibco –Life 
Technologies) 
1% (v/v) Pen/Strep (Gibco –Life 
Technologies) 
Cell fixing solution 4%  (v/v) Paraformaldehyde dissolved in 1 
x PBS 
Clearance buffer 50 mM TrisCl pH 8.0 
500 mM Sodium chloride 
10 mM EDTA 
Coomassie destain 10% (v/v) Acetic acid 
20% (v/v) Methanol 
70% (v/v) Distilled water 
Coomassie stain 50% (v/v) Ethanol 
10% (v/v) Acetic acid 
40% (v/v) Distilled water 
0.25% (w/v) Coomassie Brilliant Blue-R250 
Depolymerisation buffer 20 mM TEA (Triethanolamine) 
1 mM EDTA 
0.1% (v/v) ß-mercaptoethanol 
0.02% (v/v) Sodium azide 
pH 8.0 
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Developer solution  Carestream® Kodak® autoradiography GBX 
developer/replenisher (Sigma Aldrich) 
 
Dialysis Buffer 20 mM HEPES 
125 mM Potassium acetate 
1 mM EDTA 
pH 7.2 (with KOH) 
Elution Buffer  50 mM Tris 
150 mM Sodium chloride 
250 mM Imidazole 
pH 7.2 
Enzyme substrate solution 100 mM Tris pH 8.5 
0.18 mM Coumaric acid 
1.25 mM Luminol 
0.01% (v/v) Hydrogen peroxide 
Ficoll/sucrose buffer 6.25% (w/v)Sucrose 
6.25% (w/v)Ficoll PM 70 
In HKM buffer 
Fixer solution Carestream® Kodak® autoradiography RP 
X-Omat LO fixer/replenisher (Sigma 
Aldrich) 
 
Freezing medium 30% (v/v) FCS 
10% (v/v) DMSO (dimethyl sulfoxide) 
70% (v/v) cell culture medium 
G418 cell culture medium 750 µg/ml Geneticin (G418) in cell culture 
media 
HKM Buffer 25 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)), pH 7.2 
125 mM Potassium acetate 
5 mM Magnesium acetate 
0.002% (v/v) Sodium azide 
LB agar 37.5 g LB agar (Fisher) dissolved in 1 L 
distilled water and autoclaved. For selective 
media one or a combination of kanamycin, 
ampicillin and chloramphenicol was added 
at a final concentration of 50 µg/µl, 100 
µg/µl and 34 µg/µl respectively.  
 
LB broth 20 g LB (Melford Bioscience) dissolved in 1 
L distilled water and autoclaved. For 
selective media one or a combination of 
kanamycin, ampicillin and chloramphenicol 
was added at a final concentration of 50 
µg/µl, 100 µg/µl and 34 µg/µl respectively.  
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Lysis Buffer 50 mM Tris 
150 mM Sodium chloride 
10 mM Imidazole 
pH 7.2 
Mammalian cell lysis buffer 150 mM Sodium Chloride 
50 mM Tris pH 8.0 
1% (v/v)Triton-X100 
2.5 mM βglycerophosphate 
1 mM NH4Fl 
1mM Vanadate 
10 mM Pyro-phosphate 
3.3 µg/ml Aprotinin 
4 µg/ml E-64 
1 mM PMSF 
1 µg/ml Pepstatin 
1 mM EDTA 
McKay’s Buffer 40 mM HEPES pH 7.0 
75 mM potassium chloride 
4.5 mM magnesium acetate 
Mowiol mounting media 2.4g Mowiol 
6.0g glycerol 
6.0ml H2O 
12.0ml 0.2M Tris.Cl, pH 8.5 
2.5% 1,4-diazobicyclo-[2.2.2]-octane 
(DABCO) 
 
Polymerisation buffer 0.1 M MES (2-(N-
morpholino)ethanesulfonic acid) 
1.5 mM Magnesium chloride 
0.2 mM EGTA (ethylene glycol tetraacetic 
acid) 
0.02% (v/v) Sodium azide 
pH 6.5 
Recruitment buffer (RB) 20 mM HEPES 
125 mM Potassium acetate 
2.5 mM Magnesium acetate 
pH 7.2 (adjusted with KOH) 
Saturated ammonium sulphate solution 5.8 M Ammonium sulphate 
1L 10 mM Tris pH 7 
0.1 mM EDTA 
SDS running buffer 25 mM Tris 
190 mM Glycine 
3.5 mM SDS 
Solution 1 50 mM TrisCl pH 8.0 
10 mM EDTA 
100 µg/ml RNaseA 
Solution 2 200 mM Sodium hydroxide 
1% (w/v) SDS 
Solution 3 3 M Potassium acetate pH 5.5 
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TAE buffer 40 mM Tris 
20 mM Acetic acid 
1 mM EDTA 
pH 8.0 
TBSt 10% (v/v) 10 x TBS 
1% (v/v)Tween 20 
TE buffer 10 mM TrisCl pH 8.0 
1 mM EDTA 
TEV Dialysis buffer 50 mM Sodium phosphate 
200 mM Sodium chloride 
40% (v/v) Glycerol 
pH 8.0 
TEV elution buffer 50 mM Sodium phosphate 
200 mM Sodium chloride 
10% (v/v) Glycerol 
250 mM Imidazole 
pH 8.0 
TEV lysis buffer 50 mM Sodium phosphate 
200 mM Sodium chloride 
10% (v/v) Glycerol 
10 mM Imidazole 
pH 8.0 
Tissue culture medium 1x 500 ml bottle of Dulbecco’s Modified 
Eagle Medium (DMEM) (Gibco-Life 
Technologies) 
10% (v/v) Foetal Bovine Serum (Gibco-Life 
Technologies) 
1% (v/v) Penicillin-Streptomycin (Gibco-Life 
Technologies) 
 
Wash buffer 25 mM HEPES pH 7.0 
50 mM Potassium chloride 
1 mM Magnesium chloride 
Table 1. Buffer list. 
All the buffers used in the methods described in chapter 2.  
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2.1.2 Lipids 
 
Lipid Abbreviation 
Stock  
Concentration  
µg/µl 
Solvent Company 
 
Catalogue 
 number 
1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[4-(p-
maleimidomethyl)cyclohexane-
carboxamide] (sodium salt) 
 
PE MCC 10 
Chloroform: 
Methanol 
(2:1) 
Avanti Polar 
Lipids 
780201 
Cholesterol 
 
C 10 
Chloroform: 
Methanol 
(2:1) 
Sigma 
Aldrich 
C8667 
Phosphatidylcholine 
 
PC 25 
Chloroform: 
Methanol 
(2:1) 
Sigma 
Aldrich 
P3556 
Phosphatidylethanolamine 
 
PE 10 
Chloroform: 
Methanol 
(2:1) 
Sigma 
Aldrich 
P7943 
Phosphatidylinositol 
 
PI 1 
Chloroform: 
Methanol 
(2:1) 
Avanti Polar 
Lipids 
850091 
Phosphatidylinositol 3 
phosphate 
 
PI(3)P 1 
Chloroform: 
Methanol 
(2:1) 
Avanti Polar 
Lipids 
850150 
Phosphatidylinositol 3,5 
bisphosphate 
 
PI(3,5)P2 1 
Chloroform: 
Methanol 
(2:1) 
Avanti Polar 
Lipids 
850154 
Phosphatidylinositol 4,5-
bisphosphate 
 
PI(4,5)P2 1 
Chloroform: 
Methanol 
(2:1) 
Avanti Polar 
Lipids 
850155 
Phosphatidylserine 
 
PS 
 
10 
Chloroform: 
Methanol 
(2:1) 
Sigma 
Aldrich 
P7769 
 
1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine 
perchlorate 
DiI 1 Methanol 
Sigma 
Aldrich 
 
42364  
 
Table 2. Lipids. 
The lipids used to produce liposomes as outlined in this chapter. 
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2.1.3 Antibodies 
 
Table 3. Antibody list. 
A list of all the antibodies used in western blot and immunofluorescence analysis.   
Antibody Dilution Company Catalogue number 
ɑ-adaptin  1:1500 
Santa Cruz 
Biotechnology 
sc-398024 
Anti-mouse HRP 
conjugate 
1:4000 
Cell Signalling 
Technology 
7076 
Anti-mouse IgG Fab2 
Alexa Four 555 
1:1000 
Cell Signalling 
Technology 
4409 
Anti-rabbit HRP 
conjugate 
1:4000 
Cell Signalling 
Technology 
7074 
Anti-rabbit IgG Fab2 
Alexa Four 555 
1:1000 
Cell Signalling 
Technology 
4413 
AP-180  1:5000 
Santa Cruz 
Biotechnology 
sc-135834 
APLP2 1:1000 Abcam ab140624 
APP 1:1000 
Santa Cruz 
Biotechnology 
sc-53822 
Clathrin heavy chain  1:1500 
Santa Cruz 
Biotechnology 
sc-271178 
EEA1 1:200 BD Biosciences 610457 
GST  1: 2000 
Santa Cruz 
Biotechnology 
sc-374171 
LampI 
 
1:200 
Santa Cruz 
Biotechnology 
sc-20011 
MBP 1:2000 
Cell Signalling 
Technology 
2396 
mTOR  1:2000 
Cell Signalling 
Technology 
2972 
PIKfyve (PIP5KIII)  1:2000 
Santa Cruz 
Biotechnology 
sc-100408 
Raptor  
 
1:1000 
Santa Cruz 
Biotechnology 
sc-81537 
Rictor  1:1000 
Cell Signalling 
Technology 
9476 
Tubulin 1:2000 Abcam ab125267 
Vac14  1:2000 
Santa Cruz 
Biotechnology 
sc-271831 
γ- adaptin  1:500 
Santa Cruz 
Biotechnology 
sc-10763 
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2.2 Methods 
2.2.1 General Methods 
2.2.1.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE gels were assembled using Bio-Rad’s Mini-Protean system. 5 ml of 
separation gel was overlaid by 100% isopropanol and allowed to set. The isopropanol 
was removed by several washes with distilled water. 2 ml of the stacking gel was 
poured on top of the set separation gel and the desired comb inserted. Samples were 
run on either an 8, 10 or 15% acrylamide gel. The composition of the separation and 
stacking gels is given in the table below. 
8% Separation gel 
10% Separation 
gel 
15% Separation gel 
 
5% Stacking gel 
1.25 ml of 1.5 M Tris 
pH 8.8 
1.25 ml of 1.5 M 
Tris pH 8.8 
1.25 ml of 1.5 M Tris 
pH 8.8 
0.5 ml of 0.5 M Tris 
pH 6.5 
1 ml of 50% Glycerol 
1 ml of 50% 
Glycerol 
1 ml of 50% Glycerol 
0.4 ml of 50% 
Glycerol 
1 ml of 40% 
Bisacrylamide 
solution (Fisher 
Scientific) 
1.25 ml of 40% 
Bisacrylamide 
solution (Fisher 
Scientific) 
1.875 ml of 40% 
Bisacrylamide 
solution (Fisher 
Scientific) 
0.25 ml of 40% 
Bisacrylamide 
solution (Fisher 
Scientific) 
100 µl of 10% SDS 100 µl of 10% SDS 100 µl of 10% SDS 20 µl of 10% SDS 
50 µl of 10% 
Ammonium 
persulphate (APS) 
50 µl of 10% 
Ammonium 
persulphate (APS) 
50 µl of 10% 
Ammonium 
persulphate (APS) 
10 µl of 10% 
Ammonium 
persulphate (APS) 
1.6 ml of distilled 
water 
1.35 ml of distilled 
water 
0.725 ml of distilled 
water 
0.82 ml of distilled 
water 
2.5 µl of 
Tetramethylethylene
diamine (TEMED) 
 
2.5 µl of 
Tetramethylethylen
ediamine (TEMED) 
 
2.5 µl of 
Tetramethylethylene
diamine (TEMED) 
 
1 µl of 
Tetramethylethylene
diamine (TEMED) 
 
 
Table 4. SDS-PAGE gel components. 
The components needed to make 8%, 10% and 15% separation/resolving gels and 5% 
stacking gel.  
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4x or 2x Laemmli buffer was added to samples and a stated volume of the 
sample/Laemmli buffer mix was loaded into the wells of the gel. Gels were run at 150 V 
for approximately 1 hour. When required gels were either stained with coommasie 
stain for 1 hour followed by de-stain with Coomassie de-stain overnight, stained using 
InstantBlue (Expedeon), or subjected to Western blotting.  
2.2.1.2 Western blotting 
Western blot sandwiches were assembled as follows; 1st layer- 1 piece of Whatman 
filter paper, 2nd layer-SDS-PAGE gel, 3rd layer PVDF membrane (activated in 100% 
methanol), 4th layer- 1 piece of Whatman filter paper. The sandwich was placed into a 
cassette in the western blot tank and filled with 1x blotting buffer. Cooling pads were 
placed into the tank and the transfer ran at 200 mA for 120 minutes with 200rpm 
stirring. The PVDF membrane was placed in 5 ml of blocking solution for 1 hour at 
room temperature or overnight at 4ºC. The membrane was then incubated in 5 ml of 
blocking solution containing the desired diluted primary antibody for 1 hour at room 
temperature or at 4°C overnight. The primary antibody was removed by washing the 
membrane with 10 ml of TBSt for 30 minutes with 3 changes of buffer. The membrane 
was then incubated for 1 hour at room temperature in TBSt containing the desired 
diluted HRP conjugated secondary antibody. The secondary antibody was removed by 
washing the membrane with 10 ml of TBSt for 30 minutes with 3 changes of buffer. 
The membrane was incubated in either 2.5 ml of incubated of enzyme substrate for 1 
minute at room temperature or Pierce ECL 2 western blotting substrate (Thermo 
Scientific), which was used following the manufacturer’s instructions. The membrane 
was placed onto cling film and into the development cassette and the membrane 
exposed to X-ray films (X-ray film RX NIF sheets 130mm x 180mm Fujifilm, Fisher 
Scientific) in a dark room for various lengths of time depending on the antibodies used 
and the abundance of protein. The  film was then placed in developer solution for up to 
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5 minutes, washed with water and placed in fixer solution for up to 5 minutes, washed 
with water and left to dry at room temperature.  
2.2.1.3 Protein quantification 
Bovine serum albumin (BSA) was dissolved in distilled water to yield protein solutions 
with concentrations of 0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.4 mg/ml. 5 µl of each solution 
was added in triplicate to a 96 well plate along with 5 µl of the desired protein with an 
unknown concentration (in triplicate) and 5 µl of a 1:5 dilution of the desired protein 
with an unknown concentration. 25 µl of Bio-Rad DC protein assay reagent A was 
added to wells containing protein followed by 200 µl of Bio-Rad DC protein assay 
reagent B, mixed well, incubated at room temperature for 5 minutes and the 
absorbance read at 595 nm (A595). The absorbance readings were plotted against the 
concentrations of the BSA standards and the equation of the line was used to 
determine the concentration of desired proteins. 
2.2.1.4 Protein dialysis 
Pooled protein elution fractions were dialysed against 2 x 1 L of the appropriate 
dialysis buffer for the purified protein in order to remove imidazole or glutathione used 
to elute the proteins from an affinity column. 20 cm of dialysis tubing (14000, or 8000 
MWCO) was washed in 250 ml of distilled water followed by incubation in the dialysis 
buffer for 30 seconds.  The pooled elution fractions were added and the protein was 
dialysed in 1 L of dialysis buffer for 24 hours at 4 °C with gentle stirring and a change 
of buffer.  
2.2.1.5 Agarose gels 
1% molecular biology grade agarose was dissolved in 50 ml of TAE buffer in a 
microwave for 50 seconds. Ethidium bromide was added to a final concentration of 
0.01%.  The solution was poured into a gel caster and was allowed to set at room 
temperature. 5 µl of DNA marker (PeqLab 0.1-10kb) was loaded in the 1st well (unless 
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stated otherwise) and 6 x loading dye (PeqLab) was added to the desired samples to 
make 1 x loading dye. The gel was run at 100 V for approximately 40 minutes. 
2.2.1.6 Polymerase chain reaction (PCR)  
For a normal PCR reaction the concentration of the template DNA was adjusted to 
between 1 and 10 ng/µl for plasmid DNA. The desired primers were diluted to a 
working concentration of 10 µM. The PCR reactions were prepared differently 
depending on whether the PCR product would be used for cloning or for analytical 
purposes. The table below shows the components of the PCR reaction mixtures for 
each purpose. 
For Cloning- Total volume 50 µl For analytical purposes –Total volume 20 
µl 
5 µl of 10 x PCR buffer 2 µl of 10 x PCR buffer 
1 µl of primer 1 (10 µM) 0.4 µl of primer 1 (10 µM) 
1 µl of primer 2 (10 µM) 0.4 µl of primer 2 (10 µM) 
1 µl of dNTP’s (10 mM) 0.4 µl of dNTP’s (10 mM) 
40 µl distilled autoclaved water 16 µl distilled autoclaved water 
1 µl of DreamTaq DNA polymerase 
(Thermo Scientific) (5 units) 
0.4 µl of PFU/Taq DNA polymerase mix 
(50x) 
1-2 µl of DNA template 0.5- 1 ul of DNA template 
 
Table 5.  PCR reactions. 
The constituents of PCR reactions for both cloning and analytical purposes. For 
analytical purposes both the PFU and Taq DNA polymerases used were expressed 
and purified from E. coli.  
 
The PCR cycle was as follows: 
Step 1: 94˚C - 1:30 minutes 
Step 2: 94˚C – 30 seconds 
Step 3: 60˚C – 30 seconds (Annealing temperature depending on primer length and 
composition). 
Step 4: 72˚C – xxx minutes depending on the length of the PCR product (1 minute per 
kilobase) 
Step 5: repeat steps 2-4 35 times 
Step 6: 72˚C – 10 minutes 
Step 7: 4˚C - ∞ 
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For PCR reactions that involved the production of a PCR product longer than 3 Kbp a 
LongAmp Taq DNA polymerase (New England Biolabs) was used according to the 
manufacturer’s protocol.  
2.2.1.7 Production of electro-competent E. coli 
500 ml of LB broth was inoculated with an overnight culture of E. coli (TOP10 or 
BL21DE3) at a dilution of 1:100. The cells were grown at 37ºC shaking at 200 rpm to 
an OD600 of 0.6. Cells were chilled on ice for 20 minutes and then harvested by 
centrifugation at 4000 x g for 15 minutes at 4ºC. The supernatant was removed and 
the pellet re-suspended in 500 ml of ice cold 10% glycerol (sterilised by autoclaving). 
The solution was centrifuged at 4000 x g for 15 minutes at 4ºC and the supernatant 
discarded. The pellet was re-suspended in 250 ml of ice cold 10% glycerol and 
centrifuged as previous. The supernatant was removed and the pellet re-suspended in 
20 ml of ice cold 10% glycerol and centrifuged as above. The supernatant was 
discarded and the pellet re-suspended in a final volume of 1-2 ml of ice cold 10% 
glycerol. The cells were snap frozen in liquid nitrogen and stored at -80ºC.  
2.2.1.8 E. coli transformations 
5 µl of desired plasmid and 100 µl of electro-competent E. coli (BL21DE3 or TOP10) 
were added to an electroporation cuvette. Electroporation was carried out at 1.8 kV 
followed by the immediate addition of 1 ml of LB broth to the bacteria and incubation 
for 1 hour at 37°C with 200 rpm shaking. 100 µl of the LB-bacteria mix was then 
spread out onto selective LB agar plates and incubated at 37°C for 24 hours. 
2.2.1.9 Plasmid isolation from E. coli –small scale 
2 ml of an overnight culture of TOP10 E. coli containing the desired plasmid was 
subjected to centrifugation at 14000 rpm in a microfuge for 30 seconds. The pellet was 
then re-suspended in 200 µl of solution 1 (Table 1). 200 µl of solution 2 was added to 
the tubes and mixed, followed by the addition of 200 µl of solution 3. The solutions 
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were mixed by vortexing and then incubated for 10 minutes at room temperature 
followed by centrifugation at 14000 rpm in a microfuge for 10 minutes at room 
temperature. The supernatant was added to a new 1.5 ml Eppendorf tube along with 
700 µl of 100% 2-propanol, vortexed and incubated at room temperature for 10 
minutes. The samples were centrifuged at 14000 rpm in a microfuge for 10 minutes at 
room temperature. The supernatant was removed and 500 µl of 70% ethanol added to 
the pellet. The samples were centrifuged at 14000 rpm in a microfuge for 10 minutes at 
room temperature and the supernatant discarded. The tubes were placed in a 37°C 
incubator with the lids off until the ethanol had evaporated. The pellet was re-
suspended in 50 µl of 10 mM TrisCl pH 8.0 or distilled autoclaved water. The 
concentration of DNA was quantified using agarose gel electrophoresis and a 
nanodrop. 
A PeqGold plasmid mini prep kit (PeqLab) was also used, according to the 
manufacturer’s instructions. 
2.2.1.10 Plasmid isolation from E. coli – large scale 
200 ml LB broth was inoculated with E. coli (TOP10) containing the desired plasmid 
and grown 24 hours at 37°C in a shaking incubator set to 200 rpm. The bacteria were 
harvested by centrifugation at 2500 xg for 20 minutes at 4°C.  The supernatant was 
discarded and the pellet re-suspended in 5 ml of solution 1 (Table 1) by vortexing.  5 
ml of solution 2 was added mixed and incubated for 5 minutes at room temperature 
followed by 5 ml of solution 3. The solutions were mixed by vortexing and then 
incubated at 4°C for 30 minutes. The suspension was then spun in a Beckman table 
top centrifuge at 4000 rpm for 20 minutes at 4°C. The lipid layer was removed and the 
supernatant was passed through a 0.45 µm syringe filter followed by the addition of 15 
ml of 100% propan-2-ol, mixed and incubated on ice for 15 minutes. The solution was 
spun in a Beckman table top centrifuge at 4000 rpm for 20 minutes at 4°C, the 
supernatant discarded and the pellet washed with 10 ml 70% ethanol and centrifuged 
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at 4000 rpm for 10 minutes at 4°C. The pellet was dried at 37°C to remove the ethanol 
and was then re-suspended in 1 ml of TE buffer. 
 
2.2.1.11 Restriction digests 
Restriction digests were performed differently depending on the application of the 
digested DNA and the DNA to be digested. For digesting plasmid DNA for cloning 10 
µg of the desired plasmid was diluted in 40 µl of distilled autoclaved water containing 
the appropriate concentration of restriction enzyme buffer (Roche or New England 
BioLabs). The plasmid was digested with a total volume of 4 µl of the appropriate 
restriction enzymes (Roche or New England BioLabs) (20000 units/ml) for 3 hours at 
the appropriate temperature. For digesting a PCR product for cloning the appropriate 
volume of restriction enzyme buffer was added along with a total volume of 4 µl of the 
desired restriction enzymes (Roche or New England BioLabs) (20000 units/ml) and 
incubated at the desired temperature for 3 hours. The digestion products were then 
loaded onto an agarose gel for analysis. 
For the screening of colonies by digestion 5 µl of a plasmid (isolated by mini prep) was 
added to 15 µl of distilled autoclaved water and the desired concentration of restriction 
enzyme buffer added. A total volume of 1 µl of the chosen restriction enzymes (Roche 
or New England BioLabs) (20000 units/ml) were added and the mixture incubated at 
the appropriate temperature for 3 hours. The digestion products were then loaded onto 
an agarose gel for analysis.  
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2.2.2 Protein Expression and Purification 
2.2.2.1 Expression and purification of recombinant 6xHis-MBP tagged receptor 
tails 
1 L of LB broth (containing kanamycin or ampicillin at final concentrations of 50 µg/µl 
and 100 µg/µl respectively) was inoculated with 10 ml of an overnight culture of E. coli 
(BL21DE3) containing the expression plasmid for the desired protein. The cultures 
were grown to an optical density (OD) (600 nm) of 0.6 at 37°C in a shaking incubator at 
200 rpm.  IPTG was added at a final concentration of 100 µM and the culture was 
incubated at 37°C for 3 hours shaking at 200 rpm to induce protein expression. The 
cells were harvested by centrifugation at 2500 xg for 20 minutes at 4°C and the pellets 
stored at -20°C overnight. The bacterial pellet was re-suspended in 10 ml of lysis buffer 
containing the protease inhibitors aprotinin, E-64, PMSF and pepstatin at final 
concentrations of 3.2 µg/ml, 4 µg/ml, 1 mM and 1 µg/ml respectively. The suspension 
was subjected to sonication for 1 minute followed by incubation on ice for 3 minutes. 
This process was repeated 3 times.  The lysate was cleared by centrifugation at 10000 
rpm for 30 minutes at 4°C. The resulting supernatant was passed through a 0.45 µm 
syringe filter and loaded on to a Ni-NTA agarose column (Thermo Scientific, Pierce) 
equilibrated in lysis buffer. The flow through was collected and the column washed 6 
times with 10 ml of lysis buffer. The bound protein was eluted from the column with 5 x 
1 ml of elution buffer. 10 µl of each elution fraction were mixed with 4 x Laemmli buffer 
and loaded onto 10% SDS-PAGE gels and stained with either Coomassie stain or 
Instant Blue stain to determine which elution fractions contained the desired protein. 
The column was stripped with 10 ml of clearance buffer to remove any remaining 
bound protein. The stripped column was washed with 10 ml distilled water and stored 
at 4°C in 20% ethanol. The columns could be re-used by washing out the 20% ethanol 
and then washing the column with 5 ml of 100 mM nickel sulphate. The fractions 
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determined by SDS-PAGE to contain the desired protein were pooled and dialysed 
against dialysis buffer overnight at 4ºC with at least one buffer exchange. 
2.2.2.2 Expression and purification of recombinant tobacco etch virus protease 
(TEV) 
TEV protease was purified as described above (2.2.2.1) with the following 
modifications. E. coli (BL21DE3) containing pMalE-TEV (Addgene) was grown as 
described previously (2.2.2.1) and protein expression was inducted at 25°C with 100 
µM. TEV protease was  purified using TEV lysis buffer and TEV elution buffer (Table 
1). The eluted TEV was dialysed immediately into TEV dialysis buffer to remove the 
imidazole, which was found to effect TEV activity. The purity of TEV protease was then 
assessed by Coomassie stained SDS-PAGE.  
2.2.2.3 Expression and purification of recombinant His-Vac14 
His-Vac14 was expressed and purified from of E. coli (BL21DE3) containing the 
expression plasmid for HIS-Vac14 (a kind gift from Lois Weisman). Protein expression 
was induced using 100 µM IPTG for 18 hours (200 rpm) at 25°C. 
2.2.2.4 Expression and purification of recombinant GST-ATG18 
GST-ATG18 was purified as above (2.2.2.1) with the following modifications. 1 L of LB 
broth (containing ampicillin at a final concentration of 100 µg/µl was inoculated with 10 
ml of an overnight culture of E. coli (BL21DE3) containing pGEX 6P1- ATG18 (a kind 
gift from Scott Emr, Cornell University). The bacterial pellet was re-suspended in 10 ml 
of ATG18 lysis buffer containing the protease inhibitors aprotinin, E-64, PMSF and 
pepstatin at final concentrations of 3.2 µg/ml, 4 µg/ml, 1 mM and 1 µg/ml respectively. 
The supernatant resulting from the centrifugation steps was passed through a 0.45 µm 
syringe filter and loaded on to a glutathione agarose column (Thermo Scientific, 
Pierce) equilibrated in ATG18 lysis buffer. The flow through was collected and the 
column washed 6 times with 10 ml of ATG18 lysis buffer. The bound protein was 
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eluted from the column with 5 x 1 ml of ATG18 elution buffer. The fractions determined 
by SDS-PAGE to contain GST-ATG18 were pooled and dialysed against ATG18 
dialysis buffer at 4ºC overnight with at least one buffer change. 
2.2.2.5 Isolation and Purification of Clathrin 
Clathrin was purified from pig brains (Keen, 1987) essentially as described by (Wang 
et al., 2014b). Approximately 8 pig brains (frozen at – 80˚C) were divided between two 
1 L beakers and topped up with 1 x HKM buffer to an approximate volume of 600 ml. 
The protease inhibitors aprotinin, E-64, PMSF and pepstatin were added at final 
concentrations of 3.2 µg/ml, 4 µg/ml 1 mM and 1 µg/ml respectively. The brains were 
blended a beaker at a time until completely homogenised, using an electric blender. 
The blended pig brains were centrifuged at 7000 rpm for 30 minutes at 4˚C in a JA-14 
rotor using a Beckman Coulter Avanti J-E centrifuge. The supernatant was collected 
and then centrifuged in a 70-Ti rotor at 36000 rpm for 45 minutes at 4˚C using a 
Beckman Coulter Optima L-100K Ultracentrifuge, to extract coated vesicles. The 
pellets were scraped into a large glass Dounce homogeniser and homogenised with 1 
x HKM buffer to a final volume of approximately 40 ml. The volume of the homogenate 
was measured and an equal volume of ficoll/sucrose buffer added and mixed well. The 
mixture was centrifuged in a JA-20 rotor at 19000 rpm for 25 minutes at 4˚C using a 
Beckman Coulter Avanti J-E centrifuge. The supernatant was isolated and four times 
as much 1 x HKM buffer was added. The mixture was stored overnight at 4˚C.  A 
sephacryl S500 column (diameter 2.6 cm, height 1 m) connected to an Akta Purifier 
(GE Healthcare, Life Sciences) was equilibrated in 1 M Tris buffer. The overnight 
sample was spun at 36000 rpm in a 70-Ti rotor (Beckman Coulter Optima L-100K 
Ultracentrifuge) for 1 hour at 4ºC. The pellets containing coated vesicles were re-
suspended in a minimal volume of 1 x HKM buffer and then homogenised using a 
Dounce homogeniser. The sample was centrifuged at 13000 rpm for 10 minutes at 4ºC 
in a microfuge to remove cytoskeletal contaminants. The supernatant was collected 
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and the same volume of 2 x 1 M Tris buffer was added, mixed and incubated on ice for 
1 hour to strip the protein coat off the lipid vesicles.  The sample was spun a 50000 
rpm (Beckman Coulter Optima TLX Ultracentrifuge) for 30 minutes at 4ºC to remove 
most of the lipid. The supernatant was retained and loaded onto the equilibrated 
sepharcryl S500 column, which was run at a flow rate of 2 ml/minute. 10 ml fractions 
were collected. The fractions were stored at 4ºC overnight. Sample of the fractions 
were run on 10% SDS-PAGE gels and stained with Instant Blue stain to determine 
which fractions contained clathrin. The clathrin containing fractions were pooled and an 
equal volume of saturated ammonium sulphate solution was added and stored at 4˚C. 
A superdex 200 column (diameter 1.6 cm, height 55 cm) was equilibrated in 1 M Tris 
buffer. The clathrin/ammonium sulphate samples were centrifuged at 20000 rpm for 30 
minutes in a JA-20 rotor at 4˚C (Beckman Coulter Avanti J-E centrifuge), the pellets re-
suspended in 3-5ml of 1 x 1 M Tris buffer and dialysed against 1 L of depolymerisation 
buffer at 4˚C for at least 2 hours with one buffer change. The sample was centrifuged 
at 65000 rpm for 30 minutes at 4˚C (Beckman Coulter Optima TLX Ultracentrifuge) to 
remove insoluble aggregates. The supernatant was loaded on the equilibrated 
superdex 200 column. The sample was run at a flow rate of 2 ml/minute and 2.5 ml 
fractions were collected using the Akta purifier (GE Healthcare, Life Sciences). A 
sample of the fractions were analysed by SDS-PAGE to determine the clathrin 
containing fractions. These were pooled together and an equal volume of saturated 
ammonium sulphate solution was added and stored at 4˚C overnight. The 
clathrin/ammonium sulphate sample was centrifuged at 20000 rpm for 30 minutes at 
4ºC in a JA-20 rotor (Beckman Coulter Avanti J-E centrifuge). The pellets were re-
suspended in 1 ml or 2 ml of 1 x 1 M Tris buffer and dialysed against 1 L of 
depolymerisation buffer at 4˚C for at least 2 hours with one buffer change. The dialysis 
buffer was changed to polymerisation buffer and dialysis continued for at least 4 hours 
with a minimum of one buffer change. The clathrin cages were harvested by 
centrifugation at 50000 rpm for 20 minutes at 4˚C (Beckman Coulter Optima TLX 
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Ultracentrifuge). The supernatant was stored at 4˚C as clathrin could be harvested 
from it at a later date. The pellet was re-suspended in 200 µl of polymerisation buffer 
and stored at 4˚C. 
2.2.2.6 Purification of Clathrin Adaptor Protein 2 (AP-2) 
The purification of AP-2 was carried out as with the purification of clathrin up until the 
Sephacryl S-500 column. The adaptor protein containing fractions from the separation 
of Tris extracted clathrin cages, were pooled and dialysed against Buffer C (1x) 
containing 10 mM potassium phosphate and 0.2 mM PMSF overnight with at least one 
buffer change. The dialysed adaptor proteins were loaded onto a Hydroxyapatite Bio-
gel column (bed volume 5 ml) connected to an Akta Purifier (GE Healthcare, Life 
Sciences) which had been equilibrated in Buffer C (1x) containing 10 mM potassium 
phosphate pH 7.2 and 0.2 mM PMSF. AP-2 was eluted from the column using an 
increasing phosphate gradient from 10 mM potassium phosphate pH 7.2 to 500 mM 
potassium phosphate in Buffer C (1x) for a duration of 100 minutes with a flow rate of 1 
ml/min. 5 ml fractions were collected and samples subjected to SDS-PAGE and instant 
blue staining. The fractions containing AP-2 were pooled and an equal amount 
saturated ammonium sulphate solution added. The AP-2/ ammonium sulphate mixture 
was centrifuged at 19000 rpm for 30 minutes at 4ºC in a JA-20 rotor (Beckman Coulter 
Avanti J-E centrifuge). The pellet was re-suspended in 0.5 ml of Buffer C (1x) 
containing 10 mM potassium phosphate and 0.2 mM PMSF and dialysed against 1 x 1 
M Tris buffer containing 0.2 mM PMSF overnight with at least one buffer change. The 
concentration of AP-2 was determined (2.2.1.3) and aliquots stored at -80ºC. 
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2.2.3 Proteo-liposome Recruitment  
2.2.3.1 Preparation of pig brain cytosol for proteo-liposome recruitment 
Pig brains were washed with recruitment buffer and then homogenised in an electric  
blender with an equal volume of recruitment buffer (w/v) containing the protease 
inhibitors aprotinin, E-64, PMSF and pepstatin at final concentrations of 3.2 µg/ml, 4 
µg/ml 1 mM and 1 µg/ml respectively. The suspension was centrifuged at 2500 xg for 
30 minutes at 4˚C. The supernatant was harvested and centrifuged at 100000 xg for 1 
hour at 4˚C to remove endogenous membranes. The resulting supernatant was 
aliquoted and the samples were flash frozen in liquid nitrogen and stored at -80˚C.  
2.2.3.2 Production of liposomes with coupled cytoplasmic receptor tails 
Recombinant 6xHis MBP tagged cytoplasmic receptor tails were expressed in E.coli 
(Bl21DE3) and were purified as explained in 2.2.2.1. 500 µg of each receptor tail was 
digested with 5 µg of purified recombinant tobacco etch virus protease (TEV) (2.2.2.2) 
and 1 mM tris(2-carboxyethyl)phosphine (TCEP) overnight at 25˚C to remove the 
6xHis MBP tag.  
Liposomes were prepared from a mixture of the following lipids; PC, PE, PS, C, PE 
MCC and one of the phosphatidylinositol containing lipids (either PI, PI(3)P, PI(3,5)P2 
or PI(4,5)P2) unless stated otherwise (2.1.2). The final amounts of each lipid were 200 
nmol, 150 nmol, 50 nmol, 50 nmol, 50 nmol and 5 nmol respectively. The lipid mixture 
was dried under nitrogen gas and re-suspended in 0.65 ml of recruitment buffer. The 
re-suspended lipid film was subjected to 5 freeze/thaw cycles in liquid nitrogen and 
warm water. 100 µl of the liposome suspension was incubated with one TEV digested 
protein sample for 60 minutes in the dark at room temperature. The coupling of the 
cytoplasmic receptor tails to the liposomes is due to the formation of a sulphydryl bond 
between an extra cysteine residue at the N terminus of the receptor tail and the 
activated maleimide head group on the anchor lipid (PE-MCC) (Pocha et al., 2011). 
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The liposomes containing the coupled receptor tail will be referred to as proteo-
liposomes. The proteo-liposomes were pelleted by centrifugation at 100000 xg for 20 
minutes at 4˚C, re-suspended in 1 ml of 10 mM L-cysteine (in RB) and incubated for 15 
minutes in the dark at room temperature. This step was important for quenching 
unreactive maleimide head groups, and for the creation of cysteine control samples. 
The sample was subjected to centrifugation (as above) the supernatant discarded and 
the pellet re-suspended in 100 µl of recruitment buffer. 
2.2.3.3 Proteo-liposome recruitment experiments  
Pig brain cytosol was centrifuged for 1 hour at 100000 xg and at 4˚C to remove any 
remaining endogenous membranes. The GTP analogue GTPγS (or GMPNP) was 
added to the cleared pig brain cytosol (unless stated otherwise) at a final concentration 
of 0.15 mM. 900 µl of cleared pig brain cytosol was added to 100 µl of proteo-
liposomes and incubated for 30 minutes at 37˚C. Here the pig brain cytosol acts as a 
protein reservoir. Recruitment was also carried out using purified protein instead of the 
pig brain cytosol. Here GTPγS (or GMPpnp) was not added to the recruitment mixture. 
The proteo-liposomes were separated from the cytosol or purified recombinant protein 
using a sucrose cushion (2 ml 60% sucrose in RB and 8 ml 5% sucrose in RB) in a 
Beckman Coulter Optima L-100k ultracentrifuge (SW40 rotor) at 38000 rpm for 90 
minutes at 4˚C. The interface between the two sucrose layers containing the proteo-
liposomes was removed and re-suspended in 11 ml of RB and centrifuged in a 
Beckman Coulter Optima L-100k ultracentrifuge (SW40 rotor) at 38000 rpm for 1 hour 
at 4˚C. The supernatant was removed and the pellet re-suspended in 100 µl of 2x 
Laemmli buffer (unless stated otherwise). The samples were analysed by SDS-PAGE 
and western blotting for interacting proteins.   
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2.2.3.4 Flow cytometry analysis of liposomes 
Liposomes were produced as explained in 2.2.3.2 except they also contained 2 mol% 
of the fluorescent lipophilic dye DiI, and the liposomes were re-suspended in 1 ml 
instead of 100 µl. Six sets of liposomes were prepared containing  66 µg, 164 µg, 329 
µg, 657 µg, 1350 µg and 2694 µg of  coupled GFP.  These liposomes were analysed 
using flow cytometry in a Beckman Coulter Cell Lab Quanta SC flow cytometer. GFP 
was excited at 498 nm and DiI at 549 nm and 10000 events were counted.  
2.2.3.5 Pull downs with purified His-Vac14 
20 µg of purified recombinant, MBP-AICD, MBP-Tr1, MBP-Tr2, MBP-Tr3, MBP-Tr4 
and MBP (negative control) were incubated with 10 µg of purified HIS-Vac14 for 1 hour 
rocking on ice. The volumes were adjusted to 200 µl with wash buffer. The samples 
were centrifuged in a bench top centrifuge at maximum speed for 5 minutes to remove 
any aggregates. The supernatant was transferred to a tube containing 20 µl of amylose 
resin beads (New England BioLabs) which had been washed 3 x in wash buffer. The 
samples were incubated rocking on ice for 1 hour and the amylose beads washed 5 
times with wash buffer. The proteins were eluted by incubating the beads with 50 µl of 
PD elution buffer for 10 minutes on ice. The samples were centrifuged at 2000 rpm in a 
bench top centrifuge for 1 minute at 4˚C. The supernatant was transferred to a new 
tube containing 12.5 µl of 4 x Laemmli buffer. The sample was heated at 95˚C for 5 
minutes before being subjected to SDS-PAGE and western blotting. 25 µl of each pull 
down sample was loaded on an 8% acrylamide gel.  
2.2.3.6 Clathrin recruitment assay 
Clathrin recruitment assays were based on those used in Kelly et al. (2014). 
Liposomes were created comprising 10% cholesterol, 5% PE-MCC, 5% PI(4,5)P2 
(unless stated otherwise) 80% PC:PE in a ratio of 3:2. The liposomes were incubated 
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in 182 µg of TEV digested purified receptor tail (AICD and Crbs2) or cysteine (negative 
control). The liposomes were centrifuged at 50000 rpm for 10 minutes at 4ºC in a 
(Beckman Coulter Optima TLX Ultracentrifuge) and the pellet re-suspended in 1 ml of 
10 mM cysteine in 1 x HKM buffer to saturate any free anchor lipid. The liposomes 
were centrifuged again and re-suspended in 1 ml of 1 x HKM buffer to obtain a final 
lipid concentration of 0.4 mg/ml. Purified AP-2 (2.2.2.6) was added at a final 
concentration of 0.8 µM to 50 µl of the liposomes and incubated for 30 minutes on ice. 
The liposomes were centrifuged at 50000 rpm for 10 minutes at 4ºC in a (Beckman 
Coulter Optima TLX Ultracentrifuge) the supernatant removed and the pellet re-
suspended in 50 µl of 1 x HKM buffer. Purified clathrin (2.2.2.5) previously dialysed 
against de-polymerisation buffer to disassembly the clathrin cages was added to the 
liposomes at a final concentration of 0.2 µM and incubated for 30 minutes on ice and 
then 15 minutes at 37ºC. The sample was centrifuged at 50000 rpm for 10 minutes at 
4ºC in a (Beckman Coulter Optima TLX Ultracentrifuge) and the pellet and supernatant 
adjusted with 2 x Laemmli buffer. The samples were subjected to analysis by western 
blotting and SDS-PAGE stained with Coomassie.  
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2.2.4 Mammalian Tissue Culture Experiments 
2.2.4.1 Transfections  
HeLa cells were seeded into 24 well plates at a density of 100000 cells per well for 
transfection using Lipofectamine 2000 (Invitrogen Life Technologies). The following 
day 1 µg of plasmid DNA was diluted in 50 µl of OptiMEM medium and added to 2 µl of 
Lipofectamine 2000 diluted in 50 µl of OptiMEM medium. This transfection mix was for 
one well in a 24 well plate. The transfection mixture was incubated for 15 minutes at 
room temperature and added to the 24 well plate. A list of the plasmids used for 
transfections can be seen in the appendix (A1). The cells were incubated with the 
transfection mixture for approximately 18 hours at 37ºC, 5% CO2, washed several 
times with tissue culture medium to completely remove the transfection reagent and 
incubated overnight at 37ºC, 5% CO2.  
For analysis by live cell imaging the transfected cells were then transferred to a glass 
bottom dish for imaging and incubated overnight at 37ºC, 5% CO2. Before imaging the 
tissue culture medium was removed and replaced by OptiMEM medium.  
For analysis of fixed cells the cells were fixed using cell fixing solution for 30 minutes at 
room temperature, and were washed with 1 X PBS and then distilled water. The 
excess liquid was removed, and the cells mounted on a glass slide using 20 µl of 
Mowiol mounting media. The slides were left to dry overnight. 
2.2.4.2 PIKfyve inhibition 
To inhibit PIKfyve activity HeLa cells were treated with 4 µM of the PIKfyve inhibitor 
YM201636 (dissolved in DMSO) (Santa Cruz Biotechnology) for 4 hours at 37˚C 5% 
CO2 (unless stated otherwise). The medium was removed, the cells washed with 1 x 
PBS, fixed and mounted onto glass slides.  
  103 
  
2.2.4.3 Lysis of HeLa cells for Western blotting 
HeLa cells were seeded into 6 well plates at a density of 400000 cells per well and 
incubated at 37˚C with 5% CO2 overnight. The medium was removed and the cells 
washed with 1 x PBS (ice cold). 200 µl of mammalian cell lysis buffer was added to 
each well and the cells scraped off the bottom of the well. The cell suspension was 
centrifuged for 15 minutes at max speed in a benchtop centrifuge at 4˚C. 4 x Laemmli 
buffer was then added to the supernatant to make a 1 x solution. The samples were 
analysed by SDS-PAGE and western blotting using APP, APLP2 and tubulin 
antibodies.  
2.2.4.4 Microscopy 
Live cell imaging was carried out using a Leica Microsystems DM14000B inverted 
microscope in a temperature control chamber set to 37ºC. 
Fixed cell imaging was conducted using a Leica Microsystems SP5 TCS II MP 
DM16000B up-right confocal microscope. The GFP and YFP constructs were excited 
using the 488 nm and 514 nm lasers set to 22% and 33% respectively. The mCherry 
construct was imaged using the 594 laser set at 33% with a constant gain of 821 HV. 
Z-stacks were taken of the cells with a 0.5 µm distance between slices.  
 
2.2.4.5 Quantification of ML1Nx2 positive vesicles 
For the quantification of mCherry- ML1Nx2 positive structures in cells co-expressing 
mCherry-ML1Nx2 and a GFP or YFP tagged APP/ACID constructs Z-stacked images 
were obtained using a Lecia SP5 TCS II MP confocal microscope. The images were 
imported into ImageJ and maximum projections created from the Z-stacks. Each cell to 
be quantified was individually selected and all background removed. The mCherry 
ML1Nx2 positive structures were analysed using the MOSAIC plugin for ImageJ (Rizk 
et al., 2014). The image was segmented with a background subtraction was of 10 
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pixels. The background subtraction reduces the background fluorescence using the 
rolling ball algorithm.  For the segmentation parameters the regularisation was set to 
0.1 and the minimum object intensity was set to 0.3. The regularisation parameter 
determines what to class as noise and what to class as an object. Any structure with 
an intensity lower than the minimum object intensity is not classed as an object.   The 
average number of mCherry-ML1Nx2 structures per cell was calculated for each 
condition along with the average intensity of these structures. The data was analysed 
using a one way ANOVA (alpha = 0.05) with a Tukey’s post hoc test in GraphPad 
Prism 6. 
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Chapter 3- The establishment of 
the proteo-liposome recruitment 
technique and its use in the 
analysis of the AICD-mTOR 
interaction 
 
 
3.1 Introduction  
Membrane proteins are a diverse group of proteins, important in a wide variety of 
biological processes. They are involved in cell signalling, transport across the cell 
membrane and cell adhesion. The intracellular domains of membrane proteins are key 
for linking the extracellular domain with the cytoplasm. They bind to a wide variety of 
cytoplasmic proteins which allows them to exert their physiological function. It is 
therefore important that we develop ways for examining the intracellular interactome of 
membrane proteins with a view to gaining a greater insight into their function. 
Membrane protein interactions can be studied through the use of an in vitro model 
membrane system involving the use of synthetic membranes or liposomes. The use of 
a model membrane system allows for the mimicking of the intracellular domain 
attached to its natural membrane environment, and therefore takes into account any 
phospholipid based interaction. Liposome based systems have previously been used 
to examine the interactions of certain membrane proteins with cytosolic factors, with 
particular emphasis on the interactions of coat protein complexes. An overview of the 
use of liposome based model membrane systems can be seen in chapter 1 (1.3).  
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This chapter will focus on the establishment of a liposome model membrane 
recruitment system based on that of Pocha et al. (2011), using amyloid precursor 
protein as a model membrane protein.  
Previous work conducted by colleagues (Balklava et al., under revision A) utilised a 
proteo-liposome recruitment system similar to that used by Pocha et al. (2011), 
coupled with label free quantitative mass spectrometry to establish an intracellular 
interactome of APP, through the coupling of its intracellular domain (AICD) to 
liposomes, and the isolation of its binding partners from mouse brain cytosol samples. 
As well as identifying established APP interacting proteins such as Fe65 several novel 
APP interactors were identified (Balklava et al., under revision A). Among these was 
the mTOR complex involved in the integration of nutrient and energy signals (see 
chapter 1.6).  It was found that mTOR and its accessory subunits raptor and mLST8 
were significantly enriched in AICD proteo-liposome samples, raising the possibility of 
an interaction between APP and mTOR. This chapter will focus on the characterisation 
of this observed putative interaction between APP and mTOR in order further develop 
and validate the proteo-liposome recruitment system.  
3.1.1 The interaction between APP and mTOR? 
The main reason for the investigation of the interaction between APP and mTOR is to 
gain insight into the physiological function of APP. The primary focus of APP research 
has been on is proteolytic processing, and the contribution of one if its proteolytic 
products, known as Aβ, in the pathology of Alzheimer’s disease. Despite this vast 
amount of research, the physiological role of full length APP remains largely unknown 
(Caldwell et al., 2013). The potential interaction between APP and the mTOR complex 
observed by Balklava et al. (under revision A) has exciting implications for APP 
function due to the wide variety of crucial physiological processes the mTOR complex 
is involved in. 
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There is also an increasing amount of evidence that suggests that aberrant mTOR 
signalling plays a role in Alzheimer’s disease (Yates et al., 2013). mTOR signalling is 
enhanced in the brains of Alzheimer’s disease patients (Yates et al., 2013) . An 
increase in mTOR signalling has also been shown to potentiate Tau toxicity in a 
Drosophila tauopathy model (Khurana et al., 2006). Genetically increasing the levels of 
mTOR in mice increases both the levels and the phosphorylation of tau. Reducing 
mTOR signalling in a mouse model overexpressing mutant human reduces tau 
pathology (Caccamo et al., 2013). The overexpression of APP mutant proteins in 
mammalian cells is known to increase mTOR signalling, however the mechanism that 
leads to this increase in mTOR signalling remains unidentified (Caccamo et al., 2010). 
It has also been shown that insulin is able to influence the phosphorylation of APP, and 
that impaired insulin signalling can promote the formation and accumulation of Aβ 
(Pandini et al., 2013). Insulin is known to activate mTORC1 and stimulate protein 
synthesis through the phosphorylation of 4EBP1 (Wang et al., 2006). Taken together 
these findings also support the role of mTOR in Alzheimer’s disease. For these and the 
fact that the native function APP still remains largely unclear we chose to examine the 
interaction between APP and mTOR using a proteo-liposome approach whereby the 
intracellular domain of AICD was covalently coupled to liposomes.  
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3.2 Results 
3.2.1 Optimisation of the proteo-liposome recruitment technique. 
Understanding the interactions between the cytoplasmic domain of membrane proteins 
and cytosolic proteins is crucial for elucidating the function of a particular membrane 
protein. It is therefore important that we have ways of examining these interactions. 
Using the Type I transmembrane protein APP as a model protein a model membrane 
system for examining APP’s intracellular interactome was designed. A liposome 
recruitment assay based on that used by Pocha et al. (2011) was utilised as the model 
membrane system. The method involves coupling the intracellular domain of a 
membrane protein to liposomes to mimic its native configuration. For the purpose of 
this chapter the intracellular domain of APP (AICD) was coupled to these liposomes. 
AICD was expressed in E. coli using the pET-28-MBP-AICD plasmid, which is of the 
same construct as the expression plasmid used by (Pocha et al., 2011). A 
representation of the purified protein construct can be seen in figure 13A. The purified 
MBP tagged protein was digested with TEV protease overnight, which cleaved off a 
6xHis-MBP tag exposing an extra N-terminal cysteine residue. This cysteine residue 
allows for the covalent coupling of the protein to a lipid anchor (PE-MCC) in the 
liposomes. The lipid anchor PE-MCC contains an activated maleimide head group 
which covalently couples to the sufhydryl group of the N-terminal cysteine residue. 
Once the TEV protease cleave protein is attached to the liposomes cysteine is used to 
quench any unreacted maleimide head groups. These proteo-liposomes are incubated 
in brain cytosol, which acts as a protein reservoir. The proteo-liposomes and their 
interaction partners are isolated by ultracentrifugation (Figure 13C). Samples can be 
analysed by SDS-PAGE, Western blotting and mass spectrometry. 
The liposome recruitment method used by Pocha et al. (2011) was subjected to 
several modifications. The first of these was a change in the sucrose gradient used to 
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isolate the proteo-liposomes and their interaction partners. Instead of the proteo-
liposomes being loaded at the bottom of the gradient and floated, as used by Pocha et 
al. (2011), they were loaded at the top of the gradient and harvested at the interface 
between a sucrose cushion composed of 60% and 5% sucrose dissolved in 
recruitment buffer (RB). An example of the sucrose cushion used can be seen in figure 
13C. This method allows for the separation of the proteo-liposomes from the cytosolic 
protein they were incubated in. Proteo-liposome were harvested at the interface 
between the 5 and 60% sucrose whilst the cytosolic protein (0% sucrose) was 
removed from the tube before the removal of the proteo-liposomes. This method allows 
for any insoluble aggregates to be pelleted, which separates them from the proteo-
liposomes, preventing the contamination of samples. Another important advantage of 
changing the sucrose cushion is that it allows for the isolation of proteo-liposomes with 
a large density range, compared to the flotation method used by Pocha et al. (2011) 
where the heaviest proteo-liposomes may not make it to the top of the gradient for 
isolation. This modification resulted in a change in the centrifugation time from 
approximately 18 hours to 2 hours therefore saving time and energy.  
As the recruitment process is quite complex and involves several steps there was a 
need to ensure the individual steps were functioning correctly. To achieve this, 
samples were taken at different stages of the recruitment process and analysed by 
Coomassie blue stained SDS-PAGE (Figure 13B). A 2% sample (v/v) of MBP-AICD 
(pre), and a 2% sample of the TEV protease digested AICD (post) were taken to check 
for the complete digest of the protein and the consequent removal of the 6 x His-MBP 
tag. This could be viewed by Coomassie stained SDS-PAGE by the appearance of a 
band at about 5 kDa corresponding to AICD, and the presence of a band 
corresponding to the cleaved MBP tag, characterised by a lower molecular weight than 
full length MBP-AICD (Figure 13B). A sample of 2% of the volume of the supernatant 
resulting from the 1st centrifugation (see 2.2.3.3) was collected (supernatant). This 
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allowed for analysis of the coupling efficiency of AICD to PE-MCC in the liposomes 
evident by the absence of the low molecular weight AICD band, and the presence of a 
band corresponding to the cleaved MBP tag.  If the lower molecular weight AICD was 
present in the supernatant sample this could indicate liposome saturation with AICD, or 
the faulty coupling of AICD to the liposomes.  A 2% sample (v/v) of the re-suspended 
pellet was taken before the addition of pig brain cytosol to ensure AICD was coupled to 
the liposomes (pellet). This was detected by the presence the 5 kDa AICD band. This 
band was slightly higher in molecular weight than the AICD in the post digestion 
sample, due to the presence of lipid from the coupling of AICD to liposomes.  
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Figure 13. An overview of the proteo-liposome recruitment method. (A) The 
construct of the cytoplasmic receptor tail (AICD) used to allow coupling of the 
protein to PE-MCC in the liposomes. (B) A Coomassie stained SDS-PAGE gel of 
different stages in the recruitment process to check for complete digestion of the 
protein tail and its coupling to liposomes. Samples (2% v/v) taken at different points 
during the recruitment process. Pre = MBP –AICD protein, Post = TEV protease 
digested MBP-AICD, Supernatant = after 1st centrifugation of proteo-liposomes, 
Pellet = pelleted proteo-liposomes containing coupled AICD. (C) A basic overview 
of the recruitment process; AICD is coupled to liposomes (now called proteo-
liposomes) and incubated in pig brain cytosol which acts as a protein reservoir. 
The proteo-liposomes and the interaction partners are purified by density 
centrifugation and analysed by SDS-PAGE and western blotting. 
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The next stage in the refinement of the recruitment process was to determine the most 
effective amount of total lipid used to create the liposomes, in terms of the yield of 
protein recruitment. A recruitment experiment was conducted using liposomes 
containing different amounts of total lipid (500, 100 and 50 nmol). The liposomes 
comprised of 40 mol% PC, 29 mol% PE, 10 mol% PS, 10 mol% C, 10 mol% PE-MCC 
and 1 mol% PI(4,5)P2 (see table 2). The TEV protease digested AICD was coupled to 
liposomes and maltose binding protein (MBP) was coupled to liposomes as a control. 
MBP contains no internal cysteine residues so couples to liposomes via the introduced 
N-terminal cysteine residue. Therefore, it is coupled in the same orientation as AICD, 
mimicking protein coated liposomes. The liposomes were incubated in 300 µg of 
protein as established by Pocha et al. (2011). This is equivalent to 6 nmol MBP-AICD 
and 6.7 nmol MBP (control), as calculated using the full length undigested construct. 
The ratio MBP-AICD protein to the anchor lipid PE-MCC was therefore 1 nmol: 8.33 
nmol, 1 nmol: 1.67 nmol and 1 nmol: 0.833 nmol for liposomes comprising 500 nmol, 
100 nmol and 50 nmol total lipid respectively. The ratio of the MBP control protein to 
the anchor lipid PE-MCC was 1 nmol: 7.465 nmol, 1 nmol: 1.5 nmol and 1 nmol: 0.75 
nmol for liposomes comprising 500 nmol, 100 nmol and 50 nmol total lipid respectively. 
These proteo-liposomes were incubated in 900 µl of pig brain cytosol (16 mg/ml) 
(prepared as in 2.2.3.1). The proteo-liposomes and interaction partners were isolated 
by sucrose gradient density centrifugation (2.2.3.3), and samples of the final 
recruitment were subjected to SDS-PAGE stained with Coomassie blue.  Figure 14A 
shows a Coomassie blue stained SDS gel of the final recruitment products.  
AICD proteo-liposomes comprised of 100 nmol and 500 nmol total lipid significantly 
recruited more protein than MBP control proteo-liposomes comprised of 100 nmol and 
400 nmol total lipid (Figure 14 B). Overall liposomes comprising of 500 nmol total lipid 
significantly recruited more protein than those comprising 50 nmol and 100 nmol total 
lipid (blue bars on figure 14B).  
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A saturation point for the maximum amount of protein that could be recruited was not 
reached, demonstrating that the method is not at the limits of detection. Of note is the 
difference in the band pattern between the AICD proteo-liposomes and the control 
liposomes (MBP) indicating that AICD recruits different proteins to the control, as well 
as bands common to both samples. The arrows on figure 14A represent bands that are 
present in only AICD proteo-liposome samples. For future recruitment experiments 
liposomes comprising 500 nmol of total lipid were used as this produced a good yield 
of recruited protein. These results suggest that using more than 500 nmol of lipid per 
recruitment would lead to a greater yield of recruited protein; however, this would be 
costly due to an increase in the amount of lipids used.  
 
  
  115 
  
  
Figure 14. The effect of lipid amount on protein recruitment. 
Three sets of liposomes were produced with different total lipid amounts (500, 100 and 
50 nmol). These liposomes contained coupled AICD or MBP (control) at ratios of 
1:8.33 nmol, 1:1.67 nmol and 1:0.833 nmol (protein:anchor lipid) for AICD and 1: 7.465 
nmol, 1: 1.5 nmol and 1:0.75 nmol (protein:anchor lipid) for MBP control, for liposomes 
comprising 500 nmol, 100 nmol and 50 nmol total lipid respectively. The proteo-
liposomes were incubated in the same volume of pig brain cytosol, isolated by 
ultracentrifugation and analysed by SDS-PAGE. (A) A Coomassie stained SDS-PAGE 
gel of the recruitment samples of liposomes comprising 50 nmol, 100 nmol and 500 
nmol of total lipid. (B) Densitometry analysis of the amount of protein recruited was 
conducted in ImageJ (error bars = sem). Statistical analysis was conducted in 
GraphPad Prism 6.0 (n=3). A two- way ANOVA using a repeated measures design. 
Both a Tukey’s (black bars) and Sidak’s (blue bars) post hoc test was carried out (* p < 
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).  
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In the method developed by Pocha et al. (2011), 300 µg of protein was coupled to 
liposomes. Due to the alteration of the lipid amount in figure 14 compared to that used 
by Pocha et al. (2011), the amount of protein coupled to these liposomes was also 
modified. The optimum amount of protein to couple to liposomes consisting of 500 
nmol of total lipid was determined using liposomes coupled to different amounts of the 
fluorescent protein GFP. GFP contains internal cysteine residues, which when reduced 
using TCEP, are available to couple GFP to the anchor lipid PE-MCC in the liposomes. 
The amount of GFP coupled to liposomes was determined by the intensity of the GFP 
fluorescence present on liposomes as analysed by flow cytometry. Liposomes were 
produced containing 50 nmol of the anchor lipid PE-MCC, which is 10% of the total 
lipid amount of 500 nmol. These liposomes also contained 2 mol% of the fluorescent 
lipophilic dye DiI. Only liposomes exhibiting both DiI and GFP fluorescence were 
included in the analysis. Figures 15A and 15B show the presence of both GFP and DiI 
fluorescence respectively on the liposomes, indicated by a shift in the peak to the right 
when compared to control liposomes, without any coupled GFP or the fluorescent 
lipophilic dye DiI.  Figure 15C shows the saturation curve obtained from the mean 
fluorescence intensities of the liposomes containing different amounts of coupled GFP. 
Figure 15 C shows that saturation of the anchor lipid with GFP, as determined by 
fluorescence intensity, appears to occur at approximately 1400 µg of GFP.  
When examining the interaction partners of the intracellular domains of membrane 
proteins using the proteo-liposome recruitment technique, the complete saturation of 
the anchor lipid with these intracellular domains may affect the recruitment of cytosolic 
proteins. This is due to the steric hindrance that may arise from saturating the 
liposomes with these peptides, meaning the recruitment of cytosolic proteins would be 
affected, especially interacting proteins of a high molecular weight. Therefore, the 
amount of protein coupled to the liposomes needs to take this into account. 500 µg of 
protein was selected as the optimum amount to couple to liposomes, as according to 
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figure 15C this amount of protein should only saturate just below half of the anchor lipid 
present, allowing for a high yield of recruited protein whilst not selectively affecting 
protein recruitment.  
Figure 15.  The saturation of liposomes with GFP 
Different amounts (66 µg, 164 µg, 329 µg, 657 µg, 1350 µg, and 2694 µg) of the 
fluorescent protein GFP were coupled to liposomes containing 50 nmol of the anchor 
lipid PE-MCC and 2 mol% of the fluorescent lipophilic dye DiI. The fluorescence 
intensity of these liposomes were analysed using flow cytometry. GFP was excited at 
498 nm (A) and DiI was excited at 549 nm (B) and 10000 events were analysed. The 
intensity of GFP on the liposomes with different coupled amounts was used to 
determine the saturation of the anchor lipid PE-MCC with GFP (C). A saturation curve 
was fitted to these data points in Graphpad Prism 6.0 using non-linear regression with 
the least squares fit and the saturation one site, total and nonspecific binding model. 
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3.2.2 AICD containing proteo-liposomes selectively recruit mTOR, raptor 
and rictor. 
Once the proteo-liposome recruitment method was fully established this technique was 
then used to examine the interaction of AICD with the mTOR complex. Using mass 
spectrometry Balklava et al. (under revision A) established the intracellular interactome 
of AICD, and using a similar liposome recruitment method they identified several novel 
interaction partners of AICD, as well as the known interactors. One of these novel 
interactors was the kinase mammalian target of rapamycin (mTOR). Using this as a 
basis, the potential interaction between AICD and mTOR was examined. This allowed 
for the development of the liposome recruitment method, to enable the identification of 
interactions from the recruitments using western blotting. 
Proteo-liposome recruitments were conducted where AICD was coupled to liposomes 
and incubated in brain cytosol. For the recruitment process cysteine and MBP 
liposomes were used as controls. Cysteine was used to quench unreactive maleimide 
groups. These control liposomes ensured that any selective recruitment observed was 
due to the presence of a specific tail (AICD). The liposomes were produced from 500 
nmol total lipid. The final recruitment products were analysed by SDS-PAGE and 
western blotting for mTOR, and the subunits raptor and rictor (Figure 16A). The 
recruitments showed that AICD containing proteo-liposome samples were significantly 
enriched in mTOR, raptor and rictor (Figure 16B), demonstrating an interaction 
between the intracellular domain of AICD and the mTOR complex.  
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Figure 16. The mTOR kinase and the mTOR complex subunits Raptor and Rictor 
interact with the intracellular domain of APP (AICD). (A) Proteo-liposome 
recruitments were analysed by SDS-PAGE and western blotting for mTOR and the 
subunits Raptor and Rictor (see 2.1.3 for the antibodies used).  (B, C, D) mTOR, 
Raptor and Rictor were significantly recruited from brain cytosol onto proteo-liposomes 
containing coupled AICD compared to control liposomes (Cysteine and MBP). 
Densitometry analysis was conducted in ImageJ. The area obtained was expressed as 
a percentage of the area corresponding to the input. Statistical analysis was carried out 
in Graphpad Prism 6.0 using a one way ANOVA with a Tukey’s post hoc test. (** p < 
0.01) (n = 5).  
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3.2.3 mTOR directly binds to AICD via its C-terminal kinase domain. 
The mTOR complex is selectively recruited onto AICD presenting proteo-liposomes, 
demonstrating an interaction between the two proteins (3.2.2).The next stage was to 
determine if this observed interaction between AICD and mTOR was due to the direct 
binding to each other or was it mediated via other proteins? In order to conclude 
whether this interaction is direct, the recruitment method was modified. In previous 
recruitments pig brain cytosol acted as a protein reservoir for the recruitment. 
However, it does not allow for the determination of whether any interaction observed is 
direct, as the pig brain cytosol contains other proteins that could help mediate the 
interaction observed in figure 16. To overcome this, a pure source of protein was used 
instead of pig brain cytosol. Balklava et al. (under review A) created truncation mutants 
of mTOR and showed that the C-terminal mutant containing the kinase domain of 
mTOR was able to bind to AICD using affinity pull downs. To test this interaction using 
the proteo-liposome recruitment system the C-terminal kinase domain of mTOR 
(R1955-W2549) was expressed and purified in E. coli using the pET28 vector with an 
N-terminal MBP tag. Proteo-liposome recruitments were carried out, where AICD and 
control (cysteine) liposomes were incubated with two different amounts of the purified 
mTOR kinase domain (12 µg and 36 µg). The final recruitment samples were 
subjected to analysis by SDS-PAGE and western blotting using an antibody against 
mTOR (table 3).  As shown in figure 17 the kinase domain of mTOR was selectively 
recruited onto AICD presenting proteo-liposomes, showing that the mTOR kinase 
domain is able to directly bind to AICD.   
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3.2.4 The 1st 10 N-terminal amino acids of AICD are crucial for mediating 
its interaction with mTOR. 
Proteo-liposome recruitments have shown that mTOR is able to directly bind to AICD 
via its C-terminal kinase domain. The proteo-liposome recruitment method was 
modified further to allow for the determination of important interaction motifs on the 
intracellular domain of receptors. The interaction between AICD and mTOR was used 
as a model, whereby AICD was investigated for motifs that mediate its interaction with 
mTOR. This was achieved by using proteo-liposome recruitments and two different 
truncation mutants of AICD (Figure 18A).  The mutant AICD truncation 1 (Tr1) contains 
the first 10 N-terminal amino acids of AICD only. In the AICD truncation 4 (Tr4) mutant  
the 1st 10 N-terminal amino acids of AICD are deleted. These truncation mutants were 
designed to split AICD into motifs that are most likely to mediate the interaction with 
mTOR. Figure 18D shows the potential AICD interaction motifs. Truncation 1 was 
created to single out the YTSI motif of AICD and truncation 4 was created as it has 
truncation 1 deleted.These AICD truncations were expressed and purified in E.coli 
(methods 2.2.2.1). Proteo-liposome recruitment experiments were undertaken, in 
Figure 17. The Kinase domain of mTOR shows specific binding to the 
intracellular domain of APP (AICD). AICD proteo-liposomes and control liposomes 
(cysteine) were incubated in 12 and 36 µg of purified recombinant mTOR Kinase 
domain (R1955-W2549). The recruitment samples were analysed by SDS-PAGE and 
western blotting for mTOR. The specificity of the kinase domain binding to AICD 
proteo-liposomes suggests that the interaction between AICD and the mTOR kinase 
domain is direct. (n=3)  
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which AICD and the truncations 1 and 4 were coupled to liposomes along with MBP 
and cysteine (negative controls). These liposomes were incubated in pig brain cytosol 
and then isolated by sucrose density centrifugation. The final liposome pellet was 
subjected to SDS-PAGE and western blotting using an antibody against mTOR (Figure 
18B). The western blots obtained showed that mTOR was significantly recruited to 
AICD liposomes and not to control liposomes (MBP or cysteine) (Figure 18C). mTOR 
was also significantly recruited onto liposomes containing Tr1, but not liposomes 
containing Tr4 (Figures 18B and C). This indicates that mTOR is recruited to the first 
10 N-terminal amino acids of AICD. These results show that it is possible to use the 
proteo-liposome recruitment system to analyse interaction interfaces between proteins, 
through the use of truncated intracellular domains of membrane proteins.  
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Figure 18. The 1st N-terminal 10 amino acid residues of AICD are able to 
mediate mTOR recruitment. (A) The amino acid sequence of full length AICD, the 
truncation mutant Tr1 and the deletion mutant Tr4 used in the recruitment. (B) A 
representative western blot of a proteo-liposome recruitment in which AICD, Tr1, 
Tr4 and controls (MBP and cysteine) were coupled to liposomes and incubated in 
pig brain cytosol. The first 10 amino acids of AICD (Tr1) are needed to mediate the 
interaction between AICD and mTOR. (C) Densitometry analysis of B. Analysis 
was conducted using ImageJ. The area was expressed as a percentage of the 
area corresponding to the input band. Statistical analysis was carried out using a 
one-way analysis of variance (ANOVA) with a Tukey’s post hoc test in Graphpad 
Prism 6.0 (*** p < 0.001, ** p < 0.01).(n=3). (D) Important known binding motifs and 
phosphorylation sites of AICD. The phosphorylation sites are shown in red and the 
binding motifs in blue, with the interacting proteins below (adapted from Chang 
(2010)).  
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3.3 Discussion 
3.3.1 The proteo-liposome recruitment system 
This chapter focuses on the establishment and development of the proteo-liposome 
recruitment method for examining the interaction partners of the intracellular domains 
of membrane proteins. A similar liposome recruitment system has previously been 
used to examine the assembly of AP-1A protein coats onto liposomes containing the 
covalently coupled cytoplasmic tails of the gpI envelope glycoprotein of the Varicella 
zoster virus and the lysosomal integral membrane protein Limp II (Baust et al., 2006). 
In 2011 Pocha et al also used a liposome recruitment system to examine the trafficking 
of the apical determinant Crb2. They show that the intracellular domain of Crb2 
interacts with the Vps35 subunit of the retromer complex required for mediating 
retrograde trafficking (Pocha et al., 2011). There were several major changes made to 
the proteo-liposome recruitment system in this chapter which have considerably 
advanced the method. The manipulation of the sucrose cushion used to isolate and 
purify the proteo-liposomes allowed for the detection of heavy, protein dense 
liposomes, which may have otherwise not been detected using the floatation gradient 
described by Pocha et al. (2011). This means that proteo-liposomes that have 
recruited a large number of interaction partners, and interaction partners consisting of 
large protein complexes, are not excluded from analysis due their inability to float to 
the top of the sucrose gradient.  
The proteo-liposome recruitment method was modified to allow for the detection of 
direct binding. Previously the proteo-liposome recruitment method has been used to 
isolate binding partners from cytosol samples (Baust et al., 2006, Pocha et al., 2011). 
This technique allows for the detection of both direct interaction partners and 
interaction partners mediated via other proteins, known as indirect interaction partners, 
however it does not discriminate between direct and indirect interactions. This is 
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advantageous when examining the complete interaction profile of the intracellular 
domain of a membrane protein, as an overall view of the interaction partners is 
generated. Through the use of purified recombinant protein, the proteo-liposome 
method was improved to allow for the detection of direct interaction partners. Therefore 
the proteo-liposome method can be used to gain an overall insight into the intracellular 
interactome of a membrane protein, and to directly target and examine specific 
interactions.  
The proteo-liposome recruitment method was further developed to examine these 
specific interactions in more detail, in particular the discovery of binding motifs required 
for the interaction. The generation of truncated forms of AICD allowed for the 
identification of the mTOR binding site on AICD. The use of truncation mutants of a 
membrane proteins intracellular domain, allows for the detection of domains important 
for binding. To further develop the proteo-liposome recruitment method the resolving 
power of the system needs to be determined. For example, can the method detect 
differences in binding upon the manipulation of a single amino acid residue in the 
intracellular domain, and can it discriminate between several mutants each with a 
different single amino acid change? 
3.3.2 The APP-mTOR interaction 
Using the proteo-liposome recruitment system it has been established that AICD is 
able to interact with mTOR, with the N-terminal 10 amino acids of AICD, crucial for 
mediating this interaction. The use of the proteo-liposome recruitment method, 
modified in order to detect direct binding, showed that the C-terminal kinase containing 
domain of mTOR is able to directly bind to AICD. This work demonstrates an 
interaction between APP and mTOR through the N-terminus of AICD and mTOR’s 
kinase domain. This raises interesting questions about the functional significance of 
this interaction. In work conducted by other members of the group (Balklava et al., 
under review A) it was shown that overexpressed mTOR and APP co-localise on late 
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endosomes and lysosomes in HeLa cells, with APP also co-localising with endogenous 
mTOR. This co-localisation was greatly decreased when cells were amino acid 
starved, consistent with the fact mTOR is known to dissociate from endosomes when 
cells are amino acid deprived (Sancak et al., 2008).  
Balklava et al. (under review A) used the model organism C. elegans to determine that 
several mTOR dependent developmental processes, including germ line expansion, fat 
metabolism and autophagy are APL-1 sensitive. APL-1 is the C. elegans homologue, 
of APP and was required for mediating Rag-GTPase input into mTORC1 (Balklava et 
al., under review A). The findings of this chapter and work by Balklava et al. (under 
review A) raise a number of interesting questions. Firstly, how does the binding of 
mTOR to APP mediate the input by the Rag-GTPases? The mTOR activator Rheb is 
known to bind to the kinase domain of mTOR (Long et al., 2005). Therefore, could APP 
serve as an activator of mTOR through its interaction with mTOR’s kinase domain, 
raising the possibility that a complex could exist between APP/APL-1, mTORC1 and 
the Rag-GTPases? 
The binding of mTOR to APP could enhance the recruitment of mTOR to membranes. 
The membrane attachment of mTOR is crucial for the amino acid dependant activation 
of mTORC1 (Sancak et al., 2010). The activity of the Rag-GTPases and the Ragulator 
are required for the localisation of mTORC1 on late endosomes / lysosomes (Sancak 
et al., 2008, Sancak et al., 2010). If APP was involved in membrane attachment of 
mTOR, the loss of APP or its intracellular domain would limit membrane attachment, 
and consequently mTOR activation.  
The findings of this chapter establish mTOR as a novel interaction partner of APP. This 
interaction of APP with mTOR has significant implications for Alzheimer’s disease 
which will be discussed in chapter 7.  
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Chapter 4 – The analysis of the 
AICD-PIKfyve complex interaction 
through the use of proteo-
liposome recruitment 
 
 
4.1 Introduction 
In chapter 3 the proteo-liposome recruitment method was established and utilised to 
examine the interaction between APP and the mTOR complex. In this chapter the 
same proteo-liposome recruitment method is used to examine the interaction of APP 
with the PIKfyve complex, identified from a screen of APP’s interactome (Balklava et 
al., under review B). This not only examines the interaction between APP and the 
PIKfyve complex in more detail but also validates the proteo-liposome recruitment 
method for examining interactions of the intracellular domain of membrane proteins. 
4.1.1 The interaction between the PIKfyve complex and APP 
It is widely known that the intracellular trafficking of APP is important for its processing 
by secretases. APP traffics through the Golgi complex en route to the plasma 
membrane, where it is either rapidly released or internalised (Koo et al., 1996). A 
portion of internalised APP is recycled, however the majority is targeted to the 
lysosomes for degradation (Koo et al., 1996, Caporaso et al., 1994). APP is known to 
traffic between the plasma membrane, endosomes and the TGN (Burgos et al., 2010). 
APP traffics between sorting endosomes and the TGN, a process mediated by a 
trafficking complex known as the Retromer (Vieira et al., 2010).  
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The endosomal system is a key organelle in APP trafficking and processing. The 
amyloidogenic cleavage of APP mainly occurs in endosomes (Bhalla et al., 2012, 
Nixon et al., 2000). Endosomes are the ideal environment for BACE-1 activity which 
occurs at mildly acidic pH, and APP interacts with BACE-1 in the endocytic pathway 
(De Strooper et al., 2010, Kinoshita et al., 2003, Sannerud et al., 2011). The C-terminal 
fragments of APP, resulting from β-secretase cleavage, are produced in endosomes 
where they are further processed by γ-secretases (Rajendran et al., 2006, Kaether et 
al., 2006). 
 Endosomal dysfunction is thought to be key to the pathogenesis of Alzheimer’s 
disease. It has been documented that abnormal endosomal morphology, and 
increased endosomal Aβ production are found in the brains of Alzheimer disease 
patients (Cataldo et al., 2000, Nixon et al., 2000). Deficiencies in several retromer 
components and retromer receptors such as SorL1, implicated in APP trafficking, have 
been identified in late onset Alzheimer’s disease (Small et al., 2005, Muhammad et al., 
2008, Lane et al., 2012). Neurones derived from the fibroblasts of patients with 
Alzheimer’s disease, including those with presenilin mutations, have enlarged 
endosomes (Israel et al., 2012). The importance of endosomes to APP trafficking and 
Alzheimer’s disease is also evident by the fact that the crucial endosomal lipid PI(3)P is 
deficient in brain samples from Alzheimer’s disease patients, and also mouse models 
of Alzheimer’s disease. Decreasing PI(3)P levels by targeting the class 3 PI 3-kinase 
VPS34 causes endosome enlargement and enhances APP processing (Morel et al., 
2013). Given the role of the endosomal system in APP trafficking and Alzheimer’s 
disease, it is therefore interesting that the PIKfyve complex, crucial for endosomal 
homeostasis, was identified in the interactome of APP’s intracellular domain (AICD) 
(Balklava et al., under review B).  
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The PIKfyve complex is a trimeric protein complex consisting of the kinase PIKfyve, the 
scaffold protein Vac14 and the phosphatase Fig4, which together form a unique 
complex that tightly regulates the levels of the endosomal lipid PI(3,5)P2 (Bonangelino 
et al., 2002, de Lartigue et al., 2009). PI(3,5)P2 and the PIKfyve complex are required 
for the retromer dependant transport of cargo from the endosomes to the trans Golgi 
network (TGN), and are important for endosomal morphology and function (Zolov et 
al., 2012, Rutherford et al., 2006). PI(3,5)P2 regulates the calcium permeability of late 
endosomes and lysosomes by binding to TRPML-1 (Sopjani et al., 2010). The levels of 
PI(3,5)P2 are greatly reduced in loss of function mutations of the Fig4 and both Vac14 
and PIKfyve knockout mutants in in mice.  Loss of the PIKfyve complex, and therefore 
a reduction of PI(3,5)P2 levels causes the accumulation of vacuoles within the cell, 
which are through to derive from the endosomal system (Jefferies et al., 2008, Zhang 
et al., 2007b, Zolov et al., 2012). These mice also show profound neurodegeneration 
which results in the perinatal death of the animals (Chow et al., 2007, Zhang et al., 
2007b). Furthermore PI(3,5)P2 regulates the late endosomal and lysosomal TRPML-1 
calcium channel, defects in which lead to mucolipidosis type IV which is a form of 
lysosomal storage disease that causes profound neurodegeneration (Bach et al., 
2010). In humans, mutations in the gene encoding the Fig4 phosphatase leads to the 
neurodegenerative diseases Charcot-Marie-Tooth syndrome and Amyotrophic Lateral 
Sclerosis (Chow et al., 2007, Chow et al., 2009).    
The link between APP and the PIKfyve complex was selected from the AICD 
interactome data of Balklava et al. (under review B) for further investigation due to a 
number of factors. The crucial role played by the endosomal system in APP trafficking 
and Alzheimer’s disease, and PIKfyve’s importance in regulating endosomal 
homeostasis provide a basis for further study. APP’s role in the neurodegenerative 
disorder Alzheimer’s disease, and the neurodegeneration observed upon loss of the 
PIKfyve complex and PI(3,5)P2,  provide a second reason to further characterise the 
putative interaction between APP and the PIKfyve complex.  
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4.2 Results  
4.2.1 The PIKfyve complex is selectively recruited to AICD presenting 
proteo-liposomes 
The aim of this chapter is to investigate the interaction between APP and the PIKfyve 
complex observed by Balklava et al, (under review B) using the proteo-liposome 
recruitment system characterised and established in chapter 3. 
To study the interaction between APP and the PIKfyve complex in more detail, proteo-
liposome recruitments were conducted where the intracellular domain of APP (AICD) 
was coupled to liposomes along with the amino acid cysteine and MBP as negative 
controls. Cysteine and MBP were chosen as controls to show that any observed 
difference in the recruitment would be due to the presence of the AICD tail. These 
proteo-liposomes contained 1 mol% phosphatidylinositol-3-phosphate (PI(3)P), 
mimicking the natural membrane environment of PIKfyve, due to the fact that PI(3)P is 
located on the membranes of endosomes, and is recognised by the FYVE domain of 
PIKfyve. The proteo-liposomes were incubated in 900 µl of pig brain cytosol (16 
mg/ml), and the final recruitment products were analysed by SDS-PAGE and Western, 
blotting using antibodies against Vac14 and PIKfyve (Figure 19A). The experiments 
showed that both Vac14 and PIKfyve were significantly recruited to AICD presenting 
proteo-liposomes compared to control liposomes (cysteine and MBP) (Figures 19B and 
19C), demonstrating an interaction between APP and the PIKfyve complex.  
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Figure 19. AICD presenting proteo-liposomes are able to recruit the kinase 
PIKfyve and the scaffold protein Vac14 of the PIKfyve complex.  
(A) A representative western blot of a proteo-liposome recruitment in which AICD , 
MBP (negative control) and cysteine (negative control) presenting liposomes were 
incubated in pig brain cytosol and probed for Vac14 and PIKfyve. (B and C) 
Densitometry analysis of the Vac14 and PIKfyve western blots. Analysis was 
conducted using ImageJ. The area was expressed as a percentage of the area 
corresponding to the input band. Statistical analysis was carried out using a one 
way ANOVA with a Tukey’s post hoc test in Graphpad Prism 6.0 (**** p < 0.001, ** 
p < 0.01) (input = 1%) (n=4). 
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4.2.2 Purified recombinant 6 x HIS tagged Vac14 binds directly to AICD 
proteo-liposomes 
As shown in 4.2.1 AICD selectively recruits Vac14 and the kinase PIKfyve. The next 
stage in the investigation into this interaction was to determine whether the interaction 
between AICD and the PIKfyve complex is direct. To achieve this, the proteo-liposome 
system was modified through the use of purified protein rather than brain cytosol, 
allowing for the detection of direct binding partners. Proteo-liposome recruitments were 
conducted using recombinant Vac14, purified from and expressed in E. coli (Figure 
20C). Vac14 was selected over the other components of the PIKfyve complex for 
several reasons. First Vac14 is able to be recombinantly expressed and purified, 
whereas producing recombinant, intact PIKfyve is much more of a challenge, due to its 
large molecular weight. Secondly Vac14 is the scaffold protein of the PIKfyve complex, 
and is primarily composed of HEAT repeats  that provide docking sites for other 
proteins, therefore mediating protein-protein interactions (Jin et al., 2008). Therefore it 
is reasonable to think that Vac14 may provide the link between APP and the PIKfyve 
complex.  
Proteo-liposome recruitments were conducted where AICD or control proteo-liposomes 
(cysteine) were incubated in 4 µg of 6 x HIS-Vac14. The amount of HIS-Vac14 to use 
was determined from pilot proteo-liposome recruitment experiments where AICD 
liposomes and controls were incubated in several different amounts of purified HIS-
Vac14. 4 µg of HIS-Vac14 was selected as it gave a good signal in western blotting, 
without saturation, and the liposomes were in excess of HIS-Vac14. The proteo-
liposomes contained 1 mol% PI(3)P to mimic the composition of the membranes 
PIKfyve is recruited to. The recruitments were analysed by SDS-PAGE and Western 
blotting for Vac14. Vac14 was significantly enriched on AICD containing liposomes 
compared to control liposomes (cysteine) (Figures 20A and 20B), demonstrating that 
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Vac14 directly binds to AICD. This establishes that Vac14 mediates the interaction 
between APP and the PIKfyve complex, via AICD.  
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Figure 20. Purified recombinant Vac14 is able to directly bind to 
AICD presenting proteo-liposomes.  
(A) A western blot of a proteo-liposome recruitment where AICD and 
control (cysteine) liposomes were incubated in 4 µg of purified 
recombinant 6 x HIS-Vac14. The western blot was probed with an 
antibody against Vac14 (2.1.3). (B) Densitometry analysis of (A). 
Analysis was conducted using ImageJ. The area was expressed as 
a percentage of the area corresponding to the input band. Statistical 
analysis was carried out using a two-tailed unpaired T-test with a 95 
% confidence interval in Graphpad Prism 6.0 (* p < 0.05) (input = 
30%)(n=3).(C) Coomassie stained SDS-PAGE of purified His-
Vac14. 
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4.2.3 The C-terminus of AICD is crucial for the recruitment of the PIKfyve 
complex 
The next stage in the analysis of the interaction between APP and the PIKfyve 
complex was to examine AICD for domains important for the recruitment of the PIKfyve 
complex. This was achieved through the use of four truncation mutants of AICD. A 
representation of these truncations can be seen in figure 21A. AICD and its truncations 
were expressed in and purified from E. coli. Proteo-liposome recruitments were 
conducted where AICD and its truncations 1-4 were coupled to liposomes and 
incubated in 900 µl of pig brain cytosol (16 mg/ml). For these experiments PI(3)P was 
excluded from the liposomes to make sure that the choice of receptor tail (AICD or 
truncations 1-4) was the limiting factor in the recruitment, rather than PI(3)P binding by 
PIKfyve.  The final recruitment products were analysed by SDS-PAGE and Western 
blotting for Vac14 and PIKfyve. Figure 21B shows a representative western blot of the 
final recruitment products. Consistent with previous data both Vac14 and PIKfyve were 
significantly enriched on AICD liposomes compared to controls (Figures 21B, 21C and 
21D). Vac14 and PIKfyve were also significantly recruited to AICD truncation 4 (Tr4) 
compared to controls and truncations 1-3 (Figures 21B, 21C and 21D). This indicated 
that the C-terminal 7 amino acids may be important for this interaction, therefore 
demonstrating that the C-terminus of AICD is required for the recruitment of the 
PIKfyve complex from brain cytosol. 
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Figure 21. The C-terminus of AICD is important in the interaction between AICD 
and the PIKfyve complex.  
(A) A representation of the amino acid sequence of the AICD truncation mutants used 
in (B). (B) Western blot analysis of a proteo-liposome recruitment in pig brain cytosol 
where AICD, truncations 1-4 (Tr) and cysteine (control) were coupled to liposomes. 
AICD truncation 4 (tr4) is required for the recruitment of both Vac14 and PIKfyve. (C 
and D) Densitometry analysis of (B). Analysis was conducted using ImageJ. The area 
was expressed as a percentage of the area corresponding to the input band. Statistical 
analysis was carried out using a one way  ANOVA with a Tukey’s post hoc test with a 
95% confidence interval in Graphpad Prism 6.0 (* p < 0.05, *** p < 0.001. **** p < 
0.0001) (input = 1%) (n=4). 
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4.2.4 The C-terminus of AICD is needed for the direct binding of 
recombinant 6 x HIS-Vac14  
As shown in figure 21 the C-terminus of AICD was important in the recruitment of 
Vac14 and PIKfyve from brain cytosol. As Vac14 is able to directly bind to AICD 
(Figure 20), the interaction of 6 x HIS-Vac14 with AICD and its truncations (1-4) (Figure 
22C) was examined. Proteo-liposomes containing coupled AICD and the AICD 
truncations 1-4 were incubated in 4 µg of 6 x HIS-Vac14.  PI(3)P was excluded from 
the liposomes so that the cytoplasmic tails were the limiting factor in the binding, and 
not PIKfyve binding to PI(3)P. The recruitment samples were subjected to SDS-PAGE 
and Western blot analysis, using an antibody against Vac14. Vac14 is significantly and 
directly recruited to AICD proteo-liposomes (as seen previously) (Figures 22A and 
22B). Vac14 directly interacted with the truncations 2, 3 and 4, with its recruitment to 
Tr3 and Tr4 deemed significant from densitometry analysis. This result differs when 
compared to recruitments conducted using brain cytosol, where Vac14 was only 
recruited to Tr4, and not Tr3 liposomes.  
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Figure 22. The C-terminus of AICD is required for the direct binding of purified 
recombinant Vac14.  
(A) A representative western blot of a proteo-liposome recruitment in which AICD, 
AICD truncation presenting and control (cysteine) liposomes were incubated in 4 µg of 
purified recombinant 6 x HIS-Vac14 (input = 1%). (B) Densitometry analysis of (A). 
Analysis was conducted using ImageJ. The area was expressed as a percentage of 
the area corresponding to the input band. Statistical analysis was carried out using a 
one way ANOVA with a Tukey’s post hoc test with a 95% confidence interval in 
Graphpad Prism 6.0 (** p < 0.01, *** p < 0.001, **** p < 0.0001)(n=4). (C) A 
representation of the amino acid sequence of the AICD truncation mutants used in 
(A). 
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4.3 Discussion 
This chapter further establishes the use of the proteo-liposome recruitment system for 
examining the interaction partners of the intracellular domains of membrane proteins, 
by studying the interaction of AICD with a second protein complex PIKfyve. Therefore 
the proteo-liposome recruitment method has been used successfully to examine the 
interaction of AICD with two different protein complexes, mTOR and PIKfyve. The 
PIKfyve complex was recruited to AICD proteo-liposomes demonstrating and 
interaction between the two. Using the proteo-liposome system with purified protein it 
was shown that the Vac14 subunit of the PIKfyve complex binds directly to AICD, likely 
mediating the interaction between APP and the PIKfyve complex.  
Using proteo-liposome recruitments in brain cytosol it was established that the AICD-
Tr4 mutant, which lacks the first 10 N-terminal amino acids, was able to recruit both 
Vac14 and PIKfyve whereas the other three AICD mutants (Tr1-3) did not recruit 
Vac14 or PIKfyve (Figure 21). When purified recombinant Vac14 was used in the 
recruitments, it bound directly to both the AICD-Tr4 mutant and the AICD-Tr3 mutant, 
which lacks the last 7 C-terminal amino acids. This difference in recruitment between 
the different proteo-liposome recruitment methods (brain cytosol and purified 
recombinant Vac14) may be due to a number of factors. One explanation for this is that 
Vac14 is most likely in complex with Fig4 and/or PIKfyve in brain cytosol. The 
assembly of the PIKfyve complex is known to cause a conformational change in its 
components (Ikonomov et al., 2009a). The Fig4 and PIKfyve subunits of the PIKfyve 
complex are not present in purified recombinant Vac14 samples; therefore the binding 
site on AICD for Vac14 may differ depending on whether it is in complex with Fig4 and 
PIKfyve, as in brain cytosol samples, or in purified recombinant Vac14, which should 
not contain other components of the PIKfyve complex.  
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APP contains several phosphorylation sites in its intracellular domain, and the 
phosphorylation state of AICD is known to affect its binding to other proteins such as 
Fe65 (Borg et al., 1996, Oishi et al., 1997, Schettini et al., 2010). The brain cytosol 
used for the proteo-liposome recruitments is likely to contain kinases and some ATP, 
which could alter the phosphorylation state of the AICD coupled to liposomes. Purified 
recombinant Vac14 should not contain any kinases or ATP, therefore AICD should not 
be phosphorylated. This potential phosphorylation of AICD may account for the 
differing recruitment results between the use of brain cytosol and purified recombinant 
Vac14. Another factor that may be involved is the enrichment of Vac14. Brain cytosol 
would not be as enriched in Vac14 when compared to purified recombinant Vac14. 
This needs to be taken into consideration when interpreting the results of the proteo-
liposome recruitments. The recruitments in brain cytosol and purified Vac14 
demonstrate that the C-terminal half of AICD is required for its interaction with the 
PIKfyve complex. 
The biochemical analysis of the APP-PIKfyve complex interaction demonstrates that 
the two proteins interact via the scaffold protein Vac14. This poses the question; what 
is the functional relevance of this interaction? Balklava et al. (under review B) used the 
model organism C. elegans to examine the functional significance of the interaction 
between APL-1 (APP), PPK-3 (PIKfyve) and vacl-14 (Vac14). APL-1 yn5 mutants, 
lacking the intracellular domain, show hypodermal vacuolation. Hypodermal 
vacuolation is also observed in both PPK-3 partial loss of function mutant animals and 
vacl-14 deletion mutant animals. APL-1 (yn5) mutant combined with a PPK-3 partial 
loss of function mutant increases the amount of vacuolation observed, and the 
combination of both mutations is synthetically lethal (Balklava et al., under review B). 
This demonstrates that APL-1 acts upstream of PPK-3 and controls both endosomal 
and lysosomal homeostasis, and neuronal function in C. elegans.  
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The results of this chapter and the work of Balklava et al. (under review B) allows for 
the construction of a model whereby APP, up on arrival at endosomes, interacts with 
and activates the PIKfyve complex by binding to Vac14 causing the stimulation of 
endosome to TGN trafficking and endosome/lysosome fusion. This model leads to a 
number of questions. Firstly, what is the significance of the APP-PIKfyve interaction in 
terms of the levels of PI(3,5)P2? Is the relationship between APP and the PIKfyve 
complex the same in mammals and humans as observed in C. elegans? What is the 
importance of this interaction as regards the trafficking of APP? 
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Chapter 5- Functional analysis of 
the interaction between APP and 
the PIKfyve complex  
 
5.1 Introduction 
The results of chapter 4 demonstrate that the PIKfyve complex interacts with the 
intracellular domain of APP (AICD) biochemically, via the Vac14 subunit of the PIKfyve 
complex. This chapter investigates the functional significance of this interaction. In 
order to determine what effect APP has on the PIKfyve complex it is necessary to 
examine the activity of the complex in response to APP. Examining the product of the 
reaction catalysed by the PIKfyve complex is one way to determine the effect of APP 
on PIKfyve. In this case the product would be the production of the endosomal lipid 
PI(3,5)P2. 
5.1.1 Measuring PI(3,5)P2 levels  
Up until recently there have been two main ways of measuring the levels of PI(3,5)P2, 
both involving the use of radioactive isotopes with a combination of thin layer 
chromatography (TLC) and high-performance liquid chromatography (HPLC), or both.  
The first way is to examine the incorporation of tritium [3H] labelled inositol into cells 
grown in myo-inositol depleted media (Dove et al., 1997). The second way is to 
measure the incorporation of radioactive phosphate [32P] into cells grown in phosphate 
free media. The lipids then need to be extracted and de-acetylated, and the level of 
phosphoinositides can then be measured by HPLC and scintillation counting, by 
comparison with standards. PI(3,5)P2 levels have been measured using both tritium 
(Dove et al., 1997, Rudge et al., 2004, McCartney et al., 2014b, Bonangelino et al., 
2002, Cai et al., 2013, Jin et al., 2014) and 32P (Zhang et al., 2007b, Nicot et al., 2006, 
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Jefferies et al., 2008). While this method has several advantages it also has some 
disadvantages. The first being the low abundance of PI(3,5)P2 can make it difficult to 
detect (Zhang et al., 2007b). The second disadvantage is that it requires the use of 
radiolabeling and access to a HPLC. The number of laboratories that have access to a 
HPLC machine available for use with radionuclides is in decline.  The use of 
radionuclides severely limits the measurement of phosphoinositides in difficult 
samples, such as animal and human tissue. More recently techniques that do not 
require the use of radionuclides have been used, such as mass spectrometry 
(Wakelam and Clark, 2011, Kielkowska et al., 2014). Whilst overcoming the use of 
radionuclides it can be difficult to analyse different phosphoinositide species using 
mass spectrometry as it does not take into account the phosphorylation position on the 
inositol ring even though the phosphorylation is detected. The low cellular 
concentrations of phosphoinositides compared to other phosphor lipids and their highly 
charged head groups that affect their solubility all complicate the analysis of 
phosphoinositides by mass spectrometry (Wakelam and Clark, 2011). Recent 
advances into the use of phosphoinositide specific probes could overcome some of the 
disadvantages of using radionuclides.   
5.1.2 Phosphoinositide specific probes 
Recent advances in the analysis of phosphoinositide binding proteins have led to the 
characterisation of phosphoinositide binding domains with distinct affinities and 
specificities (Cullen et al., 2001). These binding domains have been utilised to study 
the dynamics of phosphoinositides in cells by fusing GFP or a GFP variant to the 
relevant binding domain and analysis by microscopy.  There are now a number of 
florescent probes for specific phosphoinositides. Examples of these probes include the 
pleckstrin homology (PH) domain of phospholipase C, and more recently the Tubby 
domain as PI(4,5)P2 probes (Szentpetery et al., 2009). The PH domain of FAPP1 (four 
phosphate adaptor protein) has been used as a probe for PI(4)P. The PH domains of 
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Akt are probes for PI(3,4)P2 and PI(3,4,5)P3, and the FYVE domain of the early 
endosome antigen 1 (EEA1) is a probe for PI(3)P (Halet, 2005, Balla, 2007). Until 
recently a protein probe did not exist for PI(3,5)P2, mainly due to the lack of well 
characterised PI(3,5)P2 effectors, and PI(3,5)P2’s low abundance (Li et al., 2013).  
5.1.3 A PI(3,5)P2 probe? 
One of the most well characterised PI(3,5)P2 effectors is the yeast protein ATG18 (also 
called Svp1). It was identified as a PI(3,5)P2 effector by Dove et al. (2004) in a screen 
of Saccharomyces cerevisiae mutants that displayed a swollen vacuole phenotype, like 
that associated with the Fab1 (yeast homologue of PIKfyve) mutant. They also showed 
that ATG18p is able to bind specifically to PI(3,5)P2. ATG18p is a component of the 
autophagic and the cytosol to vacuole transport pathways (Cvt) in yeast (Efe et al., 
2007) and is related to the WIPI proteins in mammals (Proikas-Cezanne et al., 2007). It 
is a multi WD domain containing protein that is predicted to fold into a beta barrel. It 
does not display a specific PI(3,5)P2 binding motif, instead it is thought that the whole 
beta barrel plays a role in PI(3,5)P2 binding with the FRRG287 motif to be the most likely 
candidate for a specific motif (Dove et al., 2004, Krick et al., 2006).  
This chapter utilises the work of Dove et al. (2004) to examine the use of ATG18p as a 
probe for PI(3,5)P2, with a view to investigating the functional significance of the 
interaction between APP and the PIKfyve complex, by the analysis of PIKfyve activity 
in response to APP.  
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5.2 Results 
5.2.1 ATG18 binds preferentially to PI(3,5)P2 containing liposomes  
In order to examine whether ATG18p would be a suitable probe for PI(3,5)P2 a 
liposome binding assay was carried out. GST tagged ATG18p (a kind gift from Scott 
Emr) was expressed and purified from E. coli as described in chapter 2 (2.2.2.4). 
Liposomes were prepared as described in chapter 2 (2.2.3.2) with a final lipid amount 
of 252.5 nmol, which is half the amount of lipid used for previous recruitments (505 
nmol).  Seven sets of liposomes were prepared containing either 3 mol% PI, 3 mol% 
PI(3)P, 3 mol% PI(3,5)P2 or 3 mol% PI(4,5)P2. Control liposomes either did not contain 
any phosphoinositide (No PIs) or were composed entirely of PC (PC only). The 
different sets of liposomes were incubated with GST-ATG18 at a final concentration of 
4.5 µM for 30 minutes at 25ºC. The liposomes were pelleted and the samples analysed 
by SDS-PAGE and Western blotting using an antibody against the GST tag of 
ATG18p. GST-ATG18 bound significantly (p < 0.01) to PI(3,5)P2 containing liposomes 
compared to those containing other phosphoinositides and control liposomes, which 
did not bind significant amounts of GST-ATG18 (Figure 23A and 23B). This indicates 
that ATG18p could be used as a PI(3,5)P2 specific probe. 
The next stage was to determine if ATG18 could be used as an intracellular probe for 
PI(3,5)P2. ATG18p was PCR cloned into pEYFP-c1.  HeLa cells were transfected with 
pEYFP-ATG18-c1 using multiple transfection methods including  lipofectamine 2000 
and PEI. The transfected cells were analysed by confocal microscopy. However, it 
appeared that YFP-ATG18 was not expressed in HeLa cells. This was repeated 
multiple times using both HeLa and HEK-293t cells and no YFP-AGT18 fluorescence 
was visible, indicating that the construct does not express in these cell lines.  
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Figure 23. ATG18 binds to PI(3,5)P2 containing liposomes. 
(A) Liposomes were prepared containing either 3 mol% PI(3)P, 3  mol% 
PI(3,5)P2,  3 mol% PI(4,5)P2 or without any inositol containing lipid (No 
PI’s and PC only) and incubated with GST tagged ATG18 at a final 
concentration of 4.5 µM. The samples were analysed by SDS-PAGE and 
western blotting using an antibody against the GST tag on ATG18. (B) 
Densitometry analysis of (A) was conducted using ImageJ. The area was 
expressed as a percentage of the area corresponding to the input band. 
Statistical analysis was carried out using a one –way ANOVA in 
Graphpad Prism 6.0 (** p < 0.01) (input = 10%) (n=3). (C) Commassie 
stained SDS-PAGE of purified recombinant GST-ATG18. 
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Whilst attempting to express YFP-ATG18 in both HeLa and HEK-293t cells a paper 
was published that described the development of a PI(3,5)P2 probe. Li et al. (2013) 
produced a PI(3,5)P2 specific probe from the PI(3,5)P2 binding domain of the late 
endosome/lysosome calcium channel TRPML-1. The probe involved the fusion of a 
fluorescent tag to tandem repeats of the PI(3,5)P2 binding domain of TRPML-1, which 
is known as ML1N. The probe primarily localised to LAMP-1 positive structures and 
this localisation was disrupted by mutating the probe and by the genetic and 
pharmacological inhibition of the PIKfyve complex, thereby reducing cellular PI(3,5)P2 
levels. This probe allows the detection of PI(3,5)P2  in a spatially defined way that has 
not previously been possible. Due to the fact this ML1Nx2 probe was well 
characterised by Li et al. (2013) and that YFP-ATG18 would not express successfully 
in HeLa or HEK-293t cells, the ML1Nx2 probe was used to investigate the functional 
significance of the interaction between APP and the PIKfyve complex.  
5.2.2 Pharmacological inhibition of PIKfyve abolishes the vesicular 
localisation of the PI(3,5)P2 probe GFP-ML1Nx2 
In order to use the ML1Nx2 probe to investigate the functional relevance of the APP-
PIKfyve complex interaction the dynamics of the ML1Nx2 probe were examined by the 
pharmacological inhibition of PIKfyve. HeLa cells were transfected with pEGFP-c3-
ML1Nx2 (kindly provided by Dr. H. Xu (University of Michigan)) using Lipofectamine 
2000. The transfected cells were then treated with 4 µM of the PIKfyve inhibitor YM-
201636 for 4 hours or DMSO (control), and fixed on glass coverslips with 4% PFA. 
Upon image analysis by confocal microscopy it was found that in control cells the 
probe GFP-ML1Nx2 localises to vesicular structures. The inhibition of the PIKfyve 
complex by YM-201636, and therefore the decrease in the levels of PI(3,5)P2, caused 
this vesicular localisation to be abolished (Figure 24), as observed previously (Li et al., 
2013). The remaining vesicular structures observed upon PIKfyve inhibition are likely 
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due to the incomplete inhibition of the PIKfyve complex and therefore the presence of 
low levels of PI(3,5)P2 (Jefferies et al., 2008).  
 
 
 
 
 
 
 
 
 
Figure 24. Treatment of HeLa cells with the PIKfyve inhibitor 
YM201636 abolishes the vesicular localisation of the PI(3,5)P2 
probe GFP-ML1Nx2.  
(A) HeLa cells were transiently transfected with the PI(3,5)P2 
probe GFP-ML1Nx2 and then treated with 4 µM YM201636 for 4 
hours. The vesicular localisation of GFP-ML1Nx2 is greatly 
decreased upon treatment with YM201636 (scale bar = 25 
µm).The displayed image is the maximum projection of z-stacks 
taken at 0.5 µm increments. (B)The construct of the PI(3,5)P2 
probe GFP-ML1Nx2 (n=3).  
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5.2.3 The PI(3,5)P2 probe shows co-localisation with Vac14 in fixed HeLa 
cells.  
After establishing that the vesicular localisation of the probe GFP-ML1Nx2 is abolished 
upon PIKfyve inhibition the localisation of the probe and the PIKfyve complex were 
characterised. ML1Nx2 was PCR cloned from pEGFP-c3 into pMcherry-c1. HeLa cells 
were co-transfected with both mCherry-ML1Nx2 and mCitrine-Vac14 (kindly provided 
by Dr L. Weisman) or mCherry-ML1Nx2 and mCitrine (control) using lipofectamine 
2000. The cells were fixed on glass coverslips with 4% PFA and imaged using confocal 
microscopy. Overexpressed mCherry-ML1Nx2 and mCitrine-Vac14 co-localise in HeLa 
cells (Figure 25A), indicating that Vac14 is present of PI(3,5)P2 positive vesicular 
structures as detected using the probe mCherry-ML1Nx2. This was compared to the 
control transfected cells, where no co-localisation is observed (Figure 25B). This 
indicates that the PI(3,5)P2 probe mCherry ML1Nx2 is localised to a similar location as 
that of the PIKfyve complex. 
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Figure 25. The PI(3,5)P2 probe mCherry-ML1Nx2 and Vac14 co-localise in HeLa 
cells. 
HeLa cells were co-transfected with mCherry-ML1Nx2 and mCitrine-Vac14 (A) or 
mCherry-ML1Nx2 and mCitrine (control) (B). There appears to be co-localisation of 
mCherry-ML1Nx2 and mCitrine-Vac14 as indiated by arrows in A. (scale bar = 10 
µm) (n=3). The displayed image is the maximum projection of z-stacks, enlarged 
images are 5x. 
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5.2.4 APP and Vac14 co-localise and display co-movement in live HeLa 
cells 
In chapter 4 the use of the proteo-liposome recruitment system demonstrated that the 
intracellular domain of APP (AICD) was directly bound by the Vac14 subunit of the 
PIKfyve complex. This led to the question; do Vac14 and APP co-localise in cells given 
their biochemical interaction? To investigate this Vac14 was cloned from pmCitrine into 
pmCherry. Live HeLa cells co-overexpressing a combination of mCherry-Vac14 with 
APP-GFP or GFP (control) were analysed by fluorescence microscopy for 30 seconds 
with 0.15 s between frames. APP-GFP and mCherry-Vac14 co-localise on vesicular 
strictures in HeLa (Figure 26A) compared to control cells overexpressing GFP (Figure 
26B). APP-GFP and mCherry-Vac14 display co-movement on vesicular structures 
(Figure 26C). This demonstrates that APP-GFP resides on the same vesicular 
structures as mCherry-Vac14, which display co-movement, therefore suggesting that 
APP resides on the same vesicular structures as the PIKfyve complex. This further 
supports the recruitment results in chapter 4 by demonstrating that the biochemical 
interaction between APP and the PIKfyve complex in chapter 4 is likely physiologically 
relevant. 
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Figure 26. Vac14 and APP co-localise and display co-movement in HeLa 
cells using live cell imaging.  
(A and C) HeLa cells co-expressing mCherry-Vac14 and APP-GFP there is co-
localisation and co-movement of vesicular structures positive for both APP and 
Vac14. No co-localisation was observed in HeLa cells co-expressing mCherry-
Vac14 and GFP (B).  (C) Stills taken from 0.57, 1.00, 1.57, 2.00, 2.57 and 3.00 
seconds time points. Arrows represent vesicular structures displaying co-
localisation and co-movement. (Scale bar = 10 µm) (n=3). Enlarged images are 
magnified 4x. The video files for each condition can be viewed on the CD 
attached to the thesis (Appendix 2). 
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5.2.5 APP and the PI(3,5)P2 probe mCherry-ML1Nx2 show co-localisation 
and co-migration of vesicular structures in live cells 
APP and Vac14 co-localised in fixed cells (5.2.4) suggesting APP and the PIKfyve 
complex are present on the same vesicular structure. Therefore the co-localisation 
between APP and the ML1Nx2, PI(3,5)P2 probe was examined in live cells as PI(3,5)P2 
is produced by the PIKfyve complex. HeLa cells overexpressing mCherry-ML1Nx2 and 
either APP-GFP or GFP (control) were subjected to live cell imaging as described in 
chapter 2.  APP-GFP was found to co-localise with the probe mCherry-ML1Nx2 (Figure 
27A). The probe mCherry-ML1Nx2 did not co-localise with GFP (control) (Figure 27B). 
Figure 27C shows still frames of a 4 x zoomed in section of still frames taken at 3.57, 
4.00, 4.57, 5.00, 5.57 and 6.00 seconds of imaging. APP-GFP and mCherry-ML1Nx2 
displayed co-movement on vesicular structures (Figure 27C) (see video on attached 
disk). These results demonstrate that APP is localised on PI(3,5)P2 positive vesicular 
structures. 
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Figure 27. The PI(3,5)P2 probe mCherry-ML1Nx2 and APP-GFP display co-localisation 
and co-movement in live HeLa cells.  
In HeLa cells co-expressing mCherry-ML1Nx2 and APP-GFP there is co-localisation and 
co-movement of vesicular structures positive for both APP and ML1Nx2 (A and C). (C) The 
cells were imaged for 30 seconds in total. Displayed are frames of the images taken at 3.57, 
4.00, 4.57, 5.00, 5.57 and 6.00 seconds of imaging. (Scale bar = 3 µm) (n=3) (enlarged 
images are 4x).. The video files for each condition can be viewed on the CD attached to the 
thesis (Appendix 2). 
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5.2.6 APP-GFP and the PI(3,5)P2 probe mCherry-ML1Nx2 display co-
localisation on vesicular structures in fixed HeLa cells 
This chapter has so far shown that the PI(3,5)P2 probe mCherry-ML1Nx2 displays co-
localisation with mCitrine-Vac14 and that APP-GFP and Vac14-mCherry co-localise on 
vesicular structures that show co-movement. Next the effect of overexpression of APP 
on the dynamics of the PI(3,5)P2 probe mCherry-ML1Nx2 were examined. mCherry-
ML1Nx2 was expressed in HeLa cells along with either APP-GFP or GFP (control). 
The cells were fixed on glass coverslips and images were taken using a confocal 
microscope. Figure 28A shows that APP-GFP and the PI(3,5)P2 probe mCherry-
ML1Nx2 co-localise on vesicular structures, indicating that APP may play a role in 
PI(3,5)P2 production. Interestingly it was noted when imaging the cells that those 
overexpressing APP-GFP seemed to have a higher number of mCherry-ML1Nx2 
positive structures than control cells (GFP).  
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Figure 28. APP-GFP and the PI(3,5)P2 probe mCherry-ML1Nx2 co-localise in 
HeLa cells.  
In HeLa cells co-expressing APP-GFP and mCherry-ML1Nx2 there is co-localisation 
on vesicular structures in fixed cells (A). GFP shows no co-localisation with the 
mCherry-ML1Nx2 probe. This demonstrates that APP is found on mCherry-ML1Nx2 
structures. (Scale bar = 10 µm) (n=3). The displayed image is the maximum projection 
of z-stacks. Enlarged image = 5 x 
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5.2.7 The overexpression of APP increases the number of PI(3,5)P2 
positive vesicular structures 
The previous observation that the overexpression of APP-GFP seemed to increase the 
number of mCherry-ML1Nx2 positive vesicular structures was examined in more detail. 
The number of PI(3,5)P2 positive structures, as determined by the probe mCherry-
ML1Nx2, were analysed in HeLa cells overexpressing either APP-GFP, AICD-GFP, 
APP and AICD truncation mutants or GFP (control). 25 cells were analysed using the 
MOSAIC plug in for ImageJ, as described in chapter 2. The MOSAIC plugin has 
previously been used to quantify intracellular vesicular structures (Rizk et al., 2014). It 
connects image segmentation with biological reality by accounting for the microscopes 
point spread function, therefore correcting for microscope blur and noise, producing 
deconvolved segmentations. It provides data on the number of objects and the mean 
intensity of each object.  
The overexpression of APP-GFP led to a significant increase in the average number of 
PI(3,5)P2  positive vesicles per cell when compared to the overexpression of GFP 
(negative control) (Figures 29A and 29C). In contrast, the overexpression of a mutant 
of APP lacking the intracellular domain (APP∆AICD) did not significantly alter the 
number of PI(3,5)P2  positive structures, which suggests that APP’s intracellular 
domain is needed to stimulate the formation of PI(3,5)P2  positive vesicles.  
In order to confirm that the increase in the number of PI(3,5)P2  positive vesicles upon 
the overexpression of APP was PIKfyve dependant, the overexpression of APP was 
combined with the inhibition of PIKfyve by treatment with 4 µM YM-201636 for 4 hours. 
The average number of PI(3,5)P2  positive structures in cells overexpressing APP-GFP 
and treated with the PIKfyve inhibitor was significantly reduced (Figures 29B and 29C). 
This demonstrates that the increase in the number of PI(3,5)P2 positive structures upon 
overexpression of APP is dependent on the activity of PIKfyve. This is consistent with 
the recent finding that the only source for PI(3,5)P2  production in mammals is the 
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phosphorylation of PI(3)P, which is PIKfyve dependent (Zolov et al., 2012). One 
interesting observation of note was that in cells overexpressing APP-GFP the 
intracellular location of APP-GFP was altered upon treatment with the PIKfyve inhibitor 
YM-201636. This observation is examined in more detail later on in this chapter. 
 
The intensity of each PI(3,5)P2 positive vesicle was also recorded. The average 
intensity per vesicle did not differ significantly between APP, APP∆AICD and GFP 
(Figure 29D). The treatment with the PIKfyve inhibitor YM-201636 also did not alter the 
intensity of any remaining vesicles (Figure 29D). This indicates that APP drives the 
production of PI(3,5)P2  positive vesicles and not the levels of PI(3,5)P2 in individual 
vesicles.  
The fact that the APP∆AICD mutant failed to stimulate the production of PI(3,5)P2 
positive structures suggests that AICD plays an important role in the APP dependent 
production of PI(3,5)P2 positive vesicles. This led to the question: can the intracellular 
domain of APP (AICD) alone stimulate PI(3,5)P2 vesicle formation? The 
overexpression of AICD-GFP significantly increased the number of PI(3,5)P2  positive 
structures to a similar level of that observed with the overexpression of APP-GFP 
(Figures 29A and 29B). In chapter 4 it was found that the AICD truncation 4 mutant 
(AICD-Tr4) still bound to purified Vac14 and recruited both Vac14 and PIKfyve from 
brain cytosol. Therefore, the effect of AICD-Tr4 on the production of PI(3,5)P2  positive 
vesicles was examined. The overexpression of AICD-Tr4 significantly increased the 
number of PI(3,5)P2  positive structures when compared to control GFP expression. 
This increase was similar to that observed by APP and AICD overexpression (Figures 
29A and 29C). This data and that of chapter 4 suggests that APP needs to bind to 
Vac14, via AICD, to stimulate the PIKfyve dependent formation of PI(3,5)P2 positive 
vesicles.  
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Figure 27. Overexpression of APP and AICD controls PIKfyve function in 
HeLa cells. 
(A, B and C) Co-expression of GFP-tagged proteins and the mCherry-labelled 
PI(3,5)P2 probe ML1Nx2 was used to analyse the impact of APP-derived 
constructs on PI(3,5)P2 positive structures. YM201636 was used to inhibit PIKfyve 
function (4 µM). APP expression strongly increased the average number of 
PI(3,5)P2 positive vesicles (A and C). The increase could be abolished by PIKfyve 
inhibition, demonstrating the dependency on PIKfyve (B and C). APP lacking its 
intracellular domain (APPΔAICD) was unable to stimulate formation of PI(3,5)P2 
positive vesicles. AICD and AICD-Tr.4 both stimulated formation of PI(3,5)P2 
positive vesicles. The displayed image is the maximum projection of z-stacks. (C) 
Quantification of mCherry-ML1Nx2 structures of 25 cells for each condition. 
Statistical analysis was conducted in Graphpad Prism 6.0. A one- way ANOVA 
test followed by Tukey's post-hoc analysis was used (**** p < 0.0001) (n=3). Error 
bars are s.e.m. (D) APP, AICD and AICD-Tr.4 expression did not majorly affect 
the average intensity of mCherry-ML1Nx2 vesicles, suggesting that APP controls 
number of PI(3,5)P2 positive vesicles rather than PI(3,5)P2 content within a 
vesicle. Error bars are s.e.m. 
(Scale bar = 10 µm) 
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5.2.8 The YENPTY motif of AICD plays an important role in the 
relationship between APP and the PIKfyve complex 
The results of the proteo-liposome recruitments in chapter 4 showed that AICD-Tr4 
was able to bind to purified recombinant Vac14, and recruit both Vac14 and PIKfyve 
from brain cytosol. In this chapter it has so far been shown that AICD-Tr4 was able to 
stimulate the production of PI(3,5)P2  positive vesicles to a similar extent of that 
observed by APP and AICD overexpression. Therefore the question, what domain of 
AICD, present in its C-terminus, could be interacting with Vac14, was asked. The 
YENPTY motif of AICD is a known endocytosis signal, and a binding site for many 
cytosolic and adaptor proteins (Nhan and Koo, 2013). Therefore, could the YENPTY 
motif of AICD be the interaction site for Vac14? To test this theory a mutant of AICD 
was created, in which the YENPTY motif was deleted (AICD∆YENPTY). The ability of 
this mutant to stimulate the production of PI(3,5)P2  positive vesicles was examined. 
HeLa cells overexpressing AICD∆YENPTY-GFP failed to significantly stimulate the 
production of PI(3,5)P2 positive vesicles as determined by the probe mCherry-ML1Nx2, 
when compared to cells overexpressing full length AICD (Figures 30A and 30B). The 
average intensity of the PI(3,5)P2  vesicles was the same in all three overexpression 
conditions (AICD-GFP, AICD∆YENPTY-GFP and GFP), consistent with the data in 
figure 29 (Figure 30C).  
These results indicate that the YENPTY domain, at the C-terminus of AICD, is required 
for the PIKfyve dependent stimulation of PI(3,5)P2  positive vesicles production. This is 
in line with the proteo-liposome recruitment data from chapter 4, which showed that the 
C-terminus of AICD was crucial for Vac14 binding. It was not possible to conduct 
proteo-liposome recruitments with 6 x HIS-MBP-AICD∆YENPTY as the protein was 
strongly degraded when expressed and purified from E.coli, thereby preventing protein 
interaction studies.  
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Figure 28. The YENPTY motif of AICD is crucial for controlling PIKfyve function 
in HeLa cells. 
(A,B) Co-expression of AICD-GFP, AICD ∆ YENPTY-GFP and GFP with the PI(3,5)P2 
probe mCherry-ML1Nx2. The AICD ∆ YENPTY-GFP mutant fails to stimulate the 
production of mcherry-ML1Nx2 positive vesicles significantly above control (GFP) 
indicating the YENPTY motif of AICD is important in the production of PI(3,5)P2 
positive vesicles. The displayed image is the maximum projection of z-stacks. (B) 
Quantification of mCherry-ML1Nx2 structures of 25 cells for each condition. Statistical 
analysis was conducted in Graphpad Prism 6.0. A one- way ANOVA test followed by 
Tukey's post-hoc analysis was used (**** p < 0.0001) (n=3). Error bars are s.e.m. (C) 
The expression of AICD and AICD ∆ YENPTY did not affect the intensity of the 
mCherry-ML1Nx2 positive vesicles consistent with the idea that APP and therefore 
AICD controls the number of PI(3,5)P2 positive structures rather than PI(3,5)P2 levels in 
each structure.(Scale bar = 10 µm) 
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5.2.9 Inhibiting PIKfyve activity causes a re-distribution of APP 
When examining the number of PI(3,5)P2 positive structures upon APP-GFP 
overexpression it was noted that in cells treated with the PIKfyve inhibitor YM-201636 
the localisation of APP-GFP changed from small vesicular structures to what appeard 
to be  vacuolar-like structures (Figure 29). To examine this phenomenon in more detail 
APP-GFP was overexpressed in HeLa cells which were treated with 4 µM YM-201636 
for six different time points. HeLa cells overexpressing APP-GFP were exposed to YM-
201636 for 15 minutes, 30 minutes, 1 hour, 2 hours and 4 hours. After treatment with 
YM-201636 for between 30 minutes and 1 hour, vacuoles became visible in the cells. 
This is consistent with PIKfyve inhibition, both pharmacological (PIKfyve inhibitors) and 
genetic (RNAi knock-down) (Jefferies et al., 2008, Zolov et al., 2012, Zhang et al., 
2007b).  
After treatment with YM-201636 for 30 minutes, small APP-GFP positive vacuole-like 
structures were observed. After 1 hours treatment with YM-201636 it becomes 
apparent that APP-GFP accumulates in vacuole-like structures, which are highlighted 
by white arrows in figure 31. At longer time points (2 hours and 4 hours) APP becomes 
increasingly trapped in vacole like structures, reducing the the localisation of APP to 
small vesicular structures. These results indicate that APP trafficking is disrupted by 
PIKfyve inhibition. 
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Figure 29. Inhibition of PIKfyve with YM-201636 causes a re-distribution of APP-GFP  
HeLa cells overexpressing APP-GFP were treated with 4 µM of the PIKfyve inhibitor YM-201636 for 
between 15 minutes and 4 hours. Over time APP-GFP gets re-distributed from small vesicular 
structures to vaculoar like structures indicating PIKfyve could potentially be required for correct APP 
trafficking. (Scale bar = 10 µm) (n=3). The displayed image is the maximum projection of z-stacks. 
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5.2.10 Inhibition of the PIKfyve complex causes accumulation of APP 
The observation that APP-GFP becomes trapped in vacuole structures upon PIKfyve 
inhibition, and the implications of this in terms of APP trafficking led to the analysis of 
this observation in more detail.  APP endosome-to-TGN trafficking is known to be 
regulated by the retromer complex (Vieira et al., 2010). PIKfyve complex activity is also 
known to be important in the retrograde trafficking of the cation-independent mannose-
6 phosphate receptor (MPR), amongst other cargos (Rutherford et al., 2006, de 
Lartigue et al., 2009, Zhang et al., 2007b). HeLa cells overexpressing APP-GFP were 
treated for 4 hours the PIKfyve inhibitors YM-201636 Apilimod at several different 
concentrations (Figures 32A, 32B, 32C and 32D) (Cai et al., 2013). YM-201636 was 
used at concentrations of 0.1 µM, 0.33 µM, 1 µM, 3 µM and 10 µM, whilst Apilimod 
was used at concentrations of 3 nM, 10 nM, 30 nM, 100 nM and 300 nM. The inhibitor 
Apilimod was used as well as YM-201636 due to the fact that YM-201636 has been 
shown to posess some activity towards phosphoinositide 3-kinase (PI3K) family 
members (Jefferies et al., 2008, Ikonomov et al., 2009g). The cells were stained for the 
early endosome marker EEA1 (Figures 32A and 32C), and the late 
endosomal/lysosomal marker LAMP-1 (Figures 32B and 32D), and were analysed by 
confocal microscopy. It was apparent that the inhibition of PIKfyve with both YM-
201636 and Apilimod caused APP-GFP to accumulate in vacuole structures (Figures 
32A and 32B), with no difference observed between the two inhibitors. This 
accumulation of APP-GFP in vacuole like structures occurred at all concentrations of 
inhbitors used. 
APP-GFP in untreated cells exhibits a degree of colocalisation with the early 
endosome marker EEA1 (Figures 32A and 32C). The enlarged APP-GFP vacuoles co-
localise with EEA1 upon the inhibition of PIKfyve with both inibitors, and at the range of 
concentrations used. In untreated cells APP-GFP shows little co-localisation with the 
late endosomal/lysosomal marker LAMP1 (Figures 32B and 32D). The enlarged APP-
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GFP positive vacuoles upon PIKfyve inhibition do not show co-localisation with 
LAMP1. Taken together these results indicate that upon PIKfyve inhibition APP-GFP 
becomes trapped in enlarged early endosomes positive for EEA1.  
 
The protein levels of endogenous APP and its homologure APLP2 were examined. 
APLP2 is a homologue of APP and like APP is ubiqutiously expressed. APP and 
APLP2 are known to exhibit functional redundancy, therefore the effect of PIKfyve 
inhibition on the protein levels of both APP and APLP2 were examined. HeLa cells 
were treated with 4 µM of the PIKfyve inhibitor YM-201636 overnight to determine if 
endogenous APP and APLP2 protein levels are affected by PIKfyve function. The 
relative protein levels were analysed by SDS-PAGE and Western blotting of HeLa cell 
lysates, using antibodies against APP and APLP2. There was no significant difference 
in the levels of APLP2 between treated and untreated cells (Figures 32F and 32G). In 
contrast, the overall levels of APP were significantly increased upon treatment with the 
PIKfyve inhibitor YM-201636 (Figures 32E and 32G). The multiple bands observed on 
the APP Western blot (Figure 32E) represent different isoforms of APP. It was difficult 
to distinguish between these isoforms, therefore, all bands were taken into 
consideration when quantifying the level of APP. The re-distrubution of APP-GFP and 
the increase in the level of endogenous APP upon YM-201636 treatment suggests that 
APP trafficking and APP levels are dependent on the activity of PIKfyve.   
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Figure 30. PIKfyve is required for the correct trafficking and distribution of APP-
GFP 
(A) HeLa cells overexpressing APP-GFP, treated with 0.1 µM, 0.33 µM, 1 µM, 3 µM and 
10 µM of YM-201636 (4hrs), stained for the early endosome marker EEA1 using Alexa 
Flour 555 secondary antibody. (B) HeLa cells overexpressing APP-GFP, treated with 0.1 
µM, 0.33 µM, 1 µM, 3 µM and 10 µM of YM-201636 (4hrs), stained for the late 
endosomal/lysosomal marker LAMP-I using an Alexa Flour 555 secondary antibody. (C) 
HeLa cells overexpressing APP-GFP, treated with 3 nM, 10 nM, 30 nM, 100 nM and 300 
nM of Apilimod (4hrs), stained for the early endosome marker EEA1 using Alexa Flour 
555 secondary antibody. (D) HeLa cells overexpressing APP-GFP, treated with 3 nM, 10 
nM, 30 nM, 100 nM and 300 nM of Apilimod (4hrs), stained for the late 
endosomal/lysosomal marker LAMP-I using an Alexa Flour 555 secondary 
antibody.Treatment with YM-201636 and Apilimod caused the accumulation of APP-
GFP in vacuole like structures. These vacuole like structures were EEA1 but not LAMP-
1 positive. The displayed images are the maximum projection of z-stacks. (E) The 
treatment of HeLa cells overnight with YM-201636 caused and accumulation of all APP 
species detected by western blotting. It was not possible to determine if specific isoforms 
were affected. (F)Treatment with YM-201636 did not significantly affect the levels of 
APLP2 as determined by western blotting. (G) Quantification of the increase in APP was 
conducted in ImageJ. Displayed is the area corresponding to the bands in the treated 
condition compared to controls. Statistical analysis was conducted in Graphpad Prism 
6.0 using a two-tailed unpaired t-test (* p < 0.05) (n=6).  
(Scale bar =10 µm). 
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5.3 Discussion 
This chapter demonstrates that the interaction between APP and the PIKfyve complex 
is functionally relevant. Using the PI(3,5)P2 probe ML1Nx2 it was established that 
Vac14 and APP co-localise to PI(3,5)P2 positive vesicles in both fixed and live cells. 
APP overexpression stimulates the production of PI(3,5)P2 positive vesicles in a 
PIKfyve dependent process. The overexpression of a mutant protein in which the 
intracellular domain is removed, fails to stimulate PI(3,5)P2 positive vesicle production, 
demonstrating the importance of AICD. AICD alone, and the Tr4 mutant of AICD (lacks 
the 10 N-terminal amino acids) are able to stimulate PI(3,5)P2 vesicle production, again 
demonstrating the importance of AICD. An AICD mutant lacking the YENPTY motif 
fails to stimulate PI(3,5)P2 positive vesicle production, indicating that this motif is 
important for the interaction with the PIKfyve complex. The catalytic inhibition of 
PIKfyve results in the accumulation of APP-GFP in early endosome derived, positive 
vacuole like structures, and an increase in endogenous APP levels. Taken together 
these results establish a functional link between APP and the PIKfyve complex, and 
implicate PIKfyve in the trafficking and therefore the degradation of APP.  
5.3.1 The effect of APP on the PI(3,5)P2 probe mCherry-ML1Nx2 
In order to investigate the functional significance of the interplay between APP and the 
PIKfyve complex the PI(3,5)P2 probe GFP/mCherry-ML1Nx2 was of key importance. 
The probe developed by Li et al. (2014) allowed for the detection of PI(3,5)P2 in a 
spatial and temporal way, which has not previously been  possible. Here the PI(3,5)P2  
probe mCherry-ML1Nx2 was used to show that the number of PI(3,5)P2 positive 
vesicles was significantly increased upon the overexpression of APP, AICD and AICD-
Tr4. The probe ML1Nx2 has been extensively validated by Li et al. (2013). It has also 
been used by McCartney et al. (2014b) to demonstrate that dynamic changes in the 
synthesis of PI(3,5)P2 influences synaptic strength  by regulating the trafficking of the 
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AMPA-type glutamate receptor, and therefore that PI(3,5)P2 signalling plays an 
important role in synapse regulation. The use of mCherry-ML1Nx2 by McCartney et al. 
(2014b) further validates its use as a PI(3,5)P2 specific probe and therefore supports its 
use in this chapter to study changes in PI(3,5)P2 in response to APP.  
The significant increase in the number of PI(3,5)P2 positive structures in HeLa cells 
overexpressing APP is supported by work from Currinn et al. (under review) (Appndix 
3) who showed that the RNAi mediated suppression of APP reduced the number of 
PI(3,5)P2 positive structures, detected using the PI(3,5)P2 probe ML1Nx2. Knock down 
experiments of APP in mammalian cells are complicated by the fact that APP has two 
homologues, APLP1 and APLP2. The APP family members exhibit functional 
redundancy, therefore the effect of knocking down one member may be alleviated by 
the function of the other two members. The suppression of the APP homologue APLP2 
also reduced the amount of PI(3,5)P2  positive vesicles (Currinn et al., under review) 
(Appendix 3). The double knock down of APP and APLP2 enhanced the decrease in 
the number of PI(3,5)P2 positive vesicles, suggesting functional redundancy between 
APP and APLP2 in terms of PIKfyve dependent PI(3,5)P2 positive vesicle production 
(Currinn et al., under review) (Appendix 3). The opposite effects of APP 
overexpression and knock down demonstrate that APP activates a pathway which 
leads to the production of PI(3,5)P2 positive vesicles in a PIKfyve dependent manner.  
In this chapter it is shown that AICD is crucial for the stimulation of PI(3,5)P2  positive 
vesicles. The APP mutant APP∆AICD failed to stimulate PI(3,5)P2  vesicle production, 
whilst the overexpression of AICD increased the amount of PI(3,5)P2  positive vesicles 
to similar levels as APP overexpression. The truncation 4 mutant of AICD (AICD-Tr4), 
which lacks the 10 N-terminal amino acids, was able to stimulate the production of 
PI(3,5)P2  positive vesicles. These results are consistent with the biochemical 
interaction data from chapter 4, which showed that the C-terminal half of AICD is 
important for mediating the interaction between AICD and the PIKfyve complex. This 
indicates that the Vac14 binding motif is located within the last 20 amino acids of AICD. 
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 The inability of a mutant of AICD, in which the YENPTY motif was deleted 
(AICD∆YENPTY), to stimulate PI(3,5)P2 vesicle production, indicates that the YENPTY 
domain of AICD plays a crucial role in the interaction of APP with the PIKfyve complex. 
Unfortunately it was not possible to validate the result biochemically using proteo-
liposome recruitments due to the strong degradation of the bacterially expressed 
AICD∆YENPTY. The YENPTY motif of AICD is known for mediating a number of APP 
interactions. It is 100% conserved from C.elegans to humans, demonstrating its 
importance (King and Turner, 2004), and it contains a tyrosine based motif, which is an 
internalisation signal for clathrin mediated endocytosis (Buoso et al., 2010, Kurten, 
2003, Ohno et al., 1995, Owen and Evans, 1998). The YENPTY motif of AICD also 
contains a consensus sequence for phosphotyrosine binding (PTB) domain interaction 
(Pardossi-Piquard and Checler, 2012). Known interactors of APP’s YENPTY motif 
include the PTB domain containing protein families X11 (mint), FE65, JIP (Borg et al., 
1996, King and Turner, 2004). This demonstrates that the YENPTY motif is important 
for the interaction of APP with proteins that are crucial to its function, therefore lending 
support to the role of the YENPTY domain in the APP-PIKfyve complex interaction. 
5.3.2 A role of the PIKfyve complex in the trafficking of APP 
The catalytic inhibition of PIKfyve by the inhibitors YM-201636 and Apilimod caused 
the accumulation of APP-GFP in vacuole like structures, and an increase in the protein 
level of endogenous APP. These APP-GFP positive vacuoles displayed some co-
localisation with the early endosome marker EEA1, however there was no detectable 
overlap of these APP-GFP positive vacuoles with the late endosomal/lysosomal 
marker LAMP-1. This suggests that APP becomes trapped in vesicles derived from the 
early endosome upon the inhibition of PIKfyve. These results support the idea that 
APP trafficking is dependent of the activity of PIKfyve.  The PIKfyve complex is known 
to be important in normal endosomal function, and it is crucial in mediating endosome 
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to TGN transport, and endosome/lysosome fusion (Rutherford et al., 2006, Dong et al., 
2010). Another protein complex known to play a crucial role in regulating endosome to 
TGN trafficking is the retromer complex (Arighi et al., 2004). APP is known to traffic 
between the endosomes and the TGN in a process mediated by the retromer complex 
(Vieira et al., 2010). The results of this chapter show that PIKfyve is required to prevent 
APP becoming trapped in early endosome derived vacuoles. This is supported by the 
crucial role PIKfyve plays in the sorting of several receptors in endosomes, and the 
importance of the endosomal location of APP and its transport from endosomes.  
5.3.3 A model of APP’s interaction with the PIKfyve complex 
The results described in this chapter and those in chapter 4 allows for the proposition 
of a model for the functional significance of the interaction between APP and the 
PIKfyve complex. Upon arrival at early endosomes during APP trafficking,  APP is able 
to interact with the Vac14 subunit of the PIKfyve complex, probably via the YENPTY 
motif of AICD. This interaction stimulates the production of PI(3,5)P2 positive vesicles 
therefore allowing APP to be sorted away from the endosomal system. The inhibition of 
PIKfyve would stop this sorting of APP, causing APP to accumulate in vacuole like 
structures. This model suggests a relationship between APP and PIKfyve were APP 
can regulate its own trafficking by binding to the PIKfyve complex, and triggering the 
production of PI(3,5)P2  positive vesicles. This interplay between APP and the PIKfyve 
complex also has important implications for Alzheimer’s disease. These implications 
will be discussed in chapter 7. 
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The use of proteo-
liposomes to examine 
the interactions of the 
clathrin coat complex  
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Chapter 6- The use of proteo-
liposomes to examine 
interactions of the clathrin coat 
complex 
 
6.1 Introduction 
The proteo-liposome recruitment method established in chapter 3 was utilised in 
chapters 3 and 4 to examine the novel interactions of the intracellular domain of the 
membrane protein APP with the signalling modules mTOR and PIKfyve. 
A model membrane system based on liposomes has previously been utilised to 
examine the recruitment of protein coats involved in intracellular trafficking events. 
Protein-free liposomes have been used to study the assembly of parts of the clathrin 
coat complex from cytosol samples (Zhu et al., 1999, Drake et al., 2000). Baust et al. 
(2006) utilised a liposome based system to study the assembly of AP-1A protein coats, 
required for transport between the secretory pathway, and the endosomal and 
lysosomal systems. The recruitment of the AP-1A coat from brain cytosol onto 
liposomes containing the cytoplasmic tails of the gpI envelope glycoprotein of the 
Varicella zoster virus, and the lysosomal integral membrane protein Limp II, was 
examined.  The liposome technique was successfully used to examine the coordinated 
assembly of the AP-1A coat from brain cytosol. A liposome based recruitment system 
has also been utilised in a proteomic screen of AP-3 coats recruited from cytosol 
samples, to identify new proteins supporting the role of AP-3 in the targeting of certain 
transmembrane proteins to lysosomes (Baust et al., 2008).  
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There is a need for the proteo-liposome technique to be advanced to allow for the in-
depth analysis of the recruitment of specific proteins involved in coat assembly, 
allowing the examination of coat assembly in more detail. This chapter focuses on the 
development of the proteo-liposome recruitment system to examine the assembly of 
coat complexes from their purified components, which should enable greater analysis 
of coat protein assembly. The recruitment of the established coat complex, the AP-
2/clathrin coat from its purified components was utilised to further develop the proteo-
liposome recruitment method. The recruitment of the AP-2/clathrin coat onto liposomes 
containing the intracellular domains of two model membrane proteins was examined. 
These membrane proteins are APP and the apical determinant Crumbs. 
6.1.2 Crumbs 
Crumbs (Crb), like APP is a type 1 transmembrane protein. Its extracellular domain is 
primarily composed of epidermal growth factor (EGF)-like repeats. Its intracellular 
domain is 37 amino acids long and contains two highly conserved regions, the C-
terminal PDZ binding motif ERLI and a 4.1 protein, ezrin, radxin, moesin (FERM) 
binding domain (Bulgakova and Knust, 2009). Crumbs was first discovered in 
Drosophila melanogaster (Tepass et al., 1990), and has since been shown to play a 
crucial role in epithelial cell polarity. Crb is part of a protein complex, which in 
Drosophila, is primarily composed of Crb, the scaffold protein Stardust/Pals1, PatJ and 
Lin-7. There are 3 mammalian orthologues of the Drosophila Crb, Crb1, Crb2, and 
Crb3 (Bulgakova and Knust, 2009). This chapter will focus on the Crb2 mammalian 
orthologue, which is known to be crucial for embryonic development in mice (Xiao et 
al., 2011). The mammalian orthologue of Stardust known as Pals1 binds to the EERLI 
motif on Crb, where it acts as a scaffold protein for the assembly of the rest of the Crb 
complex (Roh et al., 2002).   
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6.1.2.3 The trafficking of Crumbs 
Due to the fact that the cellular levels of Crb are crucial for its role in cell polarity by 
maintaining the apical-basal polarity, and the integrity of epithelial cells, the trafficking 
of Crb is key. Crb is a known cargo of the retromer complex that regulates endosome-
to-TGN trafficking. Loss of the retromer complex causes Crb to be targeted to the 
lysosomes for degradation, thereby reducing the level of Crb. This reduction in the 
level of Crb causes a disruption to the apical-basal polarity of epithelial cells (Pocha 
and Wassmer, 2011, Pocha et al., 2011, Zhou et al., 2011). Given that the endosome-
to-TGN retrograde trafficking of Crb is vital to its function it is not unlikely that Crb 
endocytosis is also important for its function in regulating cell polarity. There is 
increasing evidence to suggest that Crb undergoes AP-2 dependent clathrin mediated 
endocytosis. It has been shown that the clathrin adaptor AP-2 is required for the 
endocytosis of Crb and that the Scribble protein helps to regulate the polarity of 
epithelial cells by influencing the endocytosis of Crb (de Vreede et al., 2014).   
The intracellular domains of membrane proteins are crucial for mediating their 
endocytosis as they contain endocytic motifs which are recognised by coat proteins 
(Kurten, 2003). Unlike APP, Crb2 does not contain the conventional tyrosine based 
endocytosis motif. It does however contain a potential acidic dileucine based motif 
(Klebes and Knust, 2000). These motifs are also important in protein trafficking. They 
are recognised by adaptor proteins such as the clathrin adaptor AP-2, which form part 
of coat protein complexes involved in trafficking events (Kelly et al., 2008). 
 
The aims of this chapter were to determine if the proteo-liposome recruitment system 
could be used to examine the assembly of protein coats from their purified 
components, using the AP-2/clathrin coat as a model, and to test this assembly onto 
the intracellular domains of membrane proteins containing two different motifs; the 
tyrosine based motif and the acidic dileucine based motif.  
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6.2 Results 
6.2.1 Purification of clathrin from pig brain 
In order to test whether the proteo-liposome recruitment system could be used to 
examine the assembly of coat proteins from their purified components, using the AP-
2/clathrin coat as a model, the components needed to be purified. The analysis of coat 
assembly from purified components would allow the examination of the recruitment of 
individual components in more detail than has previously been possible using earlier 
liposome based systems.  
To examine the assembly of the AP-2/ clathrin coat, clathrin was purified from pig 
brains essentially as described in Pearse (1976). A detailed method for clathrin 
purification can be seen in chapter 2. Briefly, coated vesicles were isolated from pig 
brain and the protein released from the lipid using 1 M Tris. The majority of the lipid 
was then removed by ultracentrifugation and the supernatant loaded on a Sephacryl 
S500 gel filtration column to separate the clathrin from the lipid and the clathrin 
adaptors. Figure 33A shows the UV trace obtained from the Sephacryl S500 column. 
The first peak corresponds to lipid, the second to clathrin, and the third to the clathrin 
adaptors, demonstrating the complete removal of protein from the lipid and therefore 
the purity of the samples. Figure 33B shows a Coomassie stained SDS-PAGE gel of 
fractions from the Sephacryl S500 column. The band at approximately 180 kDa 
corresponds to the clathrin heavy chain. The light chain was also visible at around 25 
kDa. The double band observed in the later elution fractions, at around 100 kDa is 
characteristic of the clathrin adaptors. To obtain a more pure clathrin preparation the 
clathrin containing fractions from the Sephacryl S500 column were further purified 
using a Superdex-200 column. Figures 33C and 33D show the UV trace and a 
Coomassie stained SDS-PAGE gel of the fractions obtained from the Superdex-200 
column. Note the single peak in the UV trace (Figure 33C) indicating a pure clathrin 
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sample, and the presence of the clathrin heavy chain (180kDa) and light chain (25kDa) 
shown on the gel in figure 33D. Clathrin was re-assembled into empty cages for 
storage, by dialysis into a buffer with a pH of 6.5 (polymerisation buffer).  
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Figure 31. Purification of Clathrin from pig brain. 
(A) UV trace after gel filtration using Sephacryl S500. The first peak corresponds to the 
lipid containing fractions, the second peak to the clathrin containing fractions and the 
third peak to the adaptor protein containing fractions. (B) A Coomassie stained SDS-
gel of fractions from gel filtration with Sephacryl S500. The coloured bars indicate 
which fractions correspond to which peak shown in A. (C) The UV trace after the 
clathrin containing fractions from A and B were run on aSuperdex-200 gel filtration 
column. (D). A Coomassie stained SDS-gel of the fractions from the clathrin peak in C. 
HC indicates the clathrin heavy chain and LC the light chain.  
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6.2.2 Purification of mixed clathrin adaptors and AP-2 from pig brain 
As well as the purification of clathrin, the purification of the clathrin adaptors, in 
particular AP-2, was also required to test the creation of artificial clathrin coated 
vesicles. Mixed clathrin adaptors were obtained from the final elution peak following gel 
filtration of the stripped coated vesicles using Sephacryl S500 as described previously 
(Figure 34A and 34B). These mixed adaptors were either concentrated down by 
precipitation with ammonium sulphate and used as a population of mixed clathrin 
adaptors for the proteo-liposome recruitments, or they were subjected to further 
purification steps to isolate the clathrin adaptor AP-2.  
AP-2 was purified from these isolated mixed adaptors essentially as described by 
Pearse and Robinson (1984). A more detailed AP-2 purification method can be seen in 
chapter 2. Essentially AP-2 was purified from mixed adaptors using hydroxyapatite Bio-
gel. The proteins were eluted from the column using an increasing phosphate gradient 
to a final concentration of 500mM potassium phosphate. Figures 34A and 34B show 
the UV trace obtained from the elution from the hydroxyapatite Bio-gel column and 
Coomassie stained SDS-PAGE gels of the fractions from the elution. AP-2 bound to 
the hydroxyapatite and was eluted from the column at higher phosphate 
concentrations. The final peak (highlighted by the purple bar) corresponds to the AP-2 
containing fractions (Figure 34A). The Coomassie stained gel (Figure 34B) of the AP-2 
containing fractions (again highlighted by the purple bar) showed three distinct bands 
which correspond the α, β and µ subunits of AP-2.  The σ subunit has a molecular 
weight of 17 kDa and therefore is smaller than the 30 kDa cut-off of the 8% SDS-PAGE 
gel. Both purified AP-2 and the less pure mixed adaptors were used in the proteo-
liposome recruitments for the analysis of the interaction between Crumbs and AP-2.   
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Figure 32. Purification of Adaptor protein 2 (AP-2) from pig brain.  
 (A) The UV trace from mixed adaptors run on hydroxyapatite biogel. AP-2 was 
eluted from the column with a linear phosphate gradient from 10 mM phosphate 
to 500 mM phosphate. The green line represents the expected increase in 
phosphate concentration and the brown line represents the detected salt 
concentration, corresponding to an increase in the amount of phosphate 
present. (B) Coomassie stained SDS-gels of the fractions obtained from the 
hydroxyapatite column. The coloured lines indicate the peaks in C that the 
fractions correspond to.  
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6.2.3 Both Crumbs and AICD recruit AP-2 from brain cytosol 
Not all AP-2 is membrane bound; as well as existing on clathrin coated vesicles there 
is a cytosolic pool of AP-2 (Jackson et al., 2010). Therefore, the interaction of Crumbs 
and APP with cytosolic AP-2, using brain cytosol as with previous proteo-liposome 
recruitments, was examined. The intracellular domain of Crb2 was coupled to 
liposomes along with cysteine as a negative control (Pocha et al., 2011). The Crb2 
human homologue was chosen due to the fact it is mainly expressed in the brain, as 
well as the retina and kidneys (van den Hurk et al., 2005), and that the recruitments 
were carried out in either brain cytosol or purified proteins isolated from brain.  AICD 
was coupled to liposomes as a positive control. Full length APP is known to undergo 
AP-2 dependent clathrin mediated endocytosis, and AICD contains the tyrosine sorting 
motif (YXXϕ) which is recognised by the µ subunit of AP-2 (King and Turner, 2004, 
Owen and Evans, 1998, Ohno et al., 1995, Koo and Squazzo, 1994). The proteo-
liposomes were incubated in brain cytosol, and contained 1 mol% PI(4,5)P2 to help 
mimic the lipid composition of the plasma membrane. Also cytoplasmic AP-2 is thought 
to be in a locked form, blocking its binding to the cytoplasmic tails of membrane 
proteins. PI(4,5)P2   in the plasma membrane causes a conformational change of AP-2 
allowing the simultaneous binding of PI(4,5)P2 and the cytoplasmic domains of 
membrane proteins (Jackson et al., 2010, Höning et al., 2005). The proteo-liposomes 
and their interaction partners were recovered by ultracentrifugation and samples were 
subjected to SDS-PAGE and Western blot analysis, using an antibody against the α 
subunit of AP-2 (Figure 35). Both AICD and Crb2 presenting liposomes were able to 
recruit AP-2 from brain cytosol. Both AICD and Crb2 were more efficient in recruiting 
AP-2 than control liposomes (cysteine). These control liposomes also showed some 
residual recruitment of AP-2 which is likely due to the PI(4,5)P2 binding of AP-2. 
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Figure 33 AP-2 is recruited from brain cytosol to AICD and Crb2 
proteo-liposomes.  
AICD, Crb2 and control (Cysteine) proteo-liposomes were incubated in 
brain cytosol. The final recruitment samples were analysed by SDS-
PAGE and western blotting using an antibody against the α subunit of 
AP-2. (Input = 1%) (n=3). 
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6.2.4 AP-2 is recruited from mixed adaptors onto Crb2 proteo-liposomes 
To develop the proteo-liposome recruitment system to allow for the creation and 
examination of artificial clathrin coated vesicles from purified components, the proteo-
liposome method was modified through the use of the semi-pure mixed clathrin 
adaptors. These mixed adaptors were harvested from clathrin coated vesicles isolated 
from brain (6.2.2), and are therefore more pure than the previously used brain cytosol.   
 Figure 36A shows a Coomassie stained SDS-PAGE gel of the mixed adaptors used to 
test the effectiveness of the proteo-liposome recruitment system in the analysis of coat 
assembly from their purified components. Of note is the characteristic double band at 
around 80 to 100 kDa corresponding to the α and β subunits of AP-2. Figure 36B 
shows a comparison of the mixed adaptors and pig brain cytosol. Equal amounts of 
total protein were subjected to SDS-Page and Western blotting. AP-2 was found to be  
highly enriched in the mixed adaptors compared to brain cytosol, as determined using 
an antibody specific for the α subunit (Figure 36B). This was also the case for AP-1 as 
visualised using an antibody against its γ subunit. The clathrin adaptor AP180 was not 
enriched in the mixed adaptors compared to the brain cytosol (Figure 36B). Also of 
importance was that the Pals1 (Stardust) subunit of the Crumbs complex was not 
present in the mixed adaptors, this indicates that any interaction seen was not 
mediated by Pals1. 
Proteo-liposome recruitments were conducted where PI(4,5)P2 was excluded from the 
liposomes to allow for the specific analysis of the interaction partners of the 
cytoplasmic domains. AICD, Crb2 and control (cysteine) liposomes were incubated in 
two different amounts (25 µg and 125 µg) of mixed adaptors. Samples were isolated by 
ultracentrifugation and analysed by Western blotting using antibodies against the α-
subunit of AP-2, the γ subunit of AP-1 and Pals-1. AP-2 was recruited from mixed 
adaptors to AICD and Crbs proteo-liposomes (Figure 36C). At lower amounts (25 µg) 
of mixed adaptors it becomes apparent that AP-2 has a lower affinity for Crb2 than it 
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does for AICD. The recruitment showed that no Pals1 was found in the samples. This 
and the fact that the mixed adaptors are semi-pure indicates that AP-2 is likely binding 
directly to the intracellular domain of Crb2 and AICD, and therefore that the interaction 
between AP-2 and Crb2 is not mediated by Pals1. It was also found that AP-1 was 
recruited to both AICD and Crb2 containing liposomes with a greater affinity for AICD 
than Crb2 at lower amounts of mixed adaptors (25 µg) (Figure 36C).   
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Figure 34 . AP-2 is recruited from mixed adaptors onto AICD and Crb2 
proteo-liposomes. 
(A) A Coomassie stained SDS-PAGE gel of the mixed adaptors used for 
the recruitment in C. (B) Western blot analysis of brain cytosol and mixed 
adaptors. Equal amounts of protein were loaded. Both AP-2 (α-adaptin) 
and AP-1 (γ-adaptin) are enriched in the mixed adaptors with the Pals1 
subunit of the Crumbs complex is enriched in brain cytosol and not mixed 
adaptors. AICD, Crb2 and control (cysteine) proteo-liposomes were 
incubated with 25 µg and 125 µg of mixed adaptors. The samples were 
analysed by SDS-PAGE and western blotting using antibodies against the 
subunit of AP-2, the γ subunit of AP-1 and Pals-1 of the Crb complex. 
Brain cytosol was used as an input for Pals1 rather than mixed adaptors as 
B showed that Pals1 was not present in the mixed adaptors. (C) Both AP-2 
and AP-1 are recruited to both AICD and Crb2 containing liposomes. (Input 
for α and γ adaptin = 14% of 125 µg and 71% of 25 µg) (n=3). 
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6.2.5 The C-terminal PEERLI motif of Crb2 is important for its interaction 
with AP-2 from mixed adaptors 
The next stage in the development of the proteo-liposome recruitment system to 
analyse the assembly of protein coats from their purified components, was to 
determine if this modified system would allow for the examination of motifs in the 
intracellular domain of Crb2 that are important for AP-2 recruitment and binding.  
Unlike APP, Crb2 does not contain a conventional tyrosine based sorting motif 
required for AP-2 binding. However, AP-2 can also recognise acidic dileucine based 
motifs in the cytoplasmic domains or membrane proteins. The dileucine motif 
[ED]xxxL[LI] is recognised by the σ subunit of AP-2 (Kelly et al., 2008, Janvier et al., 
2003, Doray et al., 2007). The cytoplasmic domain of Crb2 does not contain this 
conventional dileucine motif. However, it does contain a PDZ (PSD-95/Discs large/ZO-
1) binding, C-terminal EERLI motif. This motif is crucial for the interaction between Crb 
and the rest of the Crb complex (Bulgakova and Knust, 2009). The acidic dileucine like 
nature of the EERLI makes it a likely candidate for the AP-2 binding site of Crb2. To 
test this, several mutants of Crb2 C-terminal PEERLI domain were used. These mutant 
proteins were kindly provided by Elizabeth Knust’s lab, and included a deletion of the 
PEERLI motif (dPEERLI), the substitution of either the C-terminal LI, the middle EE, or 
both, for alanine’s (LI-AA, PAARLI and PAARAA respectively). The amino acid 
sequences of these Crb2 mutants can be seen in figure 37B. These mutants were 
selected to firstly determine if the PEERLI motif mediated the interaction between Crb2 
and AP-2, and if so which particular amino acids in the motif could be important for this 
interaction.  
Proteo-liposome recruitments were conducted using 25 µg of mixed adaptors, where 
wild type Crb2 (WT-Crb2) and the mutants described above were coupled to 
liposomes. Cysteine was used as a negative control to prove that any recruitment 
observed was due to the presence of the protein tails. Again no PI(4,5)P2 was included 
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in the liposomes to ensure that the recruitment was specific to the tail used and not to 
the binding of the adaptors to PI(4,5)P2 in the liposome membrane. The liposome 
samples were analysed by SDS-PAGE and Western blotting for AP-2 using an 
antibody directed against it’s α subunit. All the mutant proteo-liposomes showed a 
reduction in the recruitment of AP-2 when compared to WT-Crb2, with all the mutants 
reducing the binding of AP-2 from the mixed adaptors, to a similar level (Figure 37A). 
This indicates that the PEERLI motif of Crb2 plays a key role in the interaction of Crb2 
with AP-2.   
Figure 35. The PEERLI motif or Crb2 is crucial for the interaction 
between Crb2 and AP-2 recruited from mixed adaptors. 
Crb2, mutants of Crb2 (LI-AA, PAARLI, PAARAA and dPEERLI) and control 
(cysteine) proteo-liposomes were incubated in 25 µg of mixed adaptors. 
Samples were analysed by SDS-PAGE and western blotting using an 
antibody against the α subunit of AP-2 (A). The mutations in the PEERLI 
motif of Crb2 reduce binding to AP-2. (B) The amino acid sequences of the 
Crb2 mutants and wild type (WT) Crb2 used for the recruitment in A. (Input = 
71%) (n=3).  
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6.2.6 Disruption of the PEERLI motif of Crb2 reduces the binding of  
purifed AP-2  
So far this chapter describes th modification of the proteo-liposome recruitment system 
to examine the recruitment of purifed protein coat components using the AP-2/ clathrin 
coat as a model. Using this system the PEERLI motif of Crb2 has been shown to be 
important for the recruitment of AP-2 from a sample of mixed adaptors. Due to the fact 
that the mixed adaptors used were only semi-pure, in order to further advance this 
system to examine the assembly of coats from purifed components, the purifed 
adaptor AP-2 was utilised. AP-2 was purifed from the mixed adaptors as described 
earlier in this chapter (6.2.2). Using purifed AP-2 also further refines the proteo-lipsome 
recruitment technique to allow for the analysis of native purifed proteins, rather than 
recombinant proteins, as seen in chapters 3 and 4.  
To test whether the same effect is observed in AP-2 as well as mixed adaptors proteo-
liposome recruitment experiments were conducted where AICD, WT Crb2 or the Crb2 
mutants LI-AA, PAARLI and PAARAA, were coupled to liposomes. The amino acid 
sequence of the mutants used for this recruitment are shown in figure 38A. PI(4,5)P2 
was excluded from the liposomes to determine that any recruitment observed was due 
to binding to the cytoplasmic tail and not AP-2 binidng to PI(4,5)P2. Figure 38C shows 
a Coomassie stained SDS-PAGE gel of the purifed AP-2 used in the recruitment. The 
AP-2 was also subjected to Western blot analysis using an antibody against the α 
subunit to ensure that the purifed protein was definetely AP-2 (Figure 38D).The proteo-
liposomes containing the coupled tails were incubated in 25 µg of purifed AP-2. The 
recruitment samples were analysed by SDS-PAGE and Western blotting for AP-2 
using an antibody directed against the α subunit (Figure 38B).  
AP-2 was recruited to AICD and Crb2 proteo-liposomes (Figure 38B) demonstrating 
that this interaction due to the direct binding of AP-2 to the cytoplasmic tails. The 
mutant Crb2 proteins showed a reduction in the binding of AP-2, which supports the 
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results observed from the mixed adaptors. This demonstrates that the PEERLI motif of 
Crb2 is crucial for AP-2 binding, and adds another layer to the capabilities of the 
proteo-liposome recruitment system.  
Figure 36. The PEERLI motif of Crb2 is required for its interaction with 
purified AP-2. 
(A) The amino acid sequence of the Crb2 mutants used for the recruitment. 
AICD (positive control),Crb2, Crb2 mutants (LI-AA,PAARLI and PAARAA) and 
control (cysteine) proteo-liposomes were incubated in 25 µg of AP-2 purified 
from mixed adaptors. The recruitment samples were analysed by SDS-PAGE 
and western blotting using an antibody against the α subunit of AP-2. (B) AP-2 
purifed from the mixed adaptors isolated from pig brain binds directly to Crb2 
and the PEERLI motif is important in the AP-2/Crb2 binding.(Input = 20%) (n=3). 
(C) A Coomassie stained SDS-PAGE gel of the AP-2 purified from pig brain 
used in B. The arrows represent the α, β and µ subunits of AP-2 with the σ 
subunit being too small to appear on the gel (18 kDa). (D) Western blot of 0.5 µg 
of AP-2 using an antibody against the α-adaptin subunit.  
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6.2.7 The recruitment of clathrin to Crb2 and AICD proteo-liposomes 
The use of the modified proteo-liposome recruitment system has so far shown that the 
clathrin adaptor AP-2 is recruited onto liposomes presenting the intracellular domains 
of the membrane proteins APP and Crb2. The next stage in the modification of the 
proteo-liposome recruitment method was to examine the recruitment of clathrin onto 
AICD and Crb2 presenting proteo-liposomes which contained bound AP-2. The 
process of clathrin mediated endocytosis is vital for the internalisation of various 
membrane proteins. The disruption of clathrin mediated endocytosis is known to play a 
role in human diseases, such as Alzheimer’s disease (Wu and Yao, 2009). Therefore it 
is important that we have ways of examining the assembly and disassembly of the 
clathrin coat. 
Liposome based systems have previously been utilised for examining certain stages of 
clathrin cage assembly. Primarily liposomes have been used in one of two ways. 
Protein free liposomes were used to examine certain aspects of coat assembly. This 
technique has been used to examine the assembly of the AP-3 coat (Drake et al., 
2000), and the interaction of AP-2 with PI(4,5)P2 (Höning et al., 2005).  The second 
method involved the anchoring of a clathrin adaptor or a specific domain of a clathrin 
adaptor to the liposomes, and the examination of the assembly of a select part of the 
clathrin coat complex.  This technique has been used to study the assembly of AP-1 
coats (Crottet et al., 2002, Baust et al., 2006) , and the assembly of clathrin vesicles 
using the ENTH domain of the clathrin adaptor epsin (Dannhauser and Ungewickell, 
2012). The recruitment of clathrin coats onto liposomes containing the cytoplasmic 
domains of receptors has not been examined until very recently. Kelly et al. (2014) 
have used a small Yxxϕ tyrosine based motif peptide anchored to liposomes to 
examine the assembly of AP-2 clathrin coats using recombinantly expressed AP-2.  
The rest of this chapter examines the assembly of the AP-2/clathrin coat onto AICD 
and Crb2 containing proteo-liposomes. In this chapter it has been previously shown 
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that AP-2 was able to bind to both AICD and Crb2, but possibly with different affinities. 
Therefore the effect each receptor tail has on the recruitment of clathrin was examined. 
To do this the proteo-liposome recruitment assay was modified to resemble the 
liposome binding assay used by (Kelly et al., 2014). A detailed description of this 
method can be seen in chapter 2. Briefly AICD, Crb2 and control (cysteine) proteo-
liposomes were created with a final lipid concentration of 0.4 mg/ml. Two sets of 
liposomes were created, one containing 5 mol% PI(4,5)P2 , while PI(4,5)P2 was omitted 
from the second set. The proteo-liposomes were incubated in 0.8 µM of purified AP-2, 
followed by ultracentrifugation to recover the liposomes, and then the subsequent 
incubation in 0.2 µM clathrin. These proteo-liposomes were collected by 
ultracentrifugation and the supernatant and pellet analysed by SDS-PAGE on 
Coomassie stained gels.  
Clathrin was recruited on to AICD proteo-liposomes containing PI(4,5)P2 (Figure 39A). 
Clathrin was also recruited onto Crb2 PI(4,5)P2 containing proteo-liposomes, and to a 
minor extent to control liposomes containing PI(4,5)P2 (Figure 39A). Clathrin appeared 
to be recruited in similar levels onto AICD and Crb2 proteo-liposomes without 
PI(4,5)P2, with very little clathrin recruited to control liposomes without PI(4,5)P2 (Figure 
39B). Of note is the fact there was no clathrin found in the pellet sample when no 
liposomes were added (see no lipid in figure 39B). This showed that the clathrin was 
definitely binding to liposomes. One observation was that the AP-2 was not detected in 
the pellet samples, which was likely due to the lack of sensitivity of the Coomassie 
stain. These results indicate that the presence of the cytoplasmic domain of membrane 
proteins does promote the recruitment of clathrin to synthetic liposomes.   
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Figure 37. Clathrin is selectively recruited to AICD proteo-liposomes 
containing PI(4,5)P2. 
AICD, Crb2 and control (cysteine) proteo-liposomes with (A) and without (B) 
PI(4,5)P2 were sequentially incubated in AP-2 and clathrin. The proteo-
liposomes were collected by ultracentrifugation and samples were analysed by 
SDS-PAGE. (A) A Coomassie stained SDS-gel of the samples obtained from 
the recruitment with liposomes containing PI(4,5)P2. The arrow shows the band 
corresponding to the clathrin heavy chain. AICD and PI(4,5)P2  containing 
liposomes recruits more clathrin than both Crb2 and cysteine (input = 100%). 
(B) A Coomassie stained SDS-gel of the samples obtained from the 
recruitment where PI(4,5)P2 was omitted from the liposomes. Clathrin is 
recruited to AICD and Crb2 liposomes. The presence of both AICD PI(4,5)P2 
appears to be required for substantial clathrin recruitment.(n=3). 
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6.2.8 The clathrin/AP-2 complex is assembled on both Crb2 and AICD 
proteo-liposomes 
Previously in this chapter it has been shown that Crb2 and AICD proteo-liposomes are 
able to recruit both AP-2 and clathrin. Therefore they could potentially be used to 
examine the assembly of AP-2/clathrin coats. As the AP-2 was not detectable 
previously by Coomassie stain, Western blot analysis was therefore used to detect 
both AP-2 and clathrin. AICD, Crb2 and control (cysteine) proteo-liposomes were 
created with a final lipid concentration of 0.4 mg/ml. Two sets of liposomes were 
created, one containing 5 mol% PI(4,5)P2, and on in which PI(4,5)P2 was omitted.  
The proteo-liposomes were incubated in 0.8 µM of purified AP-2 followed by 
ultracentrifugation to recover the liposomes, and then the subsequent incubation in 0.2 
µM clathrin. These proteo-liposomes were collected by ultracentrifugation. The 
supernatant (from the clathrin incubation step as the supernatant from the AP-2 
incubation step was discarded before the incubation in clathrin) (Figure 40C) and the 
pellet were analysed by SDS-PAGE and Western blotting using antibodies against the 
clathrin heavy chain and the α subunit of AP-2.  
AP-2 was recruited to AICD and Crb2 proteo-liposomes compared to the cysteine 
control liposomes (Figures 40A and 40B). AP-2 was also preferentially recruited to 
liposomes containing PI(4,5)P2, which is consistent with the fact that AP-2 is known to 
bind to PI(4,5)P2 (Höning et al., 2005). Also of note is the difference in the recruitment 
of AP-2 observed between AICD and Crb2 proteo-liposomes, with AICD showing more 
efficient recruitment of AP-2. This demonstrates that AP-2 binds to AICD and Crb2 with 
different affinities probably due to the difference in their AP-2 binding motifs.  
Clathrin was found to be enriched on AICD proteo-liposomes compared to both Crb2 
liposomes and control liposomes (Figure 40B). Crb2 proteo-liposomes in the absence 
of PI(4,5)P2 appeared to recruit slightly more clathrin than control liposomes. In the 
presence of however Crb2 and control liposomes were able to recruit clathrin to a 
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similar extent (Figure 40B). The presence of PI(4,5)P2 in the liposome membrane, 
appeared to enhance the recruitment of clathrin (Figure 40B), indicating PI(4,5)P2 is 
key to the assembly of the clathrin complex.   
Taken together these results demonstrate that AICD proteo-liposomes are more 
efficient recruiters of the AP-2/clathrin complex than Crb2 proteo-liposomes which also 
have a slightly higher affinity for the complex than control liposomes. They also show 
that the AP-2 clathrin complex can be assembled on liposomes without the cytoplasmic 
domain of a membrane protein, likely through the binding of PI(4,5)P2, and that the 
presence of this domain enhances the recruitment of the AP-2/clathrin complex. The 
type of binding motif present in the intracellular domain of membrane proteins also 
appears to influence the recruitment of the AP-2/clathrin complex. Crucially this work 
demonstrates the ability of the modified proteo-liposome recruitment system to 
examine the assembly of the AP-2/clathrin complex protein complexes onto liposomes 
containing the intracellular domains of membrane proteins. It also allows for the 
discrimination between cytoplasmic tails containing different binding motifs. 
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Figure 38.  Both AP-2 and clathrin are recruited preferentially to AICD containing 
liposomes. 
AICD, Crb2 and control (cysteine) proteo-liposomes with and without PI(4,5)P2 were 
used to try and create in vitro clathrin coated vesicles by sequential incubation in AP-2 
and clathrin. The liposomes were pelleted by ultracentrifugation and the supernatant 
and pellet fractions adjusted with Laemmli buffer and analysed by SDS-PAGE and 
western blotting using antibodies against the α subunit of AP-2 and clathrin’s heavy 
chain. (A) AP-2 is recruited on to AICD and Crb2 liposomes compared to controls. This 
recruitment is enhanced when the liposomes contained PI(4,5)P2. (B) The presence of 
AICD and to a lesser extent Crb2 increases the recruitment of clathrin. This 
recruitment is enhanced onto liposomes containing PI(4,5)P2 . (Input = 100) (n=3) (C) 
An overview of the method used.  
C 
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6.3 Discussion 
This chapter describes the development of the proteo-liposome system to analyse the 
assembly of protein coats from their purified components, using the AP-2/clathrin coat 
as a model. It is show that AP-2 was able to directly interact with the cytoplasmic 
domain of both APP (AICD) and Crb2. Through the use of the proteo-liposome 
recruitment system and mutant proteins of Crb2 intracellular domain it was shown that 
the C-terminal PEERLI motif in the cytoplasmic domain of Crb2 was the likely binding 
site for AP-2 as mutations in this site reduced the binding of AP-2. The proteo-
liposome recruitment system was also used to create artificial clathrin coated vesicles, 
demonstrating that purified coat analysis is possible using this system.  
6.3.1 The AP-2 binds to AICD and Crb2 
The results from this chapter demonstrates that AP-2 binds to the intracellular domain 
of AICD and Crb2, and that AP-2/clathrin complex can be assembled on both AICD 
and Crb2 containing liposomes to different degrees. APP is known to undergo clathrin 
mediated endocytosis. AICD contains a tyrosine based endocytic motif recognised by 
AP-2. The endocytosis of APP is important in its trafficking and processing (Thinakaran 
and Koo, 2008).  
This interplay between Crb2 and the AP-2/clathrin links Crb2 to clathrin mediated 
endocytosis. This is consistent with previous studies that show that the Scribble 
module is able to regulate the polarity of epithelial cells by modulating the AP-2 
dependent endocytosis of Crb (de Vreede et al., 2014). The Scribble module is a 
protein complex that also controls epithelial cell polarity. It is an important regulator of 
the basolateral membrane where it excludes apical protein localisation (de Vreede et 
al., 2014). The proteo-liposome recruitment system was able to establish that a direct 
interaction exists between the intracellular domain of Crb2 and the clathrin adaptor AP-
2. 
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6.3.2 The importance of the PEERLI motif of Crb2 for its interaction with 
AP-2 
Through the use of the proteo-liposome recruitment system and the use of mutant 
proteins of the cytoplasmic domain of Crb2, it was shown that the PEERLI motif, 
located at the C-terminus of Crb2 intracellular domain, was crucial for its interaction 
with AP-2. Mutant proteins were used where EE, LI, or both from the PEERLI motif, 
were substituted for alanine. There was also a mutant where the PEERLI motif was 
removed. These mutants showed a reduction in the binding of AP-2 compared to wild 
type Crb2. However, the method could not distinguish between AP-2 binding to the 
different mutants. This could have been due to a number of factors. Firstly, the proteo-
liposome recruitment assay might not be sensitive enough to pinpoint the binding 
domain of AP-2 to one or two amino acids. On the other hand, the whole of the 
PEERLI domain might be required for AP-2 binding, and not just one or two amino 
acids in this domain. The EERLI motif in Crbs is known to be vital for the function of the 
protein. It is highly conserved between Drosophila, C. elegans and humans, and 
serves as the binding site for the Stardust/Pals1 protein (Klebes and Knust, 2000, Roh 
et al., 2002, van den Hurk et al., 2005). The EERLI motif is also required to but not 
sufficient to rescue the phenotype of Crb mutants, with rescue also requiring the N-
terminus of the intracellular domain of Crb (Klebes and Knust, 2000).  
The intracellular domain of Crb2 does not contain the conventional tyrosine based 
sorting motif for clathrin mediated endocytosis (Yxxϕ), unlike APP. However, its 
PEERLI domain does contain a C-terminal leucine and isoleucine which is 
characteristic of the classical dileucine based motif ([ED]XXXL[LI]) found in the 
cytoplasmic domains of some membrane proteins, and is recognised by the σ subunit 
of AP-2. Therefore the fact that mutating this domain reduces the binding of AP-2, 
suggests that it is this motif that is required for AP-2 binding. The binding of AP-2 to the 
PEERLI motif of Crb2 suggests that Crb2 may be internalised by AP-2 mediated 
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clathrin endocytosis. Indeed, AP-2 has been found to regulate the endocytosis of Crb2 
as the mutation of AP-2 retains Crb2 on the plasma membrane (Lin et al., 
Unpublished).  
6.3.3 The recruitment of the clathrin coat complex to proteo-liposomes 
The proteo-liposome recruitment system has been successfully used in this chapter to 
recruit the AP-2 clathrin complex. AP-2 was able to bind both AICD and Crb2 with a 
stronger binding to AICD. This is in keeping with the fact APP and Crb2 have different 
binding motifs for AP-2. APP contains a tyrosine based sorting motif (Yxxϕ), whereas 
Crb2 contains a dileucine based motif (King and Turner, 2004). These two motifs are 
known to bind AP-2 with different affinities (Jackson et al., 2010) explaining the fact 
that AICD proteo-liposomes seem more efficient at recruiting AP-2. 
 AP-2 was recruited to liposomes both with and without PI(4,5)P2, however, its 
recruitment was enhanced by the presence of PI(4,5)P2. Previous work has shown 
that AP-2 is not recruited when PI(4,5)P2 is not present (Höning et al., 2005, Jackson et 
al., 2010, Kelly et al., 2014). AP-2 is thought to recognise PI(4,5)P2  in the plasma 
membrane which causes it to switch to an “open” conformation allowing the further 
binding of PI(4,5)P2 and the intracellular domains of membrane proteins via the 
tyrosine or dileucine based sorting motifs (Jackson et al., 2010, Kelly et al., 2014).  
The modified proteo-liposome recruitment system used for the assembly of artificial 
clathrin coated vesicles was based on the method used by Kelly et al. (2014). 
However, it is worth noting that Kelly et al. (2014) utilised AP-2 that was recombinantly 
expressed and purified from E.coli, and contained a truncated α subunit. Jackson et al. 
(2010) also used individual subunits of AP-2. The proteo-liposome recruitments in this 
chapter used native full length AP-2 purified from coated vesicles, harvested from pig 
brain, indicating that all the subunits of AP-2 were present and functional. The AP-2 
purified from brain has been previously shown to contain contaminants of other clathrin 
coated vesicle components which may influence the recruitment of the clathrin 
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complex (Lindner and Ungewickell, 1992). This was used by Kelly et al. (2014) as a 
reason for the use of recombinant AP-2. Although in this chapter the Coomassie 
stained gel of the native purified AP-2 showed that it was pure, and did not visibly 
contain any contaminating proteins, the presence proteins not detected by the 
Coomassie stain may account for the slight recruitment of both AP-2 and clathrin to 
cysteine control liposomes absent of PI(4,5)P2.  
Overall this chapter shows the proteo-liposome recruitment system is both valuable 
and versatile. Its use in the analysis of the recruitment of the AP-2/clathrin complex 
demonstrates that the analysis of protein coats from their purified components is 
possible using this modified proteo-liposome recruitment method.  
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Chapter 7-Discussion 
 
This thesis describes the development of a proteo-liposome recruitment system based 
on similar methods that have been used previously. Baust et al. (2006) utilised a 
liposome based system to examine the ARF1, GTP and PI(4,5)P2 mediated assembly 
of AP-1 coats, onto liposomes presenting the cytoplasmic tails of the gpI envelope 
glycoprotein of the Varicella zoster virus and the lysosomal integral membrane protein 
Limp II (Crottet et al., 2002, Baust et al., 2006). Similar liposome based methods have 
also been used to examine the recruitment of AP-3 onto liposomes presenting the 
cytoplasmic domain of LAMP (Bourel-Bonnet et al., 2005). Pocha et al. (2011) utilised 
a proteo-liposome recruitment system to examine the interaction of the intracellular 
domain of Crb2 with the retromer complex. 
In this thesis the proteo-liposome recruitment system was developed and used for the 
analysis of the interactomes of the intracellular domains of membrane proteins, and the 
assembly of protein coats from their purified components. APP was used as a model 
membrane protein to help establish the method, and also to examine novel interactors 
of APP’s intracellular domain (AICD), with a view to gaining a greater understanding of 
APP’s physiological function. Two novel AICD binding partners the mTOR complex 
and the PIKfyve complex were investigated.  
7.1 APP interacts with both the mTOR and PIKfyve complex’s  
Using the proteo-liposome recruitment system it was established that the mTOR 
complex interacts with AICD (chapter 3). This interaction was mediated by the N-
terminal region of AICD. The interaction was also found to be enabled by the direct 
binding of mTOR to AICD, via mTOR’s kinase domain. The same proteo-liposome 
recruitment system was utilised to examine the interaction of AICD with the PIKfyve 
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complex (chapter 4). AICD was shown to recruit both PIKfyve itself, and the scaffold 
subunit Vac14, and this interaction was mediated by the C-terminal region of AICD. 
AICD was found to interact with the PIKfyve complex through direct binding between 
the C-terminus of AICD and the Vac14 subunit of the PIKfyve complex. The proteo-
liposome recruitment system was therefore able to demonstrate that the mTOR and 
PIKfyve complexes bind to different motifs on AICD. This led to the question: what 
motifs in the N-terminus and C-terminus of AICD are required for the binding to the 
mTOR and PIKfyve complexes respectively?  
 
APP is known to interact with a number of cytosolic proteins through its intracellular 
domain (Thinakaran and Koo, 2008). This intracellular domain is also crucial for APP 
endocytosis and trafficking (Thinakaran and Koo, 2008, Vieira et al., 2010). AICD has 
been shown to be an intrinsically unstructured protein that undergoes conformational 
switching, allowing it to adopt different conformations depending on the binding partner 
present (Das et al., 2012). This is one explanation of how AICD can bind to a variety of 
intracellular proteins.  
 
AICD is also known to contain several motifs important for mediating its interaction with 
other proteins, and the phosphorylation of a number of AICD residues is also crucial for 
AICD protein interactions (Oishi et al., 1997, Schettini et al., 2010) (Figure 41). The 
YTSI motif of AICD is located near the cell membrane, and is required for APP’s 
basolateral sorting in polarised epithelial cells (Icking et al., 2007, Lai et al., 1995). The 
YENPTY motif is the most widely studied AICD motif due to its array of interaction 
partners. It contains the consensus sequence for clathrin mediated endocytosis, and a 
motif for phosphotyrosine binding domain interactions. The YTSI and YENPTY motifs 
are both required for the degradation of APP in lysosomes (Lai et al., 1995, Chang, 
2010). AICD also contains an N-terminal helix capping box motif (VTPEER) which 
serves as a binding site for 14-3-3γ involved in the FE65 dependent gene transcription 
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by AICD (Sumioka et al., 2005). AICDs multiple motifs, and its phosphorylation sites, 
both contribute to its ability to bind a wide variety of adaptors, and may help explain 
how AICD is able to bind mTOR and PIKfyve. AICD is not likely to bind both the mTOR 
and PIKfyve complexes at the same time due the large size of the two complexes 
compared with the short AICD peptide. 
 
 
 
 
 
 
7.1.1 The AICD-mTOR complex interaction 
In chapter 3 it was shown that mTOR was recruited to the first 10 N-terminal amino 
acids of AICD. The only motif shown in figure 41 that is contained in these first 10 N-
terminal amino acids is the YTSI motif.  This motif is required for the basolateral sorting 
of APP, and is bound by the microtubule binding protein Pat1 (protein interacting with 
APP tail 1), and this interaction mediates APP’s transport through the secretory 
pathway (Buoso et al., 2010, Lai et al., 1998). The YTSI motif also contains 3 
phosphorylation sites Y653, T654 and S655. S655 is required for the retromer 
Figure 39. Binding motifs and phosphorylation sites on AICD. 
AICD contains 3 major binding motifs shown in blue. The binding 
partners of these motifs are shown below each motif, with the potential 
binding sites for mTOR and Vac14 included. The eight phosphorylation 
sites of AICD are shown in red. Figure adapted from Chang (2010).  
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dependent endosome to TGN trafficking of APP (Vieira et al., 2010). T654 and S655 
are known to be phosphorylated in vitro by protein kinase C, and by calcium and 
calmodulin dependent protein kinase II (CaMKII) in several cell lines (Oishi et al., 
1997). Both of these enzymes are serine/threonine protein kinases, as is mTOR. 
Therefore, this YTSI motif of AICD is a likely candidate for mTOR phosphorylation and 
would explain the results of chapter 3 where mTOR is recruited to the first 10 amino 
acids of AICD, which contains the YTSI motif. 
Work conducted by Balklava et al. (under review A) suggests that the C. elegans 
homologue of APP (APL-1) activates mTOR in concert with Rag-GTPases, and that 
several mTOR developmental processes including germ line expansion and fat 
metabolism are APL-1 sensitive. The results shown in chapter 3 and those of Balklava 
et al. (under review A) allow for the suggestion of a potential model, whereby mTOR 
binds to AICD, via its kinase domain, activating mTOR, which may lead to 
phosphorylation of APP’s YTSI motif. The interaction between APP and mTOR has 
several implications for Alzheimer’s disease. 
mTOR signalling has previously been shown to be elevated in the brains of 
Alzheimer’s disease patients, and this elevation in mTOR signalling correlates with the 
progression of the disease (Pei and Hugon, 2008). Additionally mTORC1 and 
mTORC2 have been shown to drive Tau toxicity in a Drosophila tauopathy model, with 
mTOR known to regulate the phosphorylation and degradation of Tau (Khurana et al., 
2006, Caccamo et al., 2013). Could mTOR signalling provide a link between the 
processing of APP and the modification of Tau? Does the amyloidogenic processing of 
APP lead to increase mTOR signalling, which then causes the phosphorylation of tau 
and contribute to tau toxicity? (Li et al., 2005b, Tang et al., 2013). The investigation of 
the functional significance of the interaction between APP and mTOR, as characterised 
by the proteo-liposome recruitment method, would have important implications for both 
APP function and Alzheimer’s disease.  
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7.1.2 The AICD-PIKfyve complex interaction 
Chapters 4 and 5 examined the interaction between APP and the PIKfyve complex and 
what this interaction means in terms of APP function.  Using the proteo-liposome 
recruitment method it was established that the intracellular domain of APP (AICD) 
recruits both Vac14 and PIKfyve. It was also established that the interaction was direct 
between AICD and Vac14, and was mediated by AICD’s C-terminus. The role of 
AICD’s C-terminus in mediating the interaction with the PIKfyve complex is supported 
by the results of chapter 5 which showed that APP co-localises with Vac14 and 
PI(3,5)P2 (observed with the ML1Nx2 probe) in HeLa cells and that APP, AICD and 
AICD-Tr4 overexpression drives the production of PI(3,5)P2 positive vesicles. 
A candidate AICD motif for mediating the PIKfyve interaction is the YENPTY motif. 
This motif contains the NPXY type 1 β turn and is required for AICD binding to a 
number of well-established effectors including Fe65 (Borg et al., 1996). In chapter 5 
the expression of a mutant of AICD, in which the YENPTY motif was deleted, failed to 
stimulate the production of PI(3,5)P2 positive vesicles observed upon APP, AICD and 
AICD-Tr4 overexpression, further adding support to the YENPTY motif being important 
in the APP/PIKfyve complex interaction. In AICD the YENPTY motif is followed by a 
lysine, two phenylalanine residues and a glutamic acid residue, giving rise to the 
YENPTYKFFE motif, which contains two overlapping tyrosine based motifs (Lai et al., 
1995, Tuli et al., 2009). This YKKFE motif mediates the interaction of APP with AP-4, 
which is important for mediating APP TGN-to-endosome transport (Burgos et al., 
2010). The proteo-liposome recruitments from chapter 4 demonstrate that the AICD 
mutant Tr4 was able to recruit the PIKfyve complex from brain cytosol. However, both 
Tr4 and Tr3 AICD mutants were bound directly by purified recombinant Vac14. The Tr3 
mutant lacked the C-terminal seven amino acids of AICD, present in Tr4, therefore 
deleting the two phenylalanine and the glutamic acid residues from the end of the 
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YENPTYKFFE motif. One explanation for this result could be that one tyrosine based 
motif in the YEPNTYKFFE domain might be enough to mediate the interaction with 
purified recombinant Vac14 alone; however, both tyrosine motifs may be required to 
recruit the whole PIKfyve complex. 
7.1.2.1 Implications of the relationship between APP and PIKfyve in Alzheimer’s 
disease 
In chapter 5 a potential model for the role of the PIKfyve complex in APP trafficking 
was proposed. APP, upon arrival at endosomes interacts with the PIKfyve complex 
through direct binding to Vac14, stimulating the PIKfyve dependent production of 
PI(3,5)P2 positive vesicles, leading to APP sorting away from the endosomal system. 
This model can be used to propose a novel mechanism for the role of APP in 
Alzheimer’s disease. Rather than the toxic gain of the beta amyloid peptide upon APP 
cleavage, could it be that the cleavage of APP may prevent APP from activating the 
PIKfyve complex, and therefore reduce the levels of PI(3,5)P2? This would interrupt the 
function of endosomes, resulting in vacuolation of the cell, characteristic of decreased 
PI(3,5)P2 levels. Interestingly enlarged vesicles with the characteristics of endosomes 
and lysosomes have been observed in the brains of Alzheimer’s disease patients 
(Nixon et al., 2000). The disruption of the endosomal and lysosomal systems could 
also account for the accumulation of beta amyloid through the defective clearance of 
the peptide.  
The results of chapter 4 and 5 demonstrate that APP interacts with the PIKfyve 
complex, both biochemically and functionally. The PIKfyve complex has previously 
been shown to be crucial for neuronal function and integrity, with the knock-out or 
pharmacological inhibition of the PIKfyve complex causing endosomal dysfunction and 
profound neurodegeneration (Chow et al., 2007, Chow et al., 2009, Zolov et al., 2012, 
Zhang et al., 2007b). The results of chapter 5 support the idea that APP may act as an 
activator of the PIKfyve complex. Balklava et al. (under revision B) showed that in C. 
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elegans, the homologue of APP (APL-1) is linked both genetically and functionally to 
PIKfyve, was required for PIKfyve function, and was able to act as an upstream 
activator of the PIKfyve complex.  
 
 
It is widely known that the aberrant processing of APP by beta and gamma secretases 
plays a crucial role in the pathology of Alzheimer’s disease. This aberrant processing 
of APP both produces Aβ, the toxic peptide that aggregates and is a key component of 
the plaques in Alzheimer’s disease brains, and also destroys full length APP.   Could it 
be that APP is able to meditate its own trafficking away from the endosomal/lysosomal 
system, which is also enriched in gamma secretases (Tam et al., 2014, Pasternak et 
al., 2003), in a PIKfyve dependent process? If this was the case the inhibition of 
PIKfyve would likely cause APP to become stuck in the endo/lysosomal system, 
making it more susceptible to cleavage by gamma secretases. PIKfyve complex 
inhibition would not only effect the trafficking of APP but would also effect the 
trafficking of other PIKfyve cargo, therefore disrupting normal endosomal homeostasis. 
It could also be possible that the aberrant processing of APP would reduce its ability to 
Figure 40. A potential model for the role of the APP/PIKfyve complex interaction 
in Alzheimer’s disease 
The model suggests that in the normal healthy state APP may be able to regulate its 
own trafficking out of the endosomal system through the activation of PIKfyve. In 
Alzheimer’s disease APP breakdown may mean APP fails to activate PIKfyve, 
resulting in aberrant APP trafficking potentially leading to APP accumulation in 
endosomes contributing to its increased breakdown by secretases residing in 
endosomal compartments. 
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interact with and activate the PIKfyve complex, which would disrupt normal endosome 
function. Abnormal endosome function is known to play a role in Alzheimer’s disease 
and it thought to be involved in neurodegeneration (Nixon et al., 2000). Figure 42 
shows schematic of the potential role the APP/PIKfyve complex interaction may have 
in Alzheimer’s disease.  
7.1.2.2 The use of a PI(3,5)P2 probe 
The use of the PI(3,5)P2 probe (ML1Nx2 fused to a fluorescent protein tag) (Li et al., 
2013) was a valuable tool for examining the functional significance of the interaction 
between APP and the PIKfyve complex. The probe allows for the dynamic analysis of 
PI(3,5)P2  which has not previously been possible. Using the probe it was established 
that APP-GFP co-localises with PI(3,5)P2  vesicular structures in HeLa cells further 
supporting the proteo-liposome recruitment data of AICD. The number of PI(3,5)P2  
positive vesicles (as observed using the probe) was increased upon over expression of 
APP, AICD and ACID-Tr4. This suggests that APP increases PIKfyve dependant 
fission of vesicles with important implications for trafficking. Also the role of PIKfyve in 
APP trafficking may have important implications for Alzheimer’s disease. According to 
our model the inhibition of PIKfyve and therefore the reduction in PI(3,5)P2 levels cause 
an accumulation of APP and inhibit its degradation. Low levels of PI(3,5)P2 have been 
associated with neurodegeneration (Zhang et al., 2007b). Therefore the PI(3,5)P2 probe 
may prove a valuable tool to examine PI(3,5)P2 dynamics in tissue from Alzheimer’s 
disease patients to ultimately see if PI(3,5)P2 loss may be a contributing factor in 
neurodegeneration. 
These ideas and the findings of chapters 4 and 5 lead to a number of questions that 
will need to be addressed to investigate any role the APP/PIKfyve complex interaction 
may have in Alzheimer’s disease. How does a dysfunctional endo/lysosomal system 
caused by PIKfyve loss of function lead to neurodegeneration? Can abnormal PIKfyve 
function be observed in Alzheimer’s disease models and in patient samples? Could 
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finding a PIKfyve activator be able to reduce endosomal and lysosomal dysfunction, 
and ultimately reduce neurodegeneration. 
7.1.3 The link between mTOR and PIKfyve  
The interactions observed between APP and mTOR, and APP and the PIKfyve 
complex are especially interesting considering the mTOR and PIKfyve complexes are 
linked. The PIKfyve dependant production of PI(3,5)P2 is known to play an important 
role in the recruitment of mTORC1 to lysosomal membranes (Bridges et al., 2012, Jin 
et al., 2014). The raptor subunit of mTORC1 is known to bind to PI(3,5)P2 aiding in the 
translocation of mTORC1 from the cytosol to late endosomal/lysosomal membranes 
(Bridges et al., 2012). Jin et al. (2014) showed that PI(3,5)P2 is required for the 
activation of TORC1 in yeast; the TORC1 inhibition of autophagy is defective in 
mutants with low levels of PI(3,5)P2, and that PI(3,5)P2 is required for complete 
autophagy in yeast. Therefore PI(3,5)P2 is a negative regulator of autophagy, by 
positively regulating TORC1 activity (Jin et al., 2014).  
The ability of APP to interact with and activate both mTOR and PIKfyve (as observed 
in this thesis, and by Balklava et al. (under revision A), and Balklava et al. (under 
revision B)) and the link between PIKfyve and mTOR undoubtedly have implications for 
APP function as well as that of PI(3,5)P2. Examining the interplay and the functional 
significance of these three proteins in more detail will have important implications for 
the roles played by these three proteins in neurodegeneration and Alzheimer’s 
disease.   
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7.2 The proteo-liposome system: a valuable tool for studying receptor 
interactions. 
The primary aim of this thesis was to validate and extend the use of a model 
membrane proteo-liposome recruitment system, as a method for determining the 
intracellular interactome of membrane receptors, and for examining these interactions 
in more detail.  
The main advantages of this technique for studying the intracellular interactome of 
membrane proteins are that the liposomes provide a membrane context where the lipid 
composition can be manipulated depending of the native lipid environment the 
membrane protein resides in. Therefore, it takes into account interactions of membrane 
proteins, in which the surrounding membrane lipids also play a role. This allows for the 
detection of interactions that would not be possible using more conventional methods 
such as pull downs or co-immunoprecipitations.  Another advantage of the proteo-
liposome recruitment method over more conventional and widely used methods, such 
as pull downs is that there is no need to include any form of detergent. This allows for 
the detection of weaker interactions as well as stronger ones. These weaker 
interactions would be disrupted by the detergent included in more conventional 
methods for examining protein-protein interactions (Otzen, 2011).  
Using APP as a model transmembrane protein the proteo-liposome recruitment 
method was used to examine two novel interaction partners of its intracellular domain 
(AICD); the mTOR and PIKfyve complexes. The proteo-liposome recruitment method 
was used to examine the interactions from brain cytosol samples where the complete 
set of proteins should be available, so both indirect and direct interactions can be 
detected. One advantage of using the proteo-liposome recruitment method in brain 
cytosol samples is that an analogue of GTP (GTPγS) can be added activating 
GTPases, and therefore allowing for the detection of interactions dependant on 
GTPase activity. Baust et al. (2006) utilised this liposome recruitment method to 
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examine the assembly of adaptor protein 1A coats, a process which requires the 
activity of ARF1, a guanine nucleotide binding protein.  
During the analysis of AICD’s interaction with the mTOR and PIKfyve complexes the 
proteo-liposome recruitment method was modified so that direct binding could be 
detected by the use of purified recombinant proteins. This shows the versatility of the 
proteo-liposome recruitment method due to the fact that interaction partners can be 
identified from a number of different samples.  
In chapter 6 the proteo-liposome recruitment method was further developed and 
validated due to its ability to examine the assembly of protein coats from their purified 
components, using the AP-2/clathrin coat as a model. This allowed for the detection of 
interactions from native purified proteins as well as recombinant proteins. The proteo-
liposome recruitment method allowed for the analysis of the difference in this complex 
assembly onto proteo-liposomes containing the intracellular domains of two membrane 
proteins with different endocytic sorting motifs. It also allowed for the analysis of the 
effect the lipid PI(4,5)P2 had on the assembly of the AP-2/clathrin coat complex. The 
binding of AP-2 to two different membrane proteins (AICD and Crb2) was scrutinised. 
These two proteins contain different sorting motifs in their intracellular domains 
(tyrosine and dileucine motifs) that are known to bind to AP-2 with different affinities, 
which supports the results from chapter 6 (Ohno et al., 1995, Kelly et al., 2008, Owen 
and Evans, 1998). This demonstrates that this system could also be utilised to 
examine other aspects of clathrin coat assembly, and to ultimately examine the 
disassembly of the coat, and what affect different cytoplasmic tails have on the 
disassembly of the clathrin coat. The success of this proteo-liposome recruitment 
system in examining the assembly of the AP-2/clathrin complex demonstrates the 
versatility of the method. It indicates that this system would be effective in examining 
the assembly of other protein coat complexes, with a view to increasing the knowledge 
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of the mechanisms that govern coat assembly, and therefore intracellular trafficking 
events. 
The proteo-liposome recruitment method was further modified to try and detect specific 
regions/motifs on the intracellular domains of membrane proteins that are required for 
the binding with interaction partners. Truncation mutants of AICD were successfully 
used to determine that the N-terminus of AICD was required for its binding to the 
mTOR complex, and that AICD’s C-terminus was required for its interaction with the 
PIKfyve complex. This further enhances the proteo-liposome method as a tool for 
defining regions required for interactions, therefore broadening the field to which this 
system is applicable. In chapter 6 mutant Crb2 proteins are used, where a small 
number of amino acid residues were substituted for alanine in order to determine if the 
PEERLI motif of Crb2 was required for its interaction with the clathrin adaptor AP-2. 
Here all the mutants reduced the binding of AP-2 to a similar level, but did not 
completely abolish binding. This observed affect could have been due to the fact that 
the whole of the PEERLI motif might be necessary for mediating the interactions. 
Therefore, suggesting that the structure and the interactions between the amino acids 
of this motif may be important for AP-2 binding. Another explanation is that the proteo-
liposome recruitment method was not sensitive enough to detect changes in binding 
observed upon the mutation of one or two amino acid residues. This is due to the fact 
that the proteo-liposome recruitment system is a qualitative method, and to truly 
pinpoint the most crucial amino acid would take more quantitative methods, such as 
surface plasmon resonance (SPR) which gives a measure of binding affinities.  
This thesis clearly demonstrates the ability and usefulness of the proteo-liposome 
recruitment system in examining interactions of the cytoplasmic domains of membrane 
proteins. This method was able to characterise the interactions of the intracellular 
domain of APP with both the mTOR and PIKfyve complexes, and was further 
developed to allow for the analysis of the AP-2/clathrin coat from purified components. 
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Taken together this demonstrates that the proteo-liposome recruitment system is a 
formidable method for examining a wide variety of both protein-protein and lipid-protein 
interactions. The proteo-liposome recruitment system could be utilised to analyse the 
interaction of any transmembrane, or membrane associated protein, to any coat, 
trafficking complex or other cytosolic factor, making it an extremely valuable and 
versatile tool.  
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Appendices 
 
Appendix 1 – Plasmid List 
 
 
pET28-MBP 
pET28-MBP-TEV –AICD 
pET28-MBP-TEV –AICD-Tr1 
pET28-MBP-TEV –AICD-Tr2 
pET28-MBP-TEV –AICD-Tr3 
pET28-MBP-TEV –AICD-Tr4 
pET28-MBP-TEV-Crb2 
pET28-MBP-mTOR kinase domain 
pMaIE-TEV 
pGEX-6P-1-ATG18 
pEGFP-n1 
pEGFP-n1-APP 
pEGFP-n1-AICD 
pEGFP-n1-APP∆YENPTY 
pEYFP-n1-APP∆AICD 
pEYFP-n1-AICD-Tr4 
pEGFP-C3-ML1Nx2 
pMCherry-c1-ML1Nx2 
pMCitrine-Vac14 
pMCherry-c1-Vac14 
pRFP-MPR 
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Appendix 2 – Live cell imaging videos 
 
 
The videos for the live cell imaging can be found on the attached disk. 
 
Figure 26  
 
Vac14-mCherry with APP-GFP 
Vac14-mCherry with GFP 
 
 
Figure 27 
 
mCherry-ML1Nx2 with APP-GFP 
mCherry-ML1Nx2 with GFP 
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